
<html lang="en"     class="pb-page"  data-request-id="45513ebe-fb18-4cd6-9602-102feeadf917"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/jm401836p;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-5;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir" /></meta><meta name="dc.Creator" content="Makonen  Belema" /></meta><meta name="dc.Creator" content="Van N.  Nguyen" /></meta><meta name="dc.Creator" content="Carol  Bachand" /></meta><meta name="dc.Creator" content="Dan H.  Deon" /></meta><meta name="dc.Creator" content="Jason&#xA;T.  Goodrich" /></meta><meta name="dc.Creator" content="Clint A.  James" /></meta><meta name="dc.Creator" content="Rico  Lavoie" /></meta><meta name="dc.Creator" content="Omar D.  Lopez" /></meta><meta name="dc.Creator" content="Alain  Martel" /></meta><meta name="dc.Creator" content="Jeffrey L.  Romine" /></meta><meta name="dc.Creator" content="Edward H.  Ruediger" /></meta><meta name="dc.Creator" content="Lawrence B.  Snyder" /></meta><meta name="dc.Creator" content="Denis R.  St. Laurent" /></meta><meta name="dc.Creator" content="Fukang  Yang" /></meta><meta name="dc.Creator" content="Juliang  Zhu" /></meta><meta name="dc.Creator" content="Henry&#xA;S.  Wong" /></meta><meta name="dc.Creator" content="David R.  Langley" /></meta><meta name="dc.Creator" content="Stephen P.  Adams" /></meta><meta name="dc.Creator" content="Glenn H.  Cantor" /></meta><meta name="dc.Creator" content="Anjaneya  Chimalakonda" /></meta><meta name="dc.Creator" content="Aberra  Fura" /></meta><meta name="dc.Creator" content="Benjamin M.  Johnson" /></meta><meta name="dc.Creator" content="Jay O.  Knipe" /></meta><meta name="dc.Creator" content="Dawn D.  Parker" /></meta><meta name="dc.Creator" content="Kenneth&#xA;S.  Santone" /></meta><meta name="dc.Creator" content="Robert A.  Fridell" /></meta><meta name="dc.Creator" content="Julie A.  Lemm" /></meta><meta name="dc.Creator" content="Donald R.  O’Boyle, II" /></meta><meta name="dc.Creator" content="Richard J.  Colonno" /></meta><meta name="dc.Creator" content="Min  Gao" /></meta><meta name="dc.Creator" content="Nicholas&#xA;A.  Meanwell" /></meta><meta name="dc.Creator" content="Lawrence G.  Hamann" /></meta><meta name="dc.Description" content="The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains en..." /></meta><meta name="Description" content="The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains en..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 12, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401836p" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2014 American&#xA;Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401836p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401836p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401836p" /></link>
        
    
    

<title>Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401836p" /></meta><meta property="og:title" content="Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0015.jpeg" /></meta><meta property="og:description" content="The biphenyl derivatives 2 and 3 are&#xA;prototypes of a novel class of NS5A replication complex inhibitors&#xA;that demonstrate high inhibitory potency toward a panel of clinically&#xA;relevant HCV strains encompassing genotypes 1–6. However, these&#xA;compounds exhibit poor systemic exposure in rat pharmacokinetic studies&#xA;after oral dosing. The structure–activity relationship investigations&#xA;that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of&#xA;the highly potent NS5A replication complex inhibitor daclatasvir (33) are described. An element critical to success was the&#xA;realization that the arylglycine cap of 2 could be replaced&#xA;with an alkylglycine derivative and still maintain the high inhibitory&#xA;potency of the series if accompanied with a stereoinversion, a finding&#xA;that enabled a rapid optimization of exposure properties. Compound 33 had EC50 values of 50 and 9 pM toward genotype-1a&#xA;and -1b replicons, respectively, and oral bioavailabilities of 38–108%&#xA;in preclinical species. Compound 33 provided clinical&#xA;proof-of-concept for the NS5A replication complex inhibitor class,&#xA;and regulatory approval to market it with the NS3/4A protease inhibitor&#xA;asunaprevir for the treatment of HCV genotype-1b infection has recently&#xA;been sought in Japan." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401836p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401836p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401836p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401836p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401836p&amp;href=/doi/10.1021/jm401836p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2013-2032</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm4016203" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm401499g" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Makonen Belema</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Makonen Belema</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#2548444e4a4b404b0b474049404844654748560b464a48"><span class="__cf_email__" data-cfemail="a9c4c8c2c6c7ccc787cbccc5ccc4c8e9cbc4da87cac6c4">[email protected]</span></a>. Tel.: 1-203-677-6928.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Makonen++Belema">Makonen Belema</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Van N. Nguyen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Van N. Nguyen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Van+N.++Nguyen">Van N. Nguyen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carol Bachand</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carol Bachand</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carol++Bachand">Carol Bachand</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dan H. Deon</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dan H. Deon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dan+H.++Deon">Dan H. Deon</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason T. Goodrich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason T. Goodrich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason%0AT.++Goodrich">Jason T. Goodrich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Clint A. James</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Clint A. James</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Clint+A.++James">Clint A. James</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rico Lavoie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rico Lavoie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rico++Lavoie">Rico Lavoie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Omar D. Lopez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Omar D. Lopez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Omar+D.++Lopez">Omar D. Lopez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alain Martel</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alain Martel</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alain++Martel">Alain Martel</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey L. Romine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey L. Romine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+L.++Romine">Jeffrey L. Romine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Edward H. Ruediger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Edward H. Ruediger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Discovery Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute , 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Edward+H.++Ruediger">Edward H. Ruediger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence B. Snyder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence B. Snyder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+B.++Snyder">Lawrence B. Snyder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Denis R. St. Laurent</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Denis R. St. Laurent</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Denis+R.++St.+Laurent">Denis R. St. Laurent</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fukang Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fukang Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fukang++Yang">Fukang Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Juliang Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Juliang Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Discovery Chemistry Synthesis , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Juliang++Zhu">Juliang Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Henry S. Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Henry S. Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Discovery Chemistry Synthesis , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Henry%0AS.++Wong">Henry S. Wong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">David R. Langley</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">David R. Langley</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Computer-Assisted Drug Design , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=David+R.++Langley">David R. Langley</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Stephen P. Adams</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Stephen P. Adams</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Pharmaceutical Candidate Optimization , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Stephen+P.++Adams">Stephen P. Adams</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Glenn H. Cantor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Glenn H. Cantor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development , 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Glenn+H.++Cantor">Glenn H. Cantor</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anjaneya Chimalakonda</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anjaneya Chimalakonda</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development , 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anjaneya++Chimalakonda">Anjaneya Chimalakonda</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Aberra Fura</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aberra Fura</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development , Route 206 and Province Line Road, Princeton, New Jersey 08543, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aberra++Fura">Aberra Fura</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Benjamin M. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Benjamin M. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Pharmaceutical Candidate Optimization , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin+M.++Johnson">Benjamin M. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jay O. Knipe</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jay O. Knipe</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Pharmaceutical Candidate Optimization , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jay+O.++Knipe">Jay O. Knipe</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dawn D. Parker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dawn D. Parker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Pharmaceutical Candidate Optimization , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dawn+D.++Parker">Dawn D. Parker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kenneth S. Santone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kenneth S. Santone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Pharmaceutical Candidate Optimization , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kenneth%0AS.++Santone">Kenneth S. Santone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Robert A. Fridell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Robert A. Fridell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Virology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Robert+A.++Fridell">Robert A. Fridell</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julie A. Lemm</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julie A. Lemm</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Virology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julie+A.++Lemm">Julie A. Lemm</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Donald R. O’Boyle II</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Donald R. O’Boyle, II</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Virology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Donald+R.++O%E2%80%99Boyle%2C++II">Donald R. O’Boyle, II</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Richard J. Colonno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard J. Colonno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Virology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+J.++Colonno">Richard J. Colonno</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Min Gao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Min Gao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Virology, Bristol-Myers Squibb Research and Development , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Min++Gao">Min Gao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicholas A. Meanwell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicholas A. Meanwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas%0AA.++Meanwell">Nicholas A. Meanwell</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Lawrence G. Hamann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence G. Hamann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info"> Departments of Discovery Chemistry , 5 Research Parkway, Wallingford, Connecticut 06492, United States </div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence+G.++Hamann">Lawrence G. Hamann</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401836p&amp;href=/doi/10.1021%2Fjm401836p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2013–2032</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 12, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 November 2013</li><li><span class="item_label"><b>Published</b> online</span>12 February 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 March 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401836p" title="DOI URL">https://doi.org/10.1021/jm401836p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American
Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2013%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMakonen%2BBelema%252C%2BVan%2BN.%2BNguyen%252C%2BCarol%2BBachand%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D5%26contentID%3Djm401836p%26title%3DHepatitis%2BC%2BVirus%2BNS5A%2BReplication%2BComplex%2BInhibitors%253A%2BThe%2BDiscovery%2Bof%2BDaclatasvir%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2032%26publicationDate%3DMarch%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401836p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2680</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">61</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401836p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Hepatitis C Virus NS5A Replication Complex Inhibitors: The Discovery of Daclatasvir&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Makonen&quot;,&quot;last_name&quot;:&quot;Belema&quot;},{&quot;first_name&quot;:&quot;Van&quot;,&quot;last_name&quot;:&quot;N. Nguyen&quot;},{&quot;first_name&quot;:&quot;Carol&quot;,&quot;last_name&quot;:&quot;Bachand&quot;},{&quot;first_name&quot;:&quot;Dan&quot;,&quot;last_name&quot;:&quot;H. Deon&quot;},{&quot;first_name&quot;:&quot;Jason\nT.&quot;,&quot;last_name&quot;:&quot;Goodrich&quot;},{&quot;first_name&quot;:&quot;Clint&quot;,&quot;last_name&quot;:&quot;A. James&quot;},{&quot;first_name&quot;:&quot;Rico&quot;,&quot;last_name&quot;:&quot;Lavoie&quot;},{&quot;first_name&quot;:&quot;Omar&quot;,&quot;last_name&quot;:&quot;D. Lopez&quot;},{&quot;first_name&quot;:&quot;Alain&quot;,&quot;last_name&quot;:&quot;Martel&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;L. Romine&quot;},{&quot;first_name&quot;:&quot;Edward&quot;,&quot;last_name&quot;:&quot;H. Ruediger&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;B. Snyder&quot;},{&quot;first_name&quot;:&quot;Denis&quot;,&quot;last_name&quot;:&quot;R. St. Laurent&quot;},{&quot;first_name&quot;:&quot;Fukang&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Juliang&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Henry\nS.&quot;,&quot;last_name&quot;:&quot;Wong&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;R. Langley&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;P. Adams&quot;},{&quot;first_name&quot;:&quot;Glenn&quot;,&quot;last_name&quot;:&quot;H. Cantor&quot;},{&quot;first_name&quot;:&quot;Anjaneya&quot;,&quot;last_name&quot;:&quot;Chimalakonda&quot;},{&quot;first_name&quot;:&quot;Aberra&quot;,&quot;last_name&quot;:&quot;Fura&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;M. Johnson&quot;},{&quot;first_name&quot;:&quot;Jay&quot;,&quot;last_name&quot;:&quot;O. Knipe&quot;},{&quot;first_name&quot;:&quot;Dawn&quot;,&quot;last_name&quot;:&quot;D. Parker&quot;},{&quot;first_name&quot;:&quot;Kenneth\nS.&quot;,&quot;last_name&quot;:&quot;Santone&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;A. Fridell&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;A. Lemm&quot;},{&quot;first_name&quot;:&quot;Donald&quot;,&quot;last_name&quot;:&quot;R. O’Boyle&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;J. Colonno&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Gao&quot;},{&quot;first_name&quot;:&quot;Nicholas\nA.&quot;,&quot;last_name&quot;:&quot;Meanwell&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;G. Hamann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;2013-2032&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401836p&quot;},&quot;abstract&quot;:&quot;The biphenyl derivatives 2 and 3 are prototypes of a novel class of NS5A replication complex inhibitors that demonstrate high inhibitory potency toward a panel of clinically relevant HCV strains encompassing genotypes 1–6. However, these compounds exhibit poor systemic exposure in rat pharmacokinetic studies after oral dosing. The structure–activity relationship investigations that improved the exposure properties of the parent bis-phenylimidazole chemotype, culminating in the identification of the highly potent NS5A replication complex inhibitor daclatasvir (33) are described. An element critical to success was the realization that the arylglycine cap of 2 could be replaced with an alkylglycine derivative and still maintain the high inhibitory potency of the series if accompanied with a stereoinversion, a finding that enabled a rapid optimization of exposure properties. Compound 33 had EC50 values of 50 and 9 pM toward genotype-1a and -1b replicons, respectively, and oral bioavailabilities of 38–108% in prec&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401836p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401836p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401836p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401836p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401836p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401836p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401836p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401836p&amp;href=/doi/10.1021/jm401836p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401836p" /></input><a href="/doi/pdf/10.1021/jm401836p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401836p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401836p%26sid%3Dliteratum%253Aachs%26pmid%3D24521299%26genre%3Darticle%26aulast%3DBelema%26date%3D2014%26atitle%3DHepatitis%2BC%2BVirus%2BNS5A%2BReplication%2BComplex%2BInhibitors%253A%2BThe%2BDiscovery%2Bof%2BDaclatasvir%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D5%26spage%3D2013%26epage%3D2032%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291301" title="Salts">Salts</a>,</li><li><a href="/action/doSearch?ConceptID=292234" title="Chromatography">Chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290643" title="Foams">Foams</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jmcmar.2014.57.issue-5/production/jmcmar.2014.57.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The biphenyl derivatives <b>2</b> and <b>3</b> are
prototypes of a novel class of NS5A replication complex inhibitors
that demonstrate high inhibitory potency toward a panel of clinically
relevant HCV strains encompassing genotypes 1–6. However, these
compounds exhibit poor systemic exposure in rat pharmacokinetic studies
after oral dosing. The structure–activity relationship investigations
that improved the exposure properties of the parent <i>bis</i>-phenylimidazole chemotype, culminating in the identification of
the highly potent NS5A replication complex inhibitor daclatasvir (<b>33</b>) are described. An element critical to success was the
realization that the arylglycine cap of <b>2</b> could be replaced
with an alkylglycine derivative and still maintain the high inhibitory
potency of the series if accompanied with a stereoinversion, a finding
that enabled a rapid optimization of exposure properties. Compound <b>33</b> had EC<sub>50</sub> values of 50 and 9 pM toward genotype-1a
and -1b replicons, respectively, and oral bioavailabilities of 38–108%
in preclinical species. Compound <b>33</b> provided clinical
proof-of-concept for the NS5A replication complex inhibitor class,
and regulatory approval to market it with the NS3/4A protease inhibitor
asunaprevir for the treatment of HCV genotype-1b infection has recently
been sought in Japan.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/57/5"><issue-title>HCV Therapies</issue-title></a> special issue.</p></div><div class="extra-info-sec articleNote"><h4><span></span> Note</h4><p class="last">After this paper was published ASAP
on February 12, 2014, text changes were made in last two paragraphs
of the <a class="ref internalNav" href="#sec2" aria-label="Results and Discussion">Results and Discussion</a> section. The
corrected version was reposted March 13, 2014.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87502" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87502" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The current optimal therapy for the treatment
of hepatitis C virus
(HCV) genotype-1 (GT-1) infection, the most prevalent strain, is a
combination of pegylated interferon-α and the nucleoside analogue
ribavirin in conjunction with either the nonstructural 3/4A (NS3/4A)
protease inhibitor simeprevir or the NS5B nucleotide polymerase inhibitor
sofosbuvir.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(1)</a> Although this drug regimen
improves response rates compared to therapy with pegylated interferon-α
and ribavirin alone, it is difficult to tolerate because of numerous
side effects, some of which present a significant challenge. As part
of the effort to identify direct-acting antiviral agents (DAAs) that
exhibit improved efficacy and tolerability, considerable emphasis
has been focused on inhibitors of the NS3/4A protease and the NS5B
polymerase because these enzymes are readily recapitulated in biochemical
assays that facilitate screening and evaluation of lead candidates.
However, the clinical validation of NS5A replication complex inhibitors
by daclatasvir (<b>33</b>) generated significant interest in
this target class, as reflected by the increased number of NS5A-targeting
compounds currently undergoing clinical evaluation.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(2,3)</a> Although
HCV NS5A is not associated with any enzymatic activity, various studies
indicate that this protein plays diverse but not well-defined functions
in the replication cycle of the virus.</div><div class="NLM_p last">Leads that disrupt the
function of the NS5A replication complex
were discovered using a phenotypic screen based on a GT-1b replicon
system.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(4,5)</a> We have recently disclosed the key milestones
that marked the evolution of our HCV NS5A replication complex inhibitor
program, beginning from the identification of thiazolidinone <b>1</b> as a screen hit to the elucidation of a novel and potent <i>bis</i>-phenylimidazole chemotype.<a onclick="showRef(event, 'cit5b cit5c ref7'); return false;" href="javascript:void(0);" class="ref cit5b cit5c ref7">(4b,c,6)</a> Notable issues that were addressed in this
process included chemical instability, a potential genotoxic liability,
and initial antiviral activity of limited scope toward HCV genotypes.
While the picomolar inhibitory activity of the <i>bis</i>-phenylimidazole series accomplished with two related analogues,
carbamate <b>2</b> and amine <b>3</b>, toward a broad
panel of replicon strains was attractive, their pharmacokinetic (PK)
evaluation in rats revealed poor systemic exposure following oral
dosing.<a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a> Thus, improving the PK properties
of this series while retaining the antiviral spectrum became the primary
focus of the final phase of the medicinal chemistry campaign. Herein
is described the absorption, distribution, metabolism, and excretion
(ADME) optimization effort that achieved this objective and culminated
in the identification of <b>33</b>.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45468" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45468" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">During the earlier phases of the program, the PK properties of
representative analogues from lead chemotypes with distinct structural
compositions were assessed; however, poor oral exposure was the most
frequent observation. Early indications from in vitro studies including
PAMPA permeability assays were that limited intestinal absorption,
likely because of a combination of poor intrinsic permeability, poor
pharmaceutical properties, and P-glycoprotein (P-gp) efflux, might
be playing the dominant role in hampering systemic exposure. The aqueous
solubility of carbamate <b>2</b> and amine <b>3</b>, when
assessed using amorphous material, differed considerably, with marginal
solubility (0.001 mg/mL) noted for <b>2</b> and excellent solubility
(>0.61 mg/mL) for the more basic <b>3</b>. Thus, a decision
was made to implement complementary structure–activity relationship
(SAR) optimization strategies concurrently that involved examining
both leads as part of a broader effort aimed at securing optimal exposure.
The first approach focused primarily on improving the drug-like characteristics
of the carbamate cap series, exemplified by <b>2</b>, by either
increasing its solubility and/or reducing its molecular footprint,
while the second dealt with improving the permeability properties
of the amine cap series, exemplified by <b>3</b>, through modulation
of electronic and steric parameters of the benzylic substituent (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial strategies pursued to enhance PK properties of <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As part of the initial SAR exploration, one of the phenyl
groups
of the biaryl core of <b>2</b> was replaced with six-membered
heterocyclic analogues (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). While the
introduction of polarity to the central scaffold region of <b>2</b>, as in <b>4</b>–<b>6</b>, caused variable levels
of loss in inhibitory potency toward both GT-1a (27- to 111-fold)
and GT-1b (3- to 5-fold) replicons, there was an incremental gain
in amorphous solubility when assessed in buffer at pH 6.5. In addition,
measurable PAMPA values were observed, indicative of some level of
intrinsic permeability. However, in rat PK assessments—either
a 4 h screen or a 24 h study—<b>4</b> and <b>5</b> did not exhibit measurable systemic exposure after oral dosing,
whereas <b>6</b> showed minimal plasma exposure (PO-AUC = 21
nM·h; F = 0.5%) but was not detected in either the liver or plasma
at 24 h.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(7)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Replicon
and Pharmacokinetic Assessment
of Aza-Core Analogues <b>4</b>–<b>6</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0005.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0006.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">GT-1b
CC<sub>50</sub> >10 μM.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Amorphous solubility and PAMPA values
were determined at pH 6.5 and pH 7.4, respectively.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">NC = not calculated; ND = not detected.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Reported previously in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a>.</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Null = compound was not detected
by UV plate reader in both the receiver and donor assay wells.</p></div></div><div></div></div><div class="NLM_p">It was reasoned that some degree
of molecular weight reduction
of the leads would be necessary to improve their exposure properties.
With this in mind, an SAR optimization campaign was embarked upon
to further delineate the balance that may exist between oral exposure
and potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Replacing both of the
phenylglycine caps of <b>2</b> with the unnatural enantiomer
of valine, which retained the (<i>R</i>)-stereoconfiguration
at the α-carbon, resulted in more than 40000-fold loss in GT-1a
inhibitory activity (compare <b>7</b> and <b>2</b>). A
lower but still significant loss in GT-1a inhibitory potency (410-
to 11400-fold) was also observed when one of the caps of <b>2</b> was truncated, as in <b>8</b>–<b>10</b>. It is
noteworthy that partial truncation had minimal impact on GT-1b antiviral
potency, with EC<sub>50</sub> values ≤48 pM maintained by these
analogues. Although compound <b>9</b> exhibited moderate PAMPA
permeability and some gain in amorphous solubility, it had no meaningful
exposure following oral dosing to rats. It soon became apparent from
structure–activity studies that maintaining a phenylglycine
cap at one end of the molecule and varying the alternate cap region
afforded mixed-cap analogues exhibiting GT-1a EC<sub>50</sub> values
near 100 nM but with notable improvements in PAMPA permeability compared
to the progenitor <b>2</b>. Assessment of one such analogue, <b>11</b>, in a rat PK screen indicated a marked gain in exposure
for the molecule (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Interestingly,
compound <b>12</b>, a diastereomer of <b>11</b> with similar
PAMPA permeability value, displayed a lower exposure in the rat. Compound <b>11</b> was advanced into additional rat, dog, and mouse PK studies
in order to gather information on the cross-species exposure properties
of the chemotype, and data is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. In a 24 h rat PK study, <b>11</b> exhibited low clearance,
a small volume of distribution, and a half-life of 6.9 h after IV
dosing. After oral dosing, <b>11</b> exhibited low bioavailability
(6.8%), a favorable liver/plasma ratio (26), and liver exposure at
24 h (116 nM) that is below its GT-1a EC<sub>50</sub> (138 nM). In
light of the compound’s low IV clearance, its low bioavailability
is believed to reflect incomplete absorption, attributed to P-gp efflux,
a contention supported by results from in vitro Caco-2 bidirectional
studies (<b>11</b>: A–B, <15 nm/s; B–A, 105
nm/s). Compound <b>11</b> showed higher oral bioavailability
in the mouse (17%) and dog (45%) when compared to rat (6.8%). Although
a follow-up study to probe into the reasons behind the noted differences
in oral bioavailability was not conducted, it is noteworthy that there
was evidence for enterohepatic recirculation in the mouse and dog,
which may have favorably impacted the oral bioavailability in these
species.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Replicon and PK Assessments of Cap-Truncated
Analogues <b>7</b>-<b>14</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0007.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0008.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">GT-1b CC<sub>50</sub> >10 μM
for all except <b>9</b> (>8.1 μM).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Amorphous solubility and PAMPA values
were determined at pH 6.5 and pH 7.4, respectively.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">NC = not calculated; ND = not detected.</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Reported previously in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a>.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Null = compound was not detected
by UV plate reader in both the receiver and donor assay wells.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>13</b> and <b>14</b>, the dimethyl amine
cap analogues of <b>11</b> and <b>12</b>, respectively,
were prepared and profiled in standard in vitro and rat PK studies
to gather comparative data on the two cap families in order to help
chart a path forward. These compounds exhibited improved solubility,
similar inhibitory activity in the GT-1a replicon, but lower PAMPA
permeability, when compared with their carbamate counterparts <b>11</b> and <b>12</b>, respectively. In light of the multispecies
PK data obtained for <b>11</b>, the amine cap analogue <b>13</b> was advanced directly to 24 h rat, dog, and mouse PK studies
to establish a comparative benchmark for the two versions of the phenylglycinamide
cap class. Compound <b>13</b> exhibited higher clearance and
volume of distribution in all three species and a longer half-life
in rat and mouse when compared to the carbamate counterpart <b>11</b>. After oral dosing to rats, <b>13</b> was not detected
in the plasma or liver at 24 h; however, there was measurable systemic
exposure in both the mouse and dog after PO dosing, although the absolute
levels were lower than that of <b>11</b>. Enterohepatic recirculation
was evident for <b>13</b> across species in both dosing arms,
with rising plasma levels through 24 h in some cases, which introduced
some variability to the data and complicated its interpretation. Interestingly,
in comparing the rat PO exposure of <b>11</b> to <b>14</b>, there was no correlation between exposure and the stereoconfiguration
of the tetrahydrofuran moiety, because for the carbamate cap pair <b>11</b> and <b>12</b>, the (<i>R</i>)-isomer exhibited
the better exposure, whereas for the amine cap pair <b>13</b> and <b>14</b>, it was the (<i>S</i>)-isomer that
showed higher exposure. Finally, as part of the effort to profile
lead molecules of interest for off-target liabilities, <b>11</b> and <b>13</b> were assessed in a panel of biochemical screens
conducted at a concentration of 10 μM by MDS Pharma and were
found to inhibit the binding of a radioligand to the Na<sup>+</sup> channel site-2 by 82 and 102%, respectively. In a follow-up study
conducted in-house, whole-cell patch-clamp analysis revealed that <b>11</b> and <b>13</b> inhibited Na<sup>+</sup> channel conductance
by 14 and 53%, respectively, at a concentration of 10 μM in
protein-free buffer at pH 7.4.</div><div class="NLM_p">In a concurrent effort, a complementary
SAR survey was conducted
around the second lead, amine <b>3</b>, in order to determine
the feasibility of improving its PK properties through modification
of the steric and electronic properties of the benzylic amine substituent
(Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Consistent with SAR findings disclosed
previously for the cap region when examined in the context of an anilide
chemotype, there was broad tolerance to steric bulk around the benzylic
site and that attenuation of the basicity of the amine group had a
detrimental impact on GT-1a inhibitory potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).<a onclick="showRef(event, 'cit7e'); return false;" href="javascript:void(0);" class="ref cit7e">(6e)</a> For example, in modifying
the dimethylamine moiety of <b>3</b> to a piperidine, as in <b>18</b>, the GT-1a and GT-1b inhibitory activities remained essentially
unchanged, varying by <4-fold, whereas less basic analogues, morpholine <b>19</b> and fluoro-pyrrolidine <b>20</b>, exhibited a 44-
to 101-fold diminished GT-1a antiviral activity when compared to pyrrolidine <b>17</b>. Following oral administration to rats monitored for 4
h, compounds <b>15</b>–<b>19</b> demonstrated low
plasma exposure, with AUC values ranging from 5 to 54 nM·h, although
the liver concentrations at 4 h surpassed 1.0 μM for three of
the five (<b>15</b>, <b>16</b>, and <b>18</b>) analogues.
Interestingly, although pyrrolidine <b>17</b> exhibited the
lowest PAMPA permeability value and the poorest oral exposure among
the derivatives of <b>3</b> advanced to rat PK studies, the
reason why this molecule behaves significantly different from its
close homologues <b>15</b>, <b>16</b>, and <b>18</b> is not readily apparent. A subset of the analogues were also assessed
in an IV rat PK screen and the estimated clearance ranged from 4 mL/min·kg
for <b>16</b> to 88 mL/min·kg for <b>15</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Replicon and PK Assessment of Basic
Cap Analogues <b>15</b>–<b>22</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0009.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0010.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Compound <b>20</b> and <b>21</b> are
symmetrical diastereomers but with unknown stereochemistry
at their benzylic center [i.e., either (<i>R</i>/<i>R</i>) or (<i>S</i>/<i>S</i>)], whereas
the remaining compounds have (<i>R</i>/<i>R</i>)-stereoconfiguration. Compound <b>22</b> is a mixed-cap analogue.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Amorphous solubility and PAMPA
values
were determined at pH 6.5 and pH 7.4, respectively.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">NC = not calculated; ND = not detected
with the exception that one plasma sample obtained for <b>3</b> at 0.17 h indicated 20 nM concentration.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Estimated clearance (mL/min·kg)
from 4 h IV rat PK screen (2 mg/kg dose; <i>n</i> = 2): <b>3</b> (17), <b>15</b> (88), <b>16</b> (4), <b>18</b> (58).</p></div><div class="footnote" id="t3fn5"><sup><sup>e</sup></sup><p class="last">Reported previously
in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a>.</p></div><div class="footnote" id="t3fn6"><sup><sup>f</sup></sup><p class="last">Null = compound was not detected
by UV plate reader in both the receiver and donor assay wells.</p></div></div><div></div></div><div class="NLM_p">For <b>15</b>, <b>16</b>, and <b>18</b>, the
observed 4 h PO-liver exposure would provide more than a 25000-fold
multiple over their GT-1a replicon EC<sub>50</sub> values, which was
much higher than that of compound <b>11</b>, 19-fold at 4 h.
While the high exposure multiple achieved after oral dosing by the
potent amine cap analogues in the targeted tissue was encouraging,
their plasma 4 h AUC was >10-fold lower when compared with that
of <b>11</b>. To gain additional insight into the PK properties
of this
series, <b>18</b> was advanced into more detailed 24 h rat and
dog PK studies (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Compound <b>18</b> exhibited high clearance, a high
volume of distribution, and a prolonged half-life in rats following
IV dosing. After oral dosing, the compound was barely detectable in
the plasma through 24 h, and only 1 of 3 rats exhibited liver exposure
(318 nM) at 24 h. In dog PK studies, <b>18</b> showed moderate
to high clearance, a high volume of distribution, a long half-life
after IV dosing, and an oral bioavailability of 14%. As was the case
for mixed-cap analogues <b>11</b> and <b>13</b> discussed
earlier, the homodimeric analogue <b>18</b> exhibited better
exposure in dogs than rats. It appears that oral exposure in rats
for <b>18</b> was subject to considerable variability, a concern
from developability perspective, but the likely cause for this observation
was not investigated.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Assessment of <b>11</b>, <b>13</b>, and <b>18</b> in Rats, Dogs, and/or
Mouse<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a><sup>,</sup><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="left" /></col><col align="center" char="." /></col><col align="center" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center" char="."> </th><th class="rowsep1 colsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">
									IV (24 h)</th><th class="rowsep1 colsep0" colspan="4" align="center">
									PO (24 h)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">
									compd</th><th class="colsep0 rowsep0" align="center">
									animal</th><th class="colsep0 rowsep0" align="center" char=".">
									CL (mL/min·kg)
								</th><th class="colsep0 rowsep0" align="center" char=".">
									Vd (L/kg)
								</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center">
									AUC (nM·h)
								</th><th class="colsep0 rowsep0" align="center">
									
									L-24 h (nM)</th><th class="colsep0 rowsep0" align="center">
									
									P-24 h (nM)</th><th class="colsep0 rowsep0" align="center">
									
									% <i>F</i>          
								</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="char" char="."><b>11</b></td><td class="colsep0 rowsep0" align="left">
									rat</td><td class="colsep0 rowsep0" align="center" char=".">
									4.4</td><td class="colsep0 rowsep0" align="center" char=".">
									0.3</td><td class="colsep0 rowsep0" align="center">
									6.9</td><td class="colsep0 rowsep0" align="center">
									1830</td><td class="colsep0 rowsep0" align="center">
									116</td><td class="colsep0 rowsep0" align="center">
									4.5</td><td class="colsep0 rowsep0" align="center">
									6.8%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									dog</td><td class="colsep0 rowsep0" align="center" char=".">
									22</td><td class="colsep0 rowsep0" align="center" char=".">
									7.5</td><td class="colsep0 rowsep0" align="center">
									>10</td><td class="colsep0 rowsep0" align="center">
									1520</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">
									6.0</td><td class="colsep0 rowsep0" align="center">
									45%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									mouse</td><td class="colsep0 rowsep0" align="center" char=".">
									5.3</td><td class="colsep0 rowsep0" align="center" char=".">
									1.9</td><td class="colsep0 rowsep0" align="center">
									2.9</td><td class="colsep0 rowsep0" align="center">
									15100</td><td class="colsep0 rowsep0" align="center">
									253</td><td class="colsep0 rowsep0" align="center">
									59</td><td class="colsep0 rowsep0" align="center">
									17%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="char" char="."><b>13</b></td><td class="colsep0 rowsep0" align="left">
									rat</td><td class="colsep0 rowsep0" align="center" char=".">
									57</td><td class="colsep0 rowsep0" align="center" char=".">
									60</td><td class="colsep0 rowsep0" align="center">
									14</td><td class="colsep0 rowsep0" align="center">
									NC</td><td class="colsep0 rowsep0" align="center">
									ND</td><td class="colsep0 rowsep0" align="center">
									ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									dog</td><td class="colsep0 rowsep0" align="center" char=".">
									102</td><td class="colsep0 rowsep0" align="center" char=".">
									82</td><td class="colsep0 rowsep0" align="center">
									
									NC<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a>          
								</td><td class="colsep0 rowsep0" align="center">
									436</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">
									30</td><td class="colsep0 rowsep0" align="center">
									60%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									mouse</td><td class="colsep0 rowsep0" align="center" char=".">
									18</td><td class="colsep0 rowsep0" align="center" char=".">
									14</td><td class="colsep0 rowsep0" align="center">
									7.8</td><td class="colsep0 rowsep0" align="center">
									1422</td><td class="colsep0 rowsep0" align="center">
									539</td><td class="colsep0 rowsep0" align="center">
									25</td><td class="colsep0 rowsep0" align="center">
									6.0%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char="."><b>18</b></td><td class="colsep0 rowsep0" align="left">
									rat</td><td class="colsep0 rowsep0" align="center" char=".">
									63</td><td class="colsep0 rowsep0" align="center" char=".">
									20</td><td class="colsep0 rowsep0" align="center">
									7.7</td><td class="colsep0 rowsep0" align="center">
									NC</td><td class="colsep0 rowsep0" align="center">
									
									ND<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a>          
								</td><td class="colsep0 rowsep0" align="center">
									ND</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									dog</td><td class="colsep0 rowsep0" align="center" char=".">
									28</td><td class="colsep0 rowsep0" align="center" char=".">
									10</td><td class="colsep0 rowsep0" align="center">
									>12</td><td class="colsep0 rowsep0" align="center">
									272</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">
									8.3</td><td class="colsep0 rowsep0" align="center">
									14%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Respective
IV/PO dosing levels:
rat (2/5 mg/kg), dog (1/3 mg/kg), mouse (5/20 mg/kg). Number of animals
per dosing group: rat (<i>n</i> = 3), dog (<i>n</i> = 2), mouse (<i>n</i> = 9; composite design). Vehicle:
PEG-400 for mouse-IV/PO, rat-IV/PO, and dog-PO; PEG-400/water (9:1)
for dog-IV.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">NC = not calculated;
ND = not detected.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last"><i>t</i><sub>1/2</sub> could not be calculated because of a rise
in plasma level through
24 h.</p></div><div class="footnote" id="t4fn4"><sup><sup>d</sup></sup><p class="last">Only 1 of 3 rats had
a detectable
level (318 nM).</p></div></div></div><div class="NLM_p">Compound <b>18</b> was characterized further in a select
panel of in vitro assays designed to gather additional information
about the potential off-target liabilities of analogues containing
basic phenylglycine caps. In whole-cell patch-clamp assays, performed
at a concentration of 10 μM, <b>18</b> inhibited Na<sup>+</sup>, hERG, and Ca<sup>2+</sup> channels by 94, 82, and 69%, respectively.
While no glutathione (GSH) conjugate was detected following incubation
of <b>18</b> with GSH-supplemented human and rat liver microsomes,
a cyanide adduct was detected when KCN was used in place of GSH, an
indication for the formation of a reactive metabolite. It is noteworthy
that the mixed-cap analogue <b>22</b> exhibited cyanide addition
only to the piperidine cap portion when subjected to a similar bioactivation
study, an indication that related basic cap analogues may have differentiated
liabilities.</div><div class="NLM_p">There were a number of important findings from
the in vitro and
PK studies discussed above that proved instrumental in formulating
an end-game strategy in search of a candidate exhibiting optimal virology,
ADME, and safety properties. First, it was demonstrated that reduction
of the overall molecular size of leads <b>2</b> and <b>3</b>, as in <b>11, 12</b>, and <b>14</b>, significantly enhanced
oral exposure. Moreover, both carbamate <b>12</b> and amine <b>14</b> exhibited exposure in a rat PK screen following oral solution
dosing that were within 2-fold of each other, although the potential
advantage that the relatively more soluble <b>14</b> may have
under nonsolution dosing by, for example, minimizing the likelihood
of dissolution-rate limited absorption, was not investigated. In the
case of the homodimeric amine cap series, although the liver exposure
was favorably impacted by increases in lipophilicity, plasma exposure
was low and variable. Second, a limited correlation was established
between PAMPA permeability and oral exposure in rat PK screen for
the chemotype. In addition, it was observed that rat was a more stringent
PK model to guide the SAR evolution because the compounds that were
advanced into dog and/or mouse PK studies hitherto (i.e., <b>11</b>, <b>13</b>, and <b>18</b>) demonstrated relatively enhanced
oral bioavailabilities in those species. Finally, preliminary in vitro
safety assessments revealed that analogues containing amine-based
caps may possess increased liability for ion channel inhibition. Taken
together, the carbamate series emerged as the more attractive class
for additional optimization where a combination of PAMPA and rat PK
screening were deemed sufficient to gauge progress toward compounds
with targeted exposure. The key outstanding issue that needed to be
addressed at this juncture was how to regain the significant (>4900-fold)
GT-1a inhibitory potency that was lost in pursuit of improved PK properties
in analogues such as <b>11</b>.</div><div class="NLM_p">The next phase of the
SAR exploration focused around carbamate <b>9</b> and the small
set of related analogues <b>23</b>–<b>25</b> that
were prepared as part of the initial cap truncation
exercise (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). While acetamides <b>23</b>–<b>25</b> had similar inhibitory potency toward
GT-1a or GT-1b replicon, the introduction of a methyl group with the
(<i>S</i>)-stereoconfiguration appeared to have impacted
the PAMPA permeability favorably (compare <b>23</b> and <b>25</b>). Because carbamate <b>9</b> was among the most potent
GT-1a inhibitors, EC<sub>50</sub> of 12 nM, within the cap-truncated
analogues examined hitherto, its (<i>S</i>)-alanine variant
was prepared in anticipation of enhanced PAMPA permeability. While
changing the glycine cap of <b>9</b> to the (<i>S</i>)-alanine cap of <b>26</b> had the expected favorable impact
on PAMPA permeability, this modification was also associated with
a 100-fold enhancement of potency toward the GT-1a replicon, unanticipated
based on the SAR that had been developed to date. Because it had been
demonstrated previously that the GT-1a antiviral potency of mixed-cap
analogues resided between that of the respective homodimeric cap analogues,
the gain in the GT-1a inhibitory potency with <b>26</b> strongly
suggested that the corresponding (<i>S</i>)-alanine cap
homodimer would be very potent toward a GT-1a replicon, which indeed
was the case (<b>27</b>: GT-1a EC<sub>50</sub> = 0.282 nM).<a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a> Notably, and in line with the activity of <i>bis</i>-(<i>R</i>)-valine cap analogue <b>7</b> discussed earlier, the <i>bis</i>-(<i>R</i>)-alanine
cap analogue <b>28</b> was >2000-fold weaker than its diastereomer <b>27</b> toward the GT-1a replicon. This result brought into clear
focus a difference in stereochemical requirements at the α-carbon
between the phenylglycine and the alkylglycine cap derivatives. Moreover,
this finding demonstrated that the initial assumption made in retaining
the (<i>R</i>)-stereoconfiguration during the cap truncation
exercise while going from <i>bis</i>-(<i>R</i>)-phenylglycine analogue <b>2</b> to <i>bis</i>-(<i>R</i>)-valine analogue <b>7</b>, although reasonable based
on extant SAR, was incorrect.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(8)</a></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Replicon and PK Assessment of Non-Basic
Cap-Truncated Analogues <b>23</b>–<b>31</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0011.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0012.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">GT-1b
CC<sub>50</sub> >10 μM
for all except <b>9</b> (>8.1 μM).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Amorphous solubility and PAMPA values
were determined at pH 6.5 and pH 7.4, respectively.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">NC = not calculated; ND = not detected.</p></div></div><div></div></div><div class="NLM_p">Securing subnanomolar GT-1a
inhibitory potency in the alkylglycine
cap series through stereochemical inversion was a critical milestone
for the program because it allowed a reduction in the molecular size
of the cap moiety and in the aromatic composition of the chemotype,
translating into improved aqueous solubility and rat oral exposure
(compare <b>27</b> vs <b>2</b>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(9)</a> The follow-up effort focused on this new cap series in order to
further enhance its exposure properties. Whereas the modifications
illustrated in analogues <b>29</b>–<b>31</b> were
detrimental to both GT-1a and GT-1b antiviral activity, incorporation
of other aliphatic moieties at the α-carbon favorably impacted
potency and/or PK, with compound <b>33</b> exhibiting the best
combination of replicon potency and oral exposure in the rat PK screen
among related analogues prepared in this final iteration of SAR study
(Tables <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a> and <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Removal
of the H-bond-donating capability of the carbamate moiety of <b>33</b>, as in <b>36</b>, caused a significant reduction
in GT-1a inhibitory potency while having minimal impact on the antiviral
effect in a GT-1b replicon. In addition, replacing the carbamate moiety
of <b>33</b> with an acetamide, as in <b>37</b>, which
retains H-bonding capability, was also detrimental to antiviral activity.
Despite the apparent similarity in the carbamate pharmacophoric elements
of the potent (<i>S</i>)-alkyl- and (<i>R</i>)-phenyl-glycine
cap classes, their stereochemical disparity suggests that the respective
carbamate moieties may engage the NS5A proteins in subtly different
fashions.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Replicon and PK Assessment of Advanced
Analogues <b>32</b>–<b>41</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0013.gif" alt="" id="fx9" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0014.gif" alt="" id="fx10" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">GT-1b
CC<sub>50</sub> >10 μM
for all.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Amorphous solubility
and PAMPA values
were determined at pH 6.5 and pH 7.4, respectively.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last">Virology data reported previously
in ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a>.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last">NA = not available. In 24 h rat
PK study (IV/PO: 2/5 mg/kg; <i>n</i> = 3) <b>40</b> showed an oral bioavailability of 4.3%. Following oral dosing, it
had a plasma AUC of 106 nM·h and a 24 h liver level of 132 nM,
whereas it was not detected in the plasma at 24 h.</p></div></div><div></div></div><div class="NLM_p">In a parallel effort directed toward
identifying alternate, structurally
differentiated candidates with enhanced pharmaceutical properties,
a select group of (<i>S</i>)-alkylglycine cap derivatives
was hybridized with (<i>R</i>)-<i>N</i>,<i>N</i>-diethylphenylglycine to afford the mixed-cap analogues <b>39</b>–<b>41</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).
This basic glycinamide cap was chosen over alternate variants (i.e.,
caps of <b>15</b> and <b>18</b>) because it demonstrated
improved properties in earlier studies, including a lower estimated
clearance in the rat IV PK screen and a decreased liability for bioactivation
in an in vitro assay (see Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> and earlier
discussions). Though the replicon potencies of <b>39</b>–<b>41</b> were comparable to that of homodimer <b>16</b>, the
improvement in oral plasma exposure with <b>39</b> and <b>41</b> in a 4 h rat PK screen was more limited than was the case
for <b>33</b>. Nevertheless, based on the preliminary virology
profile and rat PK screen assessment results, <b>39</b> was
selected for additional characterization along with <i>bis</i>-(<i>S</i>)-valine cap analogue <b>33</b>.</div><div class="NLM_p">Compounds <b>33</b> and <b>39</b> exhibited potent
inhibitory activities toward a broad panel of HCV genotypes, although <b>39</b> was more potent than <b>33</b> toward GT-2a and GT-3a
strains (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).<a onclick="showRef(event, 'ref3 ref11'); return false;" href="javascript:void(0);" class="ref ref3 ref11">(2,10)</a> Compound <b>39</b> inhibited Na<sup>+</sup> and hERG channels in patch-clamp
assays to a greater extent than <b>33</b>. In rat, dog, and
cynomolgus monkey PK studies, <b>33</b> demonstrated higher
oral bioavailabilities, <i>F</i> = 38–108%, compared
to <b>39</b>, <i>F</i> = 3.6–66%, and enhanced
oral plasma exposure (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). In order to
further differentiate the two compounds, they were examined in a 4
day mouse toxicology study where male and female animals were administered
doses of 15, 50, and 100 mg/kg orally on a QD regimen. Both compounds
were well-tolerated, and there were no significant exposure differences
between the genders. However, the 0–24 h plasma AUC and liver
and heart exposures of <b>39</b>, sampled at 8 and 24 h, approximately
doubled between day 1 and day 4 at each dose level while remaining
unchanged, or slightly decreasing, for <b>33</b>. Based on these
findings, <b>33</b> was deemed the preferred compound, and it
was advanced through additional ADME characterization studies and
an extensive array of standard in vitro and in vivo off-target liability
assessments, including extended multispecies toxicology. The results
of these studies supported its advancement into clinical trials.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(11)</a></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Replicon and off-Target
Liability
Assessment of <b>33</b> and <b>39</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" colspan="2" align="center">
									compd</th><th class="colsep0 rowsep0" align="center">
									
									           <b>33</b>           <a class="ref internalNav" href="#t7fn2" aria-label="b">b</a>          
								</th><th class="colsep0 rowsep0" align="center"><b>39</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="8" align="left">
									EC<sub>50</sub> (nM)</td><td class="colsep0 rowsep0" align="left">
									
									GT-2a JFH-1
								</td><td class="colsep0 rowsep0" align="center">
									0.071</td><td class="colsep0 rowsep0" align="center">
									0.020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-2a J6
								</td><td class="colsep0 rowsep0" align="center">
									7.5</td><td class="colsep0 rowsep0" align="center">
									0.99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-3a
								</td><td class="colsep0 rowsep0" align="center">
									0.146</td><td class="colsep0 rowsep0" align="center">
									0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-3a YH
								</td><td class="colsep0 rowsep0" align="center">
									364</td><td class="colsep0 rowsep0" align="center">
									59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-3a YH*
								</td><td class="colsep0 rowsep0" align="center">
									1451</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-4a
								</td><td class="colsep0 rowsep0" align="center">
									0.012</td><td class="colsep0 rowsep0" align="center">
									0.014</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-5a
								</td><td class="colsep0 rowsep0" align="center">
									0.033</td><td class="colsep0 rowsep0" align="center">
									0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									GT-6
								</td><td class="colsep0 rowsep0" align="center">
									0.054</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">
									
									% inhibition of Na<sup>+</sup> channel
at 10 μM
								</td><td class="colsep0 rowsep0" align="center">
									51%</td><td class="colsep0 rowsep0" align="center">
									62%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="2" align="left">
									
									hERG IC<sub>50</sub> (μM)
								</td><td class="colsep0 rowsep0" align="center">
									29.2</td><td class="colsep0 rowsep0" align="center">
									9.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Except
for GT-2a JFH-1, all are
hybrid replicons in either GT-2a JFH-1 or GT-1b Con1 backbone: GT-2a
J6 (JFH-1); GT-3a or GT-3a YH (Con1); GT-3a YH* (JFH-1); GT-4a (Con1);
GT-5a (JFH-1); GT-6a (JFH-1).</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">A subset of the replicon data of <b>33</b> has been reported
previously in refs <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a> and <a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(10)</a>.</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Multispecies Oral
24 h PK Assessment
of <b>33</b> and <b>39</b><a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="center" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="%" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">
									compd</th><th class="colsep0 rowsep0" align="center">
									animals</th><th class="colsep0 rowsep0" align="center" char=".">
									dose level (mg/kg)
								</th><th class="colsep0 rowsep0" align="center" char=".">
									
									AUC
									 (μM·h)
								</th><th class="colsep0 rowsep0" align="center">
									
									P-24h (nM)</th><th class="colsep0 rowsep0" align="center" char=".">
									
									L-24h (nM)</th><th class="colsep0 rowsep0" align="center" char="%">
									
									% <i>F</i>          
								</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">
									rat</td><td class="colsep0 rowsep0" align="char" char=".">
									5.0</td><td class="colsep0 rowsep0" align="center" char=".">
									4.8</td><td class="colsep0 rowsep0" align="center">
									18</td><td class="colsep0 rowsep0" align="char" char=".">
									
									103<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a>          
								</td><td class="colsep0 rowsep0" align="char" char="%">
									50%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									dog</td><td class="colsep0 rowsep0" align="char" char=".">
									2.3</td><td class="colsep0 rowsep0" align="center" char=".">
									11</td><td class="colsep0 rowsep0" align="center">
									26</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="%">
									108%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									monkey</td><td class="colsep0 rowsep0" align="char" char=".">
									2.8</td><td class="colsep0 rowsep0" align="center" char=".">
									1.93</td><td class="colsep0 rowsep0" align="center">
									6.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="%">
									38%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">
									rat</td><td class="colsep0 rowsep0" align="char" char=".">
									5.0</td><td class="colsep0 rowsep0" align="center" char=".">
									0.165</td><td class="colsep0 rowsep0" align="center">
									
									ND<a class="ref internalNav" href="#t8fn3" aria-label="c">c</a>          
								</td><td class="colsep0 rowsep0" align="char" char=".">
									178</td><td class="colsep0 rowsep0" align="char" char="%">
									3.6%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									dog</td><td class="colsep0 rowsep0" align="char" char=".">
									3.5</td><td class="colsep0 rowsep0" align="center" char=".">
									1.2</td><td class="colsep0 rowsep0" align="center">
									9.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="%">
									66%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									monkey</td><td class="colsep0 rowsep0" align="char" char=".">
									3.0</td><td class="colsep0 rowsep0" align="center" char=".">
									0.497</td><td class="colsep0 rowsep0" align="center">
									4.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="%">
									20.9%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Number
of animals: rat (3), dog
(2), monkey (3). See the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details on vehicles.</p></div><div class="footnote" id="t8fn2"><sup><sup>b</sup></sup><p class="last">L-24 h data is an average of 2 values
since <b>33</b> was not detected in the liver of 1 of 3 rats.</p></div><div class="footnote" id="t8fn3"><sup><sup>c</sup></sup><p class="last">ND = not detected.</p></div></div></div><div class="NLM_p">Compound <b>33</b> was safe
and well-tolerated when dosed
as a solution at 1 to 200 mg to healthy volunteers in a placebo-controlled,
double-blind phase I clinical study.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a> Plasma
exposure above the protein-binding adjusted GT-1a EC<sub>90</sub> of
0.38 nM was observed at all doses through 24 h. In single-ascending
dose studies conducted in HCV-infected subjects, doses of 1, 10 and
100 mg of <b>33</b> were associated with a mean 1.8, 3.2, and
3.3 log<sub>10</sub> reduction in viral RNA, respectively, measured
24 h post administration. The viral decline was more pronounced in
two GT-1b-infected subjects that received the 100 mg dose, and, most
notably, one of these subjects attained a viral titer below 25 IU/mL,
the lower limit of quantification for the study. This rate and extent
of decline of plasma HCV RNA following a single oral administration
of a small molecule was unprecedented in the field of HCV therapeutics
and provided clinical proof-of-concept for the efficacy of HCV NS5A
replication complex inhibitors. In a 14 day multiple-ascending dose
study, though a mean maximum decline in viral titer of 2.8 to 4.1
log<sub>10</sub> was observed in subjects receiving doses of 1 to
100 mg QD or 30 mg BID of <b>33</b>, viral breakthrough occurred
during treatment, indicating that the compound has a low genetic barrier
to resistance.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(12)</a> The amino acid changes
associated with the resistance correlated with those observed in the
in vitro replicon assay. In this study, the antiviral response was
relatively more pronounced in GT-1b- than GT-1a-infected subjects,
where 4 of 7 GT-1b-infected subjects compared to none of the 17 GT-1a-infected
subjects attained viral titers below 25 IU/mL at day 14.</div><div class="NLM_p last">Compound <b>33</b> is currently in phase II and III clinical
trials in combination with other DAA agents targeting the orthogonal
mechanism(s) and/or pegylated-interferon-α/ribavirin regimens.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(13,14)</a> A noteworthy finding from these studies is the demonstration that
24 weeks of therapy with a combination of <b>33</b> (60 mg QD)
and the NS3/4A inhibitor asunaprevir (600 mg BID) was associated with
a sustained viral response 24 weeks after cessation of therapy (SVR<sub>24</sub>) of 36%, providing the first demonstration that HCV infection
can be cured by a drug regimen that is free of pegylated-interferon-α
and ribavirin.<a onclick="showRef(event, 'cit14a'); return false;" href="javascript:void(0);" class="ref cit14a">(13a)</a> A dual DAA combination
therapy involving <b>33</b> and asunaprevir for the treatment
of GT-1b interferon-ineligible/-intolerant subjects or those that
are nonresponders to interferon/ribavirin therapy has completed phase
III studies. A request to market <b>33</b> and asunaprevir was
filed with the Japanese regulatory agency in October 2013. In addition,
a triple DAA combination of <b>33</b>, asunaprevir, and the
NS5B polymerase inhibitor BMS-791325 is currently undergoing phase
II evaluation for the treatment of HCV GT-1a/1b-infected subjects,
with encouraging preliminary results.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(15)</a> In addition to the evolving clinical impact that <b>33</b> has been demonstrating in the HCV field, it has also served as a
tool compound in a number of mode-of-action studies directed at deciphering
the NS5A protein’s various functions, an effort that has also
shed some light on likely reasons behind the high inhibitory potency
associated with the NS5A-targeting class of compounds.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(16)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">CHEMISTRY</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54854" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54854" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Final compounds were readily
prepared according to the synthetic
routes highlighted in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a>–<a class="ref internalNav" href="#sch3" aria-label="3">3</a>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(17)</a> In the case of aza-core
analogues <b>4</b>–<b>6</b>, key synthetic fragments <b>48a</b>, <b>48c</b>, and <b>52b</b> were initially
assembled as illustrated in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. Bromination
of ketone <b>42</b>, followed by alkylation with Boc-<span class="smallcaps smallerCapital">l</span>-proline and cyclization of the resultant ketoester <b>44</b> provided bromopyridine <b>48a</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(18)</a> Regioselective lithiation of dibromopyridine <b>45a</b> followed
by condensation with a Weinreb reagent furnished carbamate <b>46a</b>, which was elaborated to <b>48b</b> via the intermediacy of
ketoamide <b>47</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(19)</a> Bromoketone <b>50</b>, prepared from <b>45b</b> through a combination of
a Stille coupling and in situ bromination, was elaborated to chloropyrimidine <b>52a</b> via ketoester <b>51</b>. Whereas <b>48a</b> was coupled with boronate <b>53</b> under standard Suzuki-Miyaura
condition to provide <b>54a</b>, applying a similar condition
to <b>48b</b> or <b>52a</b> was not successful (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). However, protection of their imidazole moiety
with SEM ether, as in <b>48c</b> and <b>52b</b>, facilitated
the Suzuki-Miyaura coupling. It is noteworthy that the regiochemistry
of the SEM ethers was not determined. Acid-catalyzed deprotection
of intermediates <b>54a</b>, <b>55a</b>, and <b>56a</b>, followed by coupling of the resultant pyrrolidines with (2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid under
standard HATU/DIEA condition provided final products <b>4</b>–<b>6</b> (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). Homodimeric
and mixed-cap analogues of the <i>bis</i>-phenylimidazole
template were prepared from <b>57a</b> and <b>57b</b>,
respectively, according to general routes described previously (see
Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).<a onclick="showRef(event, 'ref3 cit7f'); return false;" href="javascript:void(0);" class="ref ref3 cit7f">(2,6f)</a> The majority of the cap moieties used for the final step were prepared
readily from commercially available precursors through adaptation
of literature protocols.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(17)</a> For a subset
of the cases, such as compounds <b>11</b>–<b>14</b>, the cap precursors were obtained from vendors.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>48a</b>, <b>48c</b>,
and <b>52b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a)
Br<sub>2</sub>, HBr, CH<sub>2</sub>Cl<sub>2</sub>; (b) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-proline, Et<sub>3</sub>N, CH<sub>3</sub>CN; (c) NH<sub>4</sub>OAc, xylenes, 140 °C; (d) <i>n</i>-BuLi, <i>t</i>-butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate; −78
°C to −15 °C; (e) 48% HBr, dioxane; (f) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-proline, HATU, DIEA, DMF; (g) NaH, SEM-Cl, DMF; (h)
tributyl(1-ethoxyvinyl)tin, PdCl<sub>2</sub>(Ph<sub>3</sub>P)<sub>2</sub>, DMF, 100 °C; (i) NBS, H<sub>2</sub>O/THF, 0 °C.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Aza-Core Analogues <b>4</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a)
Pd(Ph<sub>3</sub>P)<sub>4</sub>, NaHCO<sub>3</sub>, DME/H<sub>2</sub>O, 90 °C; (b) 25% TFA/CH<sub>2</sub>Cl<sub>2</sub>; (c) (2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid, HATU,
DIEA, DMF; (d) Pd(Ph<sub>3</sub>P)<sub>4</sub>, NaHCO<sub>3</sub>,
DME/H<sub>2</sub>O, 80 °C.</p></p></figure><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Homodimeric
and Mixed-Cap Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions:
(a)
R<sub>1</sub>CO<sub>2</sub>H, HATU, DIEA, DMF; (b) 25% TFA/CH<sub>2</sub>Cl<sub>2</sub> or 4 N HCl/dioxane; (c) R<sub>2</sub>CO<sub>2</sub>H, HATU, DIEA, DMF.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81304" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81304" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In
summary, distinct strategies were implemented toward enhancing
the oral exposure of two lead series of the <i>bis</i>-phenylimidazole
class of HCV NS5A replication complex inhibitor, represented by the
carbamate cap analogue <b>2</b> and the amine cap analogue <b>3</b>. Although the application of different approaches favorably
impacted the oral exposure properties of both series to varying degrees,
the more promising PK findings resulted from a cap-truncation exercise
that was performed in the context of <b>2</b>. The mixed-cap
analogue <b>11</b> emerged from this approach as a molecule
with improved PK, but the structural modification unfortunately resulted
in >4900-fold loss in GT-1a inhibitory potency. It was the combination
of PAMPA permeability and 4 h rat PK screen studies that guided additional
SAR exploration toward achieving balanced virology and oral exposure
properties. An unexpected finding with respect to the stereochemical
requirement of the two carbamate cap series was uncovered that provided
the opportunity to replace the arylglycine cap of <b>2</b> with
an alkylglycine analog, enabling the identification of <b>33</b>. Notable direct-acting antiviral therapies in clinical development
nearing fruition contain NS5A replication complex inhibitors.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">EXPERIMENTAL SECTION<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(21)</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74038" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74038" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Reactions were conducted, purified, and analyzed according
to methods
widely practiced in the field, while taking necessary precautions
in the exclusion of moisture and/or oxygen where appropriate. Final
compounds were tested as either TFA salts or free base. Although,
where relevant, the exact TFA content was not determined, its mole
equivalent was assumed to be equal to the number of basic moieties
residing in the molecule for purposes of yield and EC<sub>50</sub> calculations. LC/MS analyses were performed on a Shimadzu LC instrument
coupled to a Waters Micromass ZQ instrument or Waters 2795 HPLC with
Micromass ZQ MS (electrospray probe) and Waters 996 PDA detection.
All tested compounds exhibited >95% purity under the LC conditions
provided in Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>. HRMS analyses were conducted
on a Thermo Scientific Finnegan MAT900 or Fourier Transform Orbitrap
spectrometers, calibrated daily. NMR spectra were recorded on a Bruker
Ultrashield 400 MHz spectrometer or on a Bruker Advance-III 500 MHz
spectrometer, each equipped with a 5 mm TXI cryoprobe. Residual protio-solvent
was used as internal standard for chemical shift assignments. Coupling
constants are provided in Hz, with the following spectral pattern
designations: s, singlet; d, doublet; t, triplet; q, quartet; quint,
quintet; dd, doublet of doublets; dt, doublet of triplets; m, multiplet;
br, broad; app, apparent. <sup>1</sup>H NMR analyses of most intermediates
and final products in DMSO-<i>d</i><sub>6</sub> at ambient
temperature indicated the presence of rotamers and/or tautomers and
that the chemical shift provided is for the dominant rotamer(s) and/or
tautomer(s).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. LC/MS Conditions for the Characterization
of Final Products</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">
									method</th><th class="colsep0 rowsep0" align="center" char=".">
									columns</th><th class="colsep0 rowsep0" align="center">
									gradient
and run time</th><th class="colsep0 rowsep0" align="center" char=".">
									flow rate (mL/min)
								</th><th class="colsep0 rowsep0" align="center" char=".">
									
									solvent A
								</th><th class="colsep0 rowsep0" align="center" char=".">
									
									solvent B
								</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									1</td><td class="colsep0 rowsep0" align="char" char=".">
									1</td><td class="colsep0 rowsep0" align="left">
									
									10–100% B; 70 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.35</td><td class="colsep0 rowsep0" align="char" char=".">
									A1</td><td class="colsep0 rowsep0" align="char" char=".">
									B1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									2</td><td class="colsep0 rowsep0" align="char" char=".">
									2</td><td class="colsep0 rowsep0" align="left">
									
									10–100% B; 70 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.4</td><td class="colsep0 rowsep0" align="char" char=".">
									A2</td><td class="colsep0 rowsep0" align="char" char=".">
									B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									3</td><td class="colsep0 rowsep0" align="char" char=".">
									1</td><td class="colsep0 rowsep0" align="left">
									
									10–100% B; 70 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.3</td><td class="colsep0 rowsep0" align="char" char=".">
									A1</td><td class="colsep0 rowsep0" align="char" char=".">
									B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									4</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									3</td><td class="colsep0 rowsep0" align="left">
									
									10–50% B; 40 min
								</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									0.3</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									A2</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									50–100% B; 40–70 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									5</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="left">
									
									10–100% B; 70 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.4</td><td class="colsep0 rowsep0" align="char" char=".">
									A1</td><td class="colsep0 rowsep0" align="char" char=".">
									B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									6</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									5</td><td class="colsep0 rowsep0" align="left">
									
									10–50% B; 25 min
								</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									0.5</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									A1</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">
									B2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">
									
									50–100% B; 25–32 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									7</td><td class="colsep0 rowsep0" align="char" char=".">
									6</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 3 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									8</td><td class="colsep0 rowsep0" align="char" char=".">
									7</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 3 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									9</td><td class="colsep0 rowsep0" align="char" char=".">
									7</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 2 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									10</td><td class="colsep0 rowsep0" align="char" char=".">
									8</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 2 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="char" char=".">
									A4</td><td class="colsep0 rowsep0" align="char" char=".">
									B4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									11</td><td class="colsep0 rowsep0" align="char" char=".">
									9</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 4 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.8</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									12</td><td class="colsep0 rowsep0" align="char" char=".">
									10</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 4 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									0.8</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">
									13</td><td class="colsep0 rowsep0" align="char" char=".">
									6</td><td class="colsep0 rowsep0" align="left">
									
									0–100% B; 4 min
								</td><td class="colsep0 rowsep0" align="char" char=".">
									4</td><td class="colsep0 rowsep0" align="char" char=".">
									A3</td><td class="colsep0 rowsep0" align="char" char=".">
									B3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><p class="first last">Columns: column 1: Waters
Atlantis C18 (2.1 ×
150 mm, 3.5 μm); column 2: Agilent Zorbax Extend C18 (2.0 ×
150 mm, 5 μm); column 3: Agilent Zorbax Extend C18 (2.1 ×
150 mm, 3.5 μm); column 4: Waters Sunfire C18 (2.1 × 150
mm, 3.5 μm); column 5: Acquity UPLC BEH C18 (2.1 × 100
mm, 1.7 μm); column 6: Phenomenex-Luna C18 (4.6 × 50 mm,
S10); column 7: Phenomenex Luna C18 (3.0 × 50 mm, S10); column
8: Primesphere C18-HC (4.6 × 30 mm); column 9: Phenomenex-Luna
C18 (2.0 × 50 mm, 3 μm); column 10: Xbridge Phenyl (2.1 ×
50 mm, 2.5 μm).</p></div><div class="footnote" id="t9fn2"><p class="first last">Solvent A: solvent
A1 = 25 mM NH<sub>4</sub>OAc
in water at pH = 5; solvent A2 = 30 mM NH<sub>4</sub>HCO<sub>3</sub> in water at pH = 10; solvent A3 = 0.1% TFA in 10% MeOH/90% H<sub>2</sub>O; solvent A4 = 5 mM NH<sub>4</sub>OAc in 10% CH<sub>3</sub>CN/90% H<sub>2</sub>O. Solvent B: solvent B1 = 25 mM NH<sub>4</sub>OAc in 85% CH<sub>3</sub>CN/15% H<sub>2</sub>O; solvent B2 = CH<sub>3</sub>CN; solvent B3 = 0.1% TFA in 90% MeOH/10% H<sub>2</sub>O;
solvent B4 = 5 mM NH<sub>4</sub>OAc in 90% CH<sub>3</sub>CN/10% H<sub>2</sub>O.</p></div></div></div><div class="NLM_p">Abbreviations
used in the experimental descriptions: DIEA, <i>N</i>,<i>N</i>-diisopropylethylamine; EtOAc, ethyl
acetate; HATU, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate; MeOH,
methanol; satd. aq, saturated aqueous; RT, room temperature.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[6-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)pyridin-3-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate (<b>4</b>)</h3><div class="NLM_p">A solution of Br<sub>2</sub> (7.63 g, 47.74 mmol)
in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added dropwise over 5
min to an ice water cooled solution of 1-(6-bromopyridine-3-yl)ethanone
(9.496 g, 47.47 mmol) and 48% HBr (0.4 mL) in CH<sub>2</sub>Cl<sub>2</sub> (105 mL). The cooling bath was removed 40 min later, and
stirring was continued at ambient temperature for 66 h. The cake of
solid that formed was filtered, washed with CH<sub>2</sub>Cl<sub>2</sub>, and dried in vacuo to afford impure bromide <b>43</b> as
an off-white solid (15.94 g), which was carried forward directly.</div><div class="NLM_p">Boc-<span class="smallcaps smallerCapital">l</span>-proline (9.70 g, 45.06 mmol) was added in one batch
to a heterogeneous mixture of crude <b>43</b> (15.4 g) and CH<sub>3</sub>CN (150 mL), followed immediately by Et<sub>3</sub>N (13.0
mL, 93.2 mmol), which was added dropwise over 6 min. The reaction
mixture was stirred for 50 min, the volatile component was removed
in vacuo, and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O. The CH<sub>2</sub>Cl<sub>2</sub> layer
was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo,
and the residue was purified by flash chromatography (silica gel;
sample was loaded with eluting solvent; 25% EtOAc/hexanes) to afford
ketoester <b>44</b> as a highly viscous yellow oil (11.44 g,
61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.95 (m, 1H), 8.25–8.21 (m, 1H), 7.88 (d, <i>J =</i> 8.3, 1H), 5.65–5.46 (m, 2H), 4.36–4.31
(m, 1H), 3.41–3.29 (m, 2H), 2.36–2.22 (m, 1H), 2.14–2.07
(m, 1H), 1.93–1.83 (m, 2H), 1.4/1.36 (2 s, 9H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>NaBrN<sub>2</sub>O<sub>5</sub>, 435.1; found,
435.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>BrN<sub>2</sub>O<sub>5</sub>, 413.0712; found, 413.0717.</div><div class="NLM_p">A mixture of <b>44</b> (1.32 g, 3.19 mmol) and NH<sub>4</sub>OAc (2.729 g, 35.4 mmol) in
xylenes (18 mL) was heated in a microwave
at 140 °C for 90 min. The volatile component was removed in vacuo,
and the residue was partitioned between CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O, where enough satd. aq NaHCO<sub>3</sub> solution
was added to neutralize the aqueous medium. The aqueous phase was
extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic
phase was dried (MgSO<sub>4</sub>), filtered, and concentrated in
vacuo. The residue was purified by flash chromatography (silica gel;
50% EtOAc/hexanes) to afford imidazole <b>48a</b> as an off-white
foam (1.025 g, 82%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.33/12.09/12.02 (series of br s, 1H), 8.74
(d, <i>J =</i> 2.3 Hz, 0.93H), 8.70 (app br s, 0.07H), 8.03/7.98
(dd for the first peak, <i>J =</i> 8.3, 2.6 Hz, 1H), 7.69/7.67
(2 overlapping app br s, 1H), 7.58/7.43 (d for the first peak, <i>J =</i> 8.3 Hz, 1H), 4.80 (m, 1H), 3.53 (m, 1H), 3.36 (m, 1H),
2.33–2.11 (m, 1H), 2.04–1.79 (m, 3H), 1.39/1.15 (2 br
s, 3.9H+5.1H). LC/MS (ESI) <i>m</i>/<i>z</i>:
[M + H]<sup>+</sup>calcd for C<sub>17</sub>H<sub>22</sub>BrN<sub>4</sub>O<sub>2</sub>, 393.1; found, 393.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>17</sub>H<sub>22</sub>BrN<sub>4</sub>O<sub>2</sub>, 393.0926; found, 393.0909.</div><div class="NLM_p">Pd(Ph<sub>3</sub>P)<sub>4</sub> (115 mg, 0.100 mmol) was added
to a mixture of <b>48a</b> (992 mg, 2.52 mmol), <b>53</b> (see ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a> for
preparation; 1.207 g, 2.747 mmol), NaHCO<sub>3</sub> (698.8 mg, 8.318
mmol) in 1,2-dimethoxyethane (18 mL) and H<sub>2</sub>O (4 mL). The
reaction mixture was flushed with N<sub>2</sub>, heated at 90 °C
for 37 h using an oil bath, and allowed to cool to RT. The suspension
that formed was filtered and washed with H<sub>2</sub>O followed by
1,2-dimethoxyethane, and dried in vacuo. A silica gel mesh was prepared
from the crude solid and submitted to flash chromatography (silica
gel, EtOAc) to afford <b>54a</b> as a white solid, which yellowed
slightly upon standing at RT (1.124 g, ∼68%). <sup>1</sup>H
NMR indicated that the sample contained residual MeOH in a product/MeOH
mole ratio of 1.3. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>35</sub>H<sub>44</sub>N<sub>7</sub>O<sub>4</sub>, 626.4; found, 626.6. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>35</sub>H<sub>44</sub>N<sub>7</sub>O<sub>4</sub>, 626.3455; found,
626.3479.</div><div class="NLM_p">Carbamate <b>54a</b> (217 mg) was treated with
25% TFA/CH<sub>2</sub>Cl<sub>2</sub> (3.6 mL) and stirred at RT for
6 h. The volatile
component was removed in vacuo, and the resultant material was free-based
by MCX column (MeOH wash; 2.0 M NH<sub>3</sub>/MeOH elution) to afford <b>54b</b> as a dull, yellow foam that solidified gradually after
it was allowed to stand with no processing (150.5 mg; mass is above
theoretical yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.89 (br s, 2H), 9.01 (d, <i>J =</i> 1.8 Hz, 1H), 8.13 (dd, <i>J =</i> 8.3, 2.2 Hz, 1H), 8.07
(d, <i>J =</i> 8.6 Hz, 2H), 7.92 (d, <i>J =</i> 8.3 Hz, 1H), 7.83 (d, <i>J =</i> 8.5 Hz, 2H), 7.61 (br
s, 1H), 7.50 (br s, 1H), 4.18 (m, 2H), 3.00–2.93 (m, 2H), 2.90–2.82
(m, 2H), 2.11–2.02 (m, 2H), 1.94–1.85 (m, 2H), 1.83–1.67
(m, 4H). Note: the exchangeable pyrrolidine hydrogens were not observed.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>: 426.2; found,
426.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>,
426.2406; found, 426.2425.</div><div class="NLM_p last">To a mixture of <b>54b</b> (23.2
mg, ∼0.0512 mmol),
(2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid
(24.4 mg, 0.117 mmol), DIEA (40 μL, 0.229 mmol) in DMF (1.5
mL) was added HATU (41.9 mg, 0.110 mmol). The mixture was stirred
at RT for 1 h and directly submitted to a reverse-phase preparative
HPLC purification (MeOH/H<sub>2</sub>O/TFA) to afford the TFA salt
of <b>4</b> as an off-white foam (43.4 mg, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.33
(br s, ∼1H), 9.15−8.95 (series of m, 1H), 8.57−8.51
(m, 0.15H), 8.40−8.04 (m, 5.6H), 8.04−7.92 (m, 1.55H),
7.92−7.76 (m, 0.72H), 7.76−7.66 (m, 1.66H), 7.46−7.25
(m, 9.01H), 7.25−7.10 (m, 0.16H), 7.10−6.94 (m, 1.15H),
5.76−5.63 (2 m, 0.15H), 5.57−5.37 (2 m, 1.97H), 5.26−5.13
(m, 1.88H), 3.99−3.88/3.88−3.74 (2 m, 2H), 3.74−3.66/3.23−3.09
(2 m, 2H), 3.55/3.53 (2 s, 6H), 2.34−2.17 (m, 1.75H), 2.14−1.97
(m, 3.85H), 1.97−1.75 (m, 2.4H). LC (method 1): <i>t</i><sub>R</sub> = 31.3 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>45</sub>H<sub>46</sub>N<sub>9</sub>O<sub>6</sub>, 808.4; found, 808.5. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>45</sub>H<sub>46</sub>N<sub>9</sub>O<sub>6</sub>, 808.3571; found,
808.3576.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[5-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)pyridin-2-yl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate (<b>5</b>)</h3><div class="NLM_p"><i>n</i>-BuLi (12.0 mL of 2.5 M in hexanes,
30 mmol) was added dropwise over 15 min to a cooled (−78 °C)
semisolution of 2,5-dibromopyridine (<b>45a</b>) (6.040 g, 25.5
mmol) in toluene (300 mL), and the reaction mixture was stirred for
2.5 h. <i>t</i>-Butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate
(2.809 g, 12.87 mmol) was added in batches over 7 min, and the mixture
was stirred for 1.5 h at −78 °C. The cooling bath was
replaced with a −60 °C bath, which was allowed to warm
up to −15 °C over 2.5 h. The reaction mixture was quenched
with satd. aq NH<sub>4</sub>Cl solution (20 mL) and allowed to thaw
to ambient temperature. The organic layer was separated and concentrated
in vacuo. The crude product was purified by flash chromatography (silica
gel, 15% EtOAc/hexanes) to afford a reddish-brown semisolid, which
was washed with hexanes to remove some colored residue. Pyridine <b>46a</b> was isolated as an ash-colored solid (842 mg, 21%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ
8.89 (d, <i>J =</i> 2.3 Hz, 1H), 8.30 (dd, <i>J =</i> 8.4, 2.4 Hz, 1H), 7.90 (d, <i>J =</i> 8.3 Hz, 1H), 7.03(br
t, <i>J =</i> 5.7 Hz, 0.88H), 6.63 (app br s, 0.12H), 4.55
(d, <i>J =</i> 5.8 Hz, 2H), 1.40/1.28 (2 app s, 7.83H/1.17H).
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + Na]<sup>+ </sup>calcd for C<sub>12</sub>H<sub>15</sub>BrNaN<sub>2</sub>O<sub>3</sub>, 337.0; found, 337.1.</div><div class="NLM_p">HBr (48%, 1.0 mL) was added dropwise
to a solution of <b>46a</b> (840 mg, 2.66 mmol) in dioxane (5.0
mL) over 3 min, and the reaction mixture was stirred at RT for 17.5
h. The precipitate was filtered, washed with dioxane, and dried in
vacuo to afford the HBr salt of <b>46b</b> as an off-white solid
(672.4 mg; the precise mole equivalent of HBr was not determined). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ
8.95 (d, <i>J =</i> 2.3 Hz, 1 H), 8.37 (dd, <i>J =</i> 8.4, 2.3 Hz, 1H), 8.20 (br s, 3H), 8.00 (d, <i>J =</i> 8.3 Hz, 1H), 4.61 (s, 2H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>7</sub>H<sub>8</sub>BrN<sub>2</sub>O, 215.0; found, 215.0.</div><div class="NLM_p">DIEA (2.3 mL, 13.2 mmol)
was added dropwise over 15 min to a heterogeneous
mixture of <b>46b</b> (1.365g), (<i>S</i>)-Boc-proline
(0.957 g, 4.44 mmol) and HATU (1.70 g, 4.47 mmol) in DMF (13.5 mL),
and the mixture was stirred at RT for 1 h. The volatile component
was removed in vacuo, and the residue was partitioned between EtOAc
(40 mL) and an aqueous medium (20 mL H<sub>2</sub>O + 1 mL satd. aq
NaHCO<sub>3</sub>). The aqueous layer was washed with EtOAc (20 mL),
and the combined organic phase was dried (MgSO<sub>4</sub>), filtered,
and concentrated in vacuo. The residue was purified by flash chromatography
(silica gel; 40–50% EtOAc/hexanes) to afford <b>47</b> as a light-yellow foam (1.465g). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.90 (d, <i>J</i> = 2.3
Hz, 1H), 8.30 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 8.21−8.07
(m, 1H), 7.90 (d, <i>J</i> = 8.3 Hz, 1H), 4.80−4.69
(m, 1H), 4.64 (dd, <i>J</i> = 19.1, 5.5 Hz, 1H), 4.24−4.10
(m, 1H), 3.43−3.33 (m, 1H), 3.33−3.26 (m, 1H), 2.20−2.01
(m, 1H), 1.95−1.70 (m, 3H), 1.40/1.35 (2 app s, 9H). LC/MS
(ESI) <i>m</i>/<i>z</i>: [M + Na]<sup>+</sup> calcd
for C<sub>17</sub>H<sub>22</sub>BrN<sub>3</sub>NaO<sub>4</sub>, 434.1;
found, 434.0.</div><div class="NLM_p">A mixture of <b>47</b> (782.2 mg, 1.897
mmol) and NH<sub>4</sub>OAc (800.0 mg, 10.4 mmol) in xylenes (10 mL)
was heated in
a microwave (140 °C) for 90 min. The volatile component was removed
in vacuo, and the residue was carefully partitioned between CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O, where enough satd. aq NaHCO<sub>3</sub> was added to neutralize it. The aqueous phase was extracted
with CH<sub>2</sub>Cl<sub>2</sub> (2×), and the combined organic
phase was dried (MgSO<sub>4</sub>), filtered, and concentrated in
vacuo. The crude material was purified by flash chromatography (silica
gel; 50% CH<sub>2</sub>Cl<sub>2</sub>/EtOAc) to afford <b>48b</b> as an off-white solid (552.8 mg, 74%). <sup>1</sup>H NMR (400 MHz,
DMSO-<i>d</i><sub>6</sub>): δ 12.49/12.39/12.15/12.06
(series of br s, 1H), 8.62 (app br s, 0.2H), 8.56 (d, <i>J</i> = 2.0 Hz, 0.8H), 8.02 (br d, <i>J</i> = 8.5 Hz, 0.2H),
7.97 (br d, <i>J</i> = 7.8 Hz, 0.8H), 7.77 (d, <i>J</i> = 8.6 Hz, 0.8H), 7.72 (d, <i>J</i> = 8.6 Hz, 0.2H), 7.61–7.49
(m, 1H), 4.93–4.72 (m, 1H), 3.53 (m, 1H), 3.41–3.32
(m, 1H), 2.33–1.77 (m, 4H), 1.39 (app s, 3.7H), 1.14/1.12 (2
overlapped app s, 5.3H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M + Na]<sup>+</sup> calcd for C<sub>17</sub>H<sub>21</sub>BrN<sub>4</sub>NaO<sub>2</sub>, 415.1; found, 415.1.</div><div class="NLM_p">NaH (60% dispersion
in mineral oil; 11.6 mg, 0.29 mmol) was added
in one portion to a heterogeneous mixture of <b>48b</b> (80
mg, 0.20 mmol) and DMF (1.5 mL), and stirred at RT for 30 min. SEM-Cl
(40 μL, 0.23 mmol) was added dropwise over 2 min to the reaction
mixture, and stirring was continued for 14 h. The volatile component
was removed in vacuo and the residue was partitioned between H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>. The aqueous layer was
extracted with CH<sub>2</sub>Cl<sub>2</sub>, and the combined organic
phase was dried (MgSO<sub>4</sub>), filtered, and concentrated in
vacuo. The crude material was purified by flash chromatography (silica
gel; 20% EtOAc/hexanes) to afford <b>48c</b> as a colorless
viscous oil (87.5 mg, 84%). The exact regiochemistry of <b>48c</b> was not determined, as it was deemed inconsequential for the current
purpose. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.53
(d, <i>J</i> = 2.2 Hz, 1H), 7.91−7.82 (m, 1H), 7.82−7.72
(m, 1H), 7.52 (s, 1H), 5.87 (m, 0.46H), 5.41 (m, 0.54H), 5.16 (d, <i>J</i> = 10.8 Hz, 1H), 5.03−4.85 (m, 1H), 3.76−3.42
(series of m, 4H), 2.54−1.84 (series of m, 4H), 1.38/1.19 (2
br s, 4.3H/4.7H), 0.97−0.81 (m, 2H), −0.03 (s, 9H).
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>36</sub>BrN<sub>4</sub>O<sub>3</sub>Si, 523.2; found, 523.2.</div><div class="NLM_p">Pd(Ph<sub>3</sub>P)<sub>4</sub> (24.4
mg, 0.021 mmol) was added
to a mixture of <b>48c</b> (280 mg, 0.535 mmol), <b>53</b> (see ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a> for
preparation; 241.5 mg, 0.55 mmol) and NaHCO<sub>3</sub> (148.6 mg,
1.769 mmol) in 1,2-dimethoxyethane (4.8 mL) and H<sub>2</sub>O (1.6
mL). The reaction mixture was flushed with N<sub>2</sub>, heated with
an oil bath at 80 °C for ∼24 h, and then the volatile
component was removed in vacuo. The residue was partitioned between
CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O, and the organic phase
was dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo.
The crude material was purified by flash chromatography (silica gel;
75–100% EtOAc/hexanes) followed by a reverse-phase preparative
HPLC (H<sub>2</sub>O/MeOH/TFA). The HPLC elute was neutralized with
2 M NH<sub>3</sub>/MeOH and evaporated in vacuo, and the residue was
partitioned between H<sub>2</sub>O and CH<sub>2</sub>Cl<sub>2</sub>. The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated
in vacuo to afford <b>55a</b> as a white foam (162 mg, 40%).
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>41</sub>H<sub>58</sub>N<sub>7</sub>O<sub>5</sub>Si,
756.4; found, 756.6.</div><div class="NLM_p">Carbamate <b>55a</b> (208 mg, 0.275
mmol) was treated with
25% TFA/CH<sub>2</sub>Cl<sub>2</sub> (4.0 mL), and the mixture was
stirred at RT for 10 h. The volatile component was removed in vacuo,
and the residue was first free-based by MCX (MeOH wash; 2.0 M NH<sub>3</sub>/MeOH elution) and then purified by a reverse-phase preparative
HPLC (H<sub>2</sub>O/MeOH/TFA), and the resultant material was free-based
again (MCX) to afford <b>55b</b> as a film of oil (53.7 mg,
46%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.86 (app br s, ∼2H), 8.83 (d, <i>J</i> = 2.1 Hz, 1H), 8.07 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H),
7.87 (d, <i>J</i> = 8.5 Hz, 1H), 7.84 (d, <i>J</i> = 8.3 Hz, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 2H), 7.55 (s,
1H), 7.50 (br s, 1H), 4.20−4.15 (m, 2H), 3.00−2.94 (m,
2H), 2.89−2.83 (m, 2H), 2.11−2.02 (m, 2H), 1.95−1.86
(m, 2H), 1.83−1.67 (m, 4H). Note: the exchangeable pyrrolidine
hydrogens were not observed. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>25</sub>H<sub>28</sub>N<sub>7</sub>, 426.2; found, 426.3.</div><div class="NLM_p last">Title compound <b>5</b> (TFA salt, off-white foam) was prepared
from <b>55b</b> and (2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic
acid according to the procedure described for <b>4</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ
14.32 (br s, ∼1H), 9.14−9.00 (m, 1H), 8.45−8.34
(m, 1.82H), 8.30−8.23 (m, 0.15H), 8.23−8.13 (app s,
1.04H), 8.13−7.93 (series of m, 4.81H), 7.93−7.76 (m,
0.72H), 7.76−7.60 (m, 1.5H), 7.44−7.27 (m, 9.08H), 7.07−6.98
(m, 0.88H), 5.75−5.68 (m, 0.12H), 5.57−5.45 (m, 1.6H),
5.45−5.35 (m, 0.34H), 5.26−5.12 (m, 1.94H), 3.99−3.87/3.87−3.77
(2 m, 2H), 3.77−3.66/3.23−3.06 (2 m, 2H), 3.55/3.53
(2 s, 6H), 2.32−2.16 (m, 1.8H), 2.16−1.96 (m, 4H), 1.96−1.75
(m, 2.2H). LC (method 2): <i>t</i><sub>R</sub> = 24.0 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>45</sub>H<sub>46</sub>N<sub>9</sub>O<sub>6</sub>,
808.36; found, 808.51.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(5-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}pyrimidin-2-yl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl] carbamate (<b>6</b>)</h3><div class="NLM_p">Tributyl(1-ethoxyvinyl)tin (10.0 mL, 29.6 mmol)
and PdCl<sub>2</sub>(Ph<sub>3</sub>P)<sub>2</sub> (1.04 g, 1.48 mmol)
were added to a mixture of <b>45b</b> (5.72 g, 29.6 mmol) in
DMF (80 mL) maintained under an atmosphere of N<sub>2</sub>. The mixture
was heated at 100 °C for 3 h before being allowed to stir at
RT for 16 h. The reaction mixture was diluted with Et<sub>2</sub>O
(200 mL) and treated with aqueous KF solution (25 g of KF in 150 mL
of water). The two-phase mixture was stirred vigorously for 1 h at
RT and filtered through Celite. The organic phase of the filtrate
was separated, washed with saturated NaHCO<sub>3</sub> solution, brine
and dried (Na<sub>2</sub>SO<sub>4</sub>). The original aqueous phase
was extracted twice with Et<sub>2</sub>O, and the combined organic
extract was treated as above. The crude product was preabsorbed onto
silica gel and purified by flash chromatography (silica gel, 3–50%
EtOAc/hexanes) to afford <b>49</b> (6.1 g) as a white solid
which was slightly impure but was used as is. <sup>1</sup>H NMR (500
MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.97 (s, 2H), 5.08
(d, <i>J =</i> 3.7 Hz, 1H), 4.56 (d, <i>J =</i> 3.4 Hz, 1H), 3.94 (q, <i>J =</i> 7.0 Hz, 2H), 1.35 (t, <i>J =</i> 7.0 Hz, 3H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>8</sub>H<sub>10</sub>ClN<sub>2</sub>O, 185.1; found, 185.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>8</sub>H<sub>10</sub>ClN<sub>2</sub>O, 185.0482; found, 185.0490.</div><div class="NLM_p">NBS (3.37 g, 19.0 mmol) was added in one portion to a stirred solution
of <b>49</b> (3.5 g, ∼19.0 mmol) in THF (53 mL) and H<sub>2</sub>O (17.5 mL) at 0 °C under N<sub>2</sub>. The mixture
was stirred for 1 h at 0 °C before it was diluted with H<sub>2</sub>O and extracted with EtOAc (2×). The combined extract
was washed with satd. aq NaHCO<sub>3</sub>, brine and dried (Na<sub>2</sub>SO<sub>4</sub>) to afford <b>50</b> (4.69 g) as a pale
yellow solid, which was advanced to the next step without purification.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>6</sub>H<sub>5</sub>BrClN<sub>2</sub>O, 236.93; found,
236.78.</div><div class="NLM_p">Crude <b>50</b> (4.69 g) was dissolved in anhydrous
CH<sub>3</sub>CN (150 mL) and treated directly with <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-proline (4.08 g, 19.0 mmol) and DIEA (3.30 mL, 19.0
mmol).
After being stirred for 3 h, the solvent was removed in vacuo, and
the residue was partitioned between EtOAc and H<sub>2</sub>O. The
organic phase was washed with 0.1 N HCl, satd. aq NaHCO<sub>3</sub>, brine and dried (Na<sub>2</sub>SO<sub>4</sub>) to afford crude <b>51</b>, which was advanced to the next step without purification.</div><div class="NLM_p">Crude <b>51</b> was taken up in xylenes (60 mL) and treated
with NH<sub>4</sub>OAc (14.6 g, 190 mmol). The mixture was heated
at 140 °C for 2 h in a pressure vessel before it was cooled to
RT and suction-filtered. The filtrate was concentrated in vacuo, and
the residue was partitioned between EtOAc and satd. aq NaHCO<sub>3</sub>. The organic phase was separated, washed with brine, and dried over
Na<sub>2</sub>SO<sub>4</sub>. Purification of the residue by flash
chromatography (silica gel, 5–40% B/A, where A = CH<sub>2</sub>Cl<sub>2</sub> and B = 25% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>52a</b> as a pale, yellow foam (2.0 g, 30% yield for three steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ
12.24–12.16 (m, 1H), 9.05 (s, 2H), 7.84–7.73 (m, 1H),
4.90–4.73 (m, 1H), 3.59–3.46 (m, 1H), 3.41–3.31
(m, 1H), 2.32–2.12 (m, 1H), 2.03–1.77 (m, 3H), 1.39/1.15
(2 s, 9H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M +
H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>2</sub>, 350.1; found, 350.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>16</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>2</sub>, 350.1384; found, 350.1398.</div><div class="NLM_p">NaH (60% dispersion in mineral oil; 0.23 g, 5.72 mmol) was added
in one portion to a stirred solution of <b>52a</b> (2.00 g,
5.72 mmol) in dry DMF (45 mL) at RT under N<sub>2</sub>. The mixture
was stirred for 5 min, and SEM-chloride (1.00 mL, 5.65 mmol) was added
gradually in 0.1 mL increments. The mixture was stirred for 3 h, quenched
with satd. aq NH<sub>4</sub>Cl, and diluted with EtOAc. The organic
phase was separated, washed with satd. aq NaHCO<sub>3</sub>, brine
and dried (Na<sub>2</sub>SO<sub>4</sub>). The original aqueous phase
was extracted with EtOAc (2×), and the combined extracts were
washed with satd. aq NaHCO<sub>3</sub>, brine and dried (Na<sub>2</sub>SO<sub>4</sub>). The residue was purified by flash chromatography
(silica gel, 5–100% EtOAc/hexanes) to furnish <b>52b</b> as a pale yellow foam (2.35 g, 87%). Note that the exact regiochemistry
of <b>52b</b> was not determined as it was deemed inconsequential
for the current purpose. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.04 (s, 2H), 7.98–7.95 (m,
1H), 5.70–5.31 (3 m, 2H), 5.02–4.91 (m, 1H), 3.59–3.49
(m, 3H), 3.45–3.35 (m, 1H), 2.30–2.08 (m, 2H), 1.99–1.83
(m, 2H), 1.36/1.12 (2 s, 9H), 0.93–0.82 (m, 2H), −0.02
(s, 9H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M+H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>35</sub>ClN<sub>5</sub>O<sub>3</sub>Si, 480.2; found, 480.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M+H]<sup>+ </sup>calcd for C<sub>22</sub>H<sub>35</sub>ClN<sub>5</sub>O<sub>3</sub>Si, 480.2198; found, 480.2194.</div><div class="NLM_p">Pd(PPh<sub>3</sub>)<sub>4</sub> (0.12 g, 0.103 mmol) was added
in one portion to a stirred suspension of <b>53</b> (see ref <a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(2)</a> for preparation; 1.00 g,
2.27 mmol), <b>52b</b> (0.99 g, 2.06 mmol), and NaHCO<sub>3</sub> (0.87 g, 10.3 mmol) in a solution of DME (20 mL) and H<sub>2</sub>O (6 mL) at RT under N<sub>2</sub>. The vessel was sealed and the
mixture was heated at 80 °C with stirring for 16 h before additional
Pd(PPh<sub>3</sub>)<sub>4</sub> (0.12 g) was added. After being heated
at 80 °C for an additional 12 h, the mixture was cooled to RT,
diluted with EtOAc, washed with satd. aq NaHCO<sub>3</sub>, brine
and dried (Na<sub>2</sub>SO<sub>4</sub>). The volatile component was
removed in vacuo. Purification of the residue by flash chromatography
(silica gel, 40–100% EtOAc/hexanes) furnished <b>56a</b> as a yellow foam (1.53 g). A sample of the yellow foam was further
purified for characterization purposes by reverse-phase preparative
HPLC (CH<sub>3</sub>CN/H<sub>2</sub>O/NH<sub>4</sub>OAc) to afford
a pure sample as a white solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.30−11.88 (3 m, 1H), 9.17−9.16
(m, 2H), 8.43−8.31 (m, 2H), 7.99−7.35 (series of m,
4H), 5.72−5.30 (3 m, 2H), 5.03−4.76 (2 m, 2H), 3.64−3.50
(m, 4H), 3.48−3.31 (m, 2H), 2.36−2.07 (m, 2H), 2.05−1.80
(m, 4H), 1.46−1.08 (2 m, 18H), 0.95−0.84 (m, 2H), −0.01
(s, 9H). LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>57</sub>N<sub>8</sub>O<sub>5</sub>Si, 757.4; found, 757.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>57</sub>N<sub>8</sub>O<sub>5</sub>Si, 757.4221; found, 757.4191.</div><div class="NLM_p">TFA
(8.0 mL) was added in one portion to a stirred solution of <b>56a</b> (1.50 g, ∼1.98 mmol) in dry CH<sub>2</sub>Cl<sub>2</sub> (30
mL) at RT. The flask was sealed, and the mixture was
stirred for 16 h before the volatile component was removed in vacuo.
The residue was dissolved in MeOH and purified by a reverse-phase
preparative HPLC (MeOH/water/TFA). The desired fraction was concentrated,
and the product was dissolved in MeOH and passed through a resin cartridge
(UCT-CHQAX1 Quartnery amine hydroxide; MeOH elution) to afford the
free-base form of <b>56b</b> as a pale, mustard yellow-colored
solid (307 mg, 36%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 12.50–11.80 (br m, 2H), 9.18 (s, 2H),
8.36 (d, <i>J =</i> 8.5 Hz, 2H), 7.89 (d, <i>J =</i> 8.2 Hz, 2H), 7.77 (s, 1H), 7.61 (s, 1H), 4.34–4.24 (m, 2H),
3.09–2.89 (m, 4H), 2.18–2.07 (m, 2H), 2.02–1.89
(m, 2H), 1.88–1.72 (m, 4H). Note: the exchangeable pyrrolidine
hydrogens were not observed. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>, 427.2; found, 427.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>, 427.2359; found, 427.2363.</div><div class="NLM_p last">To
a solution of <b>56b</b> (60.0 mg, 0.14 mmol), (2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid (64.8
mg, 0.31 mmol), and DIEA (0.20 mL, 1.1 mmol) in DMF (3.5 mL) was added
HATU (123.0 mg, 0.32 mmol). The reaction mixture was stirred at RT
for 2 h. It was then diluted with MeOH (2 mL), filtered through a
Whatman 13 mm PVDF 45 μm syringe filter, and purified by reverse-phase
preparative HPLC (MeOH/H<sub>2</sub>O/TFA) to afford the TFA salt
of <b>6</b> as a light yellow solid (91.4 mg, 63% yield assuming
bis-TFA salt). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.29/9.22/9.16 (3 s, 2H), 8.60−8.50
(m, 2H), 8.23 (app s, 0.77H), 8.16−8.08 (m, 0.87H), 8.01−7.65
(series of m, 4.27H), 7.44−7.27 (series of m, 8.8H), 7.05 (app
s, 0.97H), 7.00−6.93 (m, 0.32H), 5.75−5.69 (m, 0.09H),
5.62−5.57 (m, 0.19H), 5.55−5.47 (m, 1.52H), 5.43−5.37
(m, 0.42H), 5.23−5.11 (m, 1.78H), 3.98−3.87 (m, 2H),
3.55/3.54/3.53 (3 s, 6H), 3.23−3.05 (m, 2H), 2.33−2.23
(m, 1H), 2.23−2.12 (m, 0.9H), 2.12−1.95 (m, 4H), 1.95−1.72
(m, 2.1H). LC (method 7): <i>t</i><sub>R</sub> = 1.99 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup>calcd for C<sub>44</sub>H<sub>45</sub>N<sub>10</sub>O<sub>6</sub>, 809.4; found, 809.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>44</sub>H<sub>45</sub>N<sub>10</sub>O<sub>6</sub>, 809.3524; found, 809.3505.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Synthesis
Description for Analogues of the Biphenyl
Core Series</h3><div class="NLM_p last">Homodimeric cap analogues were prepared from
pyrrolidine <b>57a</b> and appropriate acid precursors according
to the procedure described in the synthesis of <b>4</b>. The
mixed-cap analogues were prepared from mono-Boc protected <b>57b</b> through a sequence involving coupling with the first cap, deprotecting
the Boc moiety, and then installing the second cap, the details of
which are provided in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a>. Depending on the HPLC eluting medium, final products were
isolated as either TFA salt or free-base form.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Methyl <i>N</i>-[(2<i>R</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
(<b>7</b>)</h3><div class="NLM_p last">Title compound <b>7</b> (TFA salt,
white solid). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.35 (br s, ∼3H), 8.14 (app br s, 1.83H),
8.02−7.93 (m, 3.77H), 7.93−7.85 (m, 4.59H), 7.60 (app
br s, 0.18H), 7.25 (d, <i>J</i> = 8.2 Hz, 1.59H), 6.77 (app
br s, 0.04H), 5.87 (app br s, 0.24H), 5.18 (dd, <i>J</i> = 8.1, 3.8 Hz, 1.76H), 4.19 (app t, <i>J</i> = 7.8 Hz,
1.71H), 3.96−3.84 (m, 1.77H), 3.77−3.64 (m, 2.2H), 3.57/3.57
(2 overlapping s, 6H), 3.53−3.47 (m, 0.32H), 2.47−2.28
(m, 2.2H), 2.22−1.87 (series of m, 7.58H), 1.86−1.66
(m, 0.22H), 0.91 (d, <i>J</i> = 7.0 Hz, 4.9H), 0.87 (d, <i>J</i> = 6.7 Hz, 5.4H), 0.73 (d, <i>J</i> = 6.7 Hz,
0.9H), 0.40 (app br s, 0.8H). LC (method 8): <i>t</i><sub>R</sub> = 2.0 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>6</sub>, 739.4; found, 739.7. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>6</sub>, 739.3932; found,
739.3966.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-{2-[(methoxycarbonyl)amino]acetyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]
carbamate (<b>9</b>)</h3><div class="NLM_p last">Title compound <b>9</b> (TFA
salt, off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.44 (br s, ∼3H), 8.13 (app br s,
1.76H), 8.00−7.87 (2 m, 7.7H), 7.87−7.67 (series of
m, 1.51H), 7.44−7.21 (series of m, 5.45H), 7.05 (app s, 0.51H),
6.83 (app br s, 0.07H), 5.71 (app br s, 0.09H), 5.54−5.49 (m,
0.83H), 5.43−5.37 (m, 0.23H), 5.23−5.26 (m, 1.85H),
3.95−3.89 (m, 1.7H), 3.89−3.80 (m, 1.2H), 3.78−3.68
(m, 1.23H), 3.64−3.56 (m, 0.94H), 3.55/3.53/3.49 (3 s overlapped
with m, 6.28H), 3.22−3.14 (m, 0.65H), 2.46−2.32 (m,
1.36H), 2.32−2.17 (m, 0.82H), 2.12−1.96 (m, 4.52H),
1.98−1.83 (m, 1.3H). LC (method 3): <i>t</i><sub>R</sub> = 24.5 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 731.4; found, 731.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>40</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 731.3306; found, 731.3333.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-acetylpyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
(<b>10</b>)</h3><div class="NLM_p last">Title compound <b>10</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.48 (br s, ∼3H), 8.23−8.11
(m, 1.84H), 8.04−7.89 (m, 7.88H), 7.89−7.67 (m, 1.23H),
7.46−7.26 (m, 4.56H), 7.05 (s, 0.49H), 5.76 (m, 0.05H), 5.57−5.48
(m, 0.75H), 5.44−5.36 (m, 0.27H), 5.24−5.12 (m, 1.93H),
4.01−3.85 (m, 1H), 3.82−3.67 (m, 1H), 3.64−3.53
(m, 1.31H), 3.52 (s, 2.94H), 3.22−3.07 (m, 0.75H), 2.44−2.22
(2 m, 2.25H), 2.13−1.85 (series of m with s at 2.04, 8.75H).
LC (method 9): <i>t</i><sub>R</sub> = 1.32 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>40</sub>N<sub>7</sub>O<sub>4</sub>, 658.3; found, 658.4.
HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>40</sub>N<sub>7</sub>O<sub>4</sub>, 658.3142; found, 658.3135.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Methyl <i>N</i>-[(1<i>R</i>)-2-oxo-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-phenylethyl]carbamate
(<b>11</b>)</h3><div class="NLM_p last">Title compound <b>11</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.46 (br s, ∼3H), 8.17/8.15 (2 overlapping
app s, 1.63H), 8.11−8.01 (m, 0.34H), 8.01−7.94 (m, 3.57H),
7.94−7.88 (m, 3.94H), 7.88−7.65 (series of m, 1.51H),
7.44−7.27 (series of m, 4.54H), 7.05 (app s, 0.47H), 5.78−5.71
(m, 0.08H), 5.59−5.48 (m, 0.93H), 5.43−5.37 (m, 0.16H),
5.25−5.12 (m, 1.83H), 4.64 (dd, <i>J</i> = 7.9, 5.2
Hz, 0.89H), 4.29 (app t, <i>J</i> = 6.6 Hz, 0.11H), 3.98−3.90
(m, 0.81H), 3.90−3.62 (series of m, 3.25H), 3.62−3.44
(m, 1.17H), 3.54/3.53 (2 s overlapped with m of same region, 3H),
3.24−3.11 (m, 0.77H), 2.47−2.33 (m, 1.36H), 2.33−2.22
(m, 0.8H), 2.22−2.11 (m, 1.03H), 2.11−1.98 (m, 4.48H),
1.98−1.87 (m, 2.03H), 1.87−1.77 (m, 2H), 1.77−1.64
(m, 0.30H). LC (method 2): <i>t</i><sub>R</sub> = 22.5 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>44</sub>N<sub>7</sub>O<sub>5</sub>, 714.3; found, 714.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>41</sub>H<sub>44</sub>N<sub>7</sub>O<sub>5</sub>, 714.3404; found, 714.3430.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Methyl <i>N</i>-[(1<i>R</i>)-2-oxo-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-phenylethyl]carbamate
(<b>12</b>)</h3><div class="NLM_p last">Title compound <b>12</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.51 (br s, ∼3H), 8.16/8.12 (2 app
br s, 2.04H), 8.01–7.93 (m, 3.89H), 7.93–7.87 (m, 3.74H),
7.87–7.65 (series of m, 1.36H), 7.45–7.25 (m, 4.52H),
7.05 (app s, 0.45H), 5.77–5.67 (m, 0.06H), 5.59–5.49
(m, 0.94H), 5.42–5.39 (m, 0.15H), 5.24–5.14 (m, 1.85H),
4.64 (app dd, <i>J</i> = 7.8, 5.3 Hz, 0.74H), 4.54–4.48
(m, 0.26H), 3.99–3.88 (m, 0.98H), 3.88–3.65 (m, 3.64H),
3.54/3.53 (2 overlapping s, 3H), 3.50–3.33 (m, 0.75H), 3.23–3.12
(m, 0.63H), 2.45–2.12 (m, 3.52H), 2.12–1.97 (m, 4.82H),
1.97–1.86 (m, 1.21H), 1.86–1.78 (m, 1.56H), 1.78–1.69
(m, 0.89H). LC (method 2): <i>t</i><sub>R</sub> = 22.2 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>41</sub>H<sub>44</sub>N<sub>7</sub>O<sub>5</sub>,
714.34; found, 714.24.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (2<i>R</i>)-2-(Dimethylamino)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>13</b>)</h3><div class="NLM_p last">Title compound <b>13</b> (TFA salt,
light yellow solid). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.55 (br s, ∼3H), 10.24 (br s, ∼1H),
8.14 (app s, 1H), 8.07 (app br s, 1H), 8.00–7.85 (m, 7.73H),
7.72 (app br s, 0.29H), 7.67–7.53 (m, 4.46H), 7.28–7.08
(m, 0.52H), 5.77 (app br d, <i>J</i> = 7.3 Hz, 0.10H), 5.57
(app br d, <i>J</i> = 9.2 Hz, 0.12H), 5.49 (app br s, 0.11H),
5.45 (app s, 0.89H), 5.26–5.14 (m, 1.78H), 4.63 (app dd, <i>J</i> = 7.9, 5.2 Hz, 0.89H), 4.28 (app t, <i>J</i> = 6.4 Hz, 0.11H), 4.06–3.97 (m, 0.86H), 3.90–3.74
(m, 2.80H), 3.74–3.62 (m, 0.29H), 3.62–3.53 (m, 0.92H),
3.53–3.40 (m, 0.13H), 3.12–3.00 (m, 1H), 3.00–2.68
(2 overlapping br s, 3H), 2.57–2.11 (m overlapping with DMSO
signal, ∼3.7H), 2.30–2.11 (2 m, 2.1H), 2.11–1.98
(m, 4.6H), 1.981–1.67 (series of m, 4.6H). LC (method 2): <i>t</i><sub>R</sub> = 21.6 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>46</sub>N<sub>7</sub>O<sub>3</sub>, 684.4; found, 684.8. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>41</sub>H<sub>46</sub>N<sub>7</sub>O<sub>3</sub>, 684.3662;
found, 684.3671.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> (2<i>R</i>)-2-(Dimethylamino)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-oxolane-2-carbonyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>14</b>)</h3><div class="NLM_p last">Title compound <b>14</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.51 (br s, ∼1H), 10.24 (br s, ∼1H),
8.11/8.09 (2 overlapping s, 1.10H), 8.03 (br s, 0.80H), 7.98−7.84
(m, 7.04H), 7.84−7.63 (m, 0.94H), 7.63−7.52 (m, 4.16H),
7.27−7.08 (m, 0.96H), 5.75 (m, 0.07H), 5.57 (m, 0.11H), 5.49−5.42
(m, 1H), 5.23−5.15 (m, 1.82H), 4.64 (app dd, <i>J</i> = 7.7, 5.4 Hz, 0.86H), 4.54−4.48 (m, 0.14H), 4.07−3.95
(m, 0.86H), 3.86−3.70 (overlapping m, 3.74H), 3.48−3.39
(m, 0.21H), 3.34−3.25 (m, 0.19H), 3.07−2.97 (m, 1H),
2.96−2.88 (app br s, 0.34H), 2.82−2.54 (app br s, 4.66H),
2.44−2.32 (m, 1.6H), 2.30−2.11 (m, 1.4H), 2.11−1.96
(m, 6.4H), 1.96−1.65 (series of m, 3.6H). LC (method 4): <i>t</i><sub>R</sub> = 25.7 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>46</sub>N<sub>7</sub>O<sub>3</sub>, 684.4; found, 684.5. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>41</sub>H<sub>46</sub>N<sub>7</sub>O<sub>3</sub>, 684.3662;
found, 684.3692.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> (2<i>R</i>)-2-[Ethyl(methyl)amino]-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[ethyl(methyl)amino]-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>15</b>)</h3><div class="NLM_p last">Title compound <b>15</b> (TFA salt,
yellow foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 10.13/9.85 (2 overlapping br s, ∼2H), 8.05
(app br s, 1.77H), 7.96−7.83 (m, 7.63H), 7.76−7.69 (m,
0.47H), 7.69−7.61 (m, 3.49H), 7.61−7.45 (m, 5.37H),
7.45−7.35 (m, 0.21H), 7.23−7.08 (m, 1.06H), 5.91 (app
br s, 0.06H), 5.75 (m, 0.09H), 5.52/5.46 (2 overlapping app br s,
2H), 5.24−5.17 (m, 1.85H), 4.12−3.89 (m, 1.65H), 3.89−3.75
(m, 0.2H), 3.68−3.53 (m, 0.15H), 3.47−2.65 (series of
overlapping br m, ∼7.5H), 2.55−2.15 (series of m partially
overlapped with DMSO signal, ∼6.5H), 2.15−1.97 (m, 3.75H),
1.97−1.81 (m, 2H), 1.18−1.74 (m, 0.25H), 1.38−1.10
(m, 6H). LC (method 9): <i>t</i><sub>R</sub> = 1.10 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>48</sub>H<sub>55</sub>N<sub>8</sub>O<sub>2</sub>,
775.4; found, 775.5. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+ </sup>calcd for C<sub>48</sub>H<sub>55</sub>N<sub>8</sub>O<sub>2</sub>, 775.4448; found, 775.4456.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> (2<i>R</i>)-2-(Diethylamino)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>16</b>)</h3><div class="NLM_p last">Title compound <b>16</b> (TFA salt,
yellow foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.81 (br s, ∼2H), 8.13–7.98 (m, 1.8H),
7.98–7.81 (m, 7.4H), 7.81–7.76 (m, 0.3H), 7.76–7.63
(m, 3.85H), 7.63–7.43 (m, 5.59H), 7.28–7.08 (m, 1.06H),
6.02–5.94 (m, 0.2H), 5.60–5.51 (m, 0.26H), 5.44 (s,
1.76H), 5.21–5.11 (m, 1.78H),  4.18–4.01 (m, 1.59H),
3.86–3.79 (m, 0.15H), 3.67–3.54 (m, 0.13H), 3.35–2.79
(series of overlapping br m, 7.13H), 2.69–2.56 (m, 1H), 2.56–2.40
(m overlapped with DMSO signal, ∼2H), 2.29–2.14 (m,
1.84H), 2.14–1.98 (m, 3.89H), 1.98–1.80 (m, 1.95H),
1.80–1.65 (m, 0.32H), 1.37–0.94 (overlapping br m, 12H).
LC (method 9): <i>t</i><sub>R</sub> = 1.12 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 803.5; found, 803.6.
HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 803.4761; found, 803.4728.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> (2<i>R</i>)-2-Phenyl-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-phenyl-2-(pyrrolidin-1-yl)acetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-(pyrrolidin-1-yl)ethan-1-one
(<b>17</b>)</h3><div class="NLM_p last">Title compound <b>17</b> (TFA salt,
off-white solid). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub> with D<sub>2</sub>O exchange) δ 8.06 (s, 1.77H),
7.97−7.82 (m, 7.47H), 7.71−7.50 (m, 9.35H), 7.50−7.35
(m, 0.37H), 7.24−7.09 (2 m, 1.04H), 5.79−5.73 (m, 0.2H),
5.50 (s, 0.25H), 5.44 (s, 1.75H), 5.24−5.17 (m, 1.8H), 4.04−3.95
(m, 1.77H), 3.88−3.79 (m, 0.23H), 3.75−2.6 (series of
overlapping br m, ∼9H), 2.60−2.36 (m overlapped with
DMSO signal, ∼1H), 2.30−2.13 (m, 2H), 2.13−1.60
(m, 14H). LC (method 4): <i>t</i><sub>R</sub> = 36.9 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>55</sub>N<sub>8</sub>O<sub>2</sub>, 799.44; found, 799.67.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (2<i>R</i>)-2-Phenyl-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-phenyl-2-(piperidin-1-yl)acetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-(piperidin-1-yl)ethan-1-one
(<b>18</b>)</h3><div class="NLM_p last">Title compound <b>18</b> (free base,
white solid). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.98/9.81 (2 overlapping app br s, ∼2H),
8.07 (app br s, 1.56H), 7.99−7.86 (m, 7.14H), 7.86−7.68
(2 m, 1.17H), 7.68−7.62 (m, 3.16H), 7.62−7.49 (m, 5.67H),
7.45−7.37 (m, 0.40H), 7.26−7.08 (br m, 0.9H), 5.91−5.78
(m, 0.1H), 5.59−5.44 (m overlapped with app s, 2H), 5.32−5.16
(m, 1.9H), 4.12−3.17 (m, 2H), 3.70−3.24 (m, 1.7H), 3.27−2.59
(series of overlapping br m, 6.3H), 2.59−2.30 (m overlapped
with DMSO signal, ∼2H), 2.30−2.13 (m, 1.4H), 2.13−1.98
(m, 3.6H), 1.97−1.77 (m, 3.4H), 1.77−1.50 (m, 8.4H),
1.51−1.28 (m, 3.2H). LC (method 10): <i>t</i><sub>R</sub> = 1.85 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>52</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 827.5; found, 827.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>52</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 827.4761; found, 827.4733.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (2<i>R</i>)-2-(Morpholin-4-yl)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-(morpholin-4-yl)-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>19</b>)</h3><div class="NLM_p last">Title compound <b>19</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.05 (app br s, 1.84H), 7.99–7.81 (m,
7.63H), 7.77–7.67 (m, 0.61H), 7.67–7.47 (2 m, 8.89H),
7.25–7.10 (m, 1.03H), 5.82–5.77 (m, 0.26H), 5.42 (app
br s, 2H), 5.28–5.14 (m, 1.74H), 4.12–3.95 (m, 2.1H),
3.94–3.52 (series of m, 8.1H), 3.52–2.54 (series of
overlapping br m, ∼7.8H), 2.50–2.32 (m overlapped with
DMSO signal, ∼1.5H), 2.31–2.14 (m, 2.02H), 2.14–1.97
(m, 4H), 1.97–1.83 (m, 2.05H), 1.83–1.66 (m, 0.43H).
LC (method 4): <i>t</i><sub>R</sub> = 29.9 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>55</sub>N<sub>8</sub>O<sub>4</sub>, 831.43; found,
831.70.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-[(3<i>S</i>)-3-fluoropyrrolidin-1-yl]-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-{2-[(3<i>S</i>)-3-fluoropyrrolidin-1-yl]-2-phenylacetyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>20</b>)</h3><div class="NLM_p last">Title compound <b>20</b> (TFA salt,
light yellow foam; symmetrical diastereomer-1). <sup>1</sup>H NMR
(400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.57 (s,
∼1H), 10.94 (br s, ∼1H), 8.13 (br s, 2.02H), 8.05−7.87
(m, 7.79H), 7.80−7.64 (m, 4.11H), 7.64−7.53 (m, 5.35H),
7.34−7.25 (m, 0.28H), 7.18−7.11 (m, 0.45H), 5.83−5.70
(m, 0.22H), 5.60/5.50 (2 overlapped app s, 2.95H), 5.37 (app s, 1H),
5.31−5.23 (m, 1.83H), 4.04−2.78 (series of overlapped
br m, ∼11H), 2.56−2.35 (br m overlapped with DMSO signal,
∼1H), 2.35−2.11 (m, 4.4H), 2.11−1.78 (m, 7.1H),
1.78−1.57 (m, 0.5H). LC (method 4): <i>t</i><sub>R</sub> = 36.2 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>53</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>, 835.4; found, 835.3. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>53</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>, 835.4260;
found, 835.4261.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 2-[(3<i>S</i>)-3-fluoropyrrolidin-1-yl]-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-{2-[(3<i>S</i>)-3-fluoropyrrolidin-1-yl]-2-phenylacetyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-phenylethan-1-one
(<b>21</b>)</h3><div class="NLM_p last">Title compound <b>21</b> (TFA salt,
off-white foam; symmetrical diastereomer-2). <sup>1</sup>H NMR (400
MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.06 (br s, ∼1H),
8.15−7.79 (series of overlapped m, 10.5H), 7.65−7.55
(m, 3.3H), 7.55−7.48 (m, 3.2H), 7.48−7.38 (m, 3H), 5.59
(app s, 2.14H), 5.53−5.31 (m, 1.34H), 5.28−5.18 (m,
2.07H), 5.07 (app s, 0.23H), 4.94−4.88 (m, 0.22H), 3.99−2.79
(series of overlapping br m, ∼11H), 2.5−1.67 (series
of overlapping br m that is partially overlapped with DMSO signal,
∼13H). LC (method 4): <i>t</i><sub>R</sub> = 35.4
min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>53</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>, 835.4; found, 835.3. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>53</sub>F<sub>2</sub>N<sub>8</sub>O<sub>2</sub>, 835.4260;
found, 835.4266.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (2<i>R</i>)-2-(Diethylamino)-2-phenyl-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-phenyl-2-(piperidin-1-yl)acetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]ethan-1-one
(<b>22</b>)</h3><div class="NLM_p last">Title compound <b>22</b> (free base,
yellow solid). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 11.96 (app br s, 1.6H), 9.79 (app br s, 0.4H),
8.03−7.23 (series of overlapping m, 18.1H), 7.23−6.81
(m, 1.9H), 5.82−5.20 (br m, 1.3H), 5.20−4.99 (m, 1.7H),
4.36−2.25 (series of br m overlapping with each other and that
of DMSO signal, ∼11H), 2.23−1.81 (series of m, 8.6H),
1.82−1.27 (series of m, 6.4H), 1.27−0.61 (series of
m, 7H). LC (method 11): <i>t</i><sub>R</sub> = 2.53 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 815.5; found, 815.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>51</sub>H<sub>59</sub>N<sub>8</sub>O<sub>2</sub>, 815.4761; found, 815.4763.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-(2-acetamidoacetyl)pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
(<b>23</b>)</h3><div class="NLM_p last">Title compound <b>23</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.43 (br s, ∼2H), 8.16−8.10
(br m, 2H), 8.08−8.00 (m, 1.46H), 8.00−7.93 (m, 3.67H),
7.93−7.86 (m, 3.92H), 7.86−7.75 (series of m, 0.44H),
7.70 (app br d, <i>J</i> = 7.9 Hz, 0.69H), 7.44−7.28
(m, 4.39H), 7.05 (app s, 0.43H), 5.71 (app br s, 0.09H), 5.55−5.49
(m, 0.82H), 5.43−5.38 (m, 0.27H), 5.22−5.16 (m, 1.82H),
4.03−3.91 (m, 3H), 3.78−3.72 (m, 1.13H), 3.64−3.57
(m, 1.05H), 3.55/3.53 (2 s, 3H), 3.22−3.14 (m, 0.82H), 2.42−2.23
(2 m, 2.41H), 2.11−2.00 (m, 4.59H), 1.96−1.88 (m, 1H),
1.85/1.81 (2 s, 3H). LC (method 5): <i>t</i><sub>R</sub> = 21.1 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M
+ H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>43</sub>N<sub>8</sub>O<sub>5</sub>, 715.3; found, 715.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>43</sub>N<sub>8</sub>O<sub>5</sub>, 715.3356; found, 715.3369.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-acetamidopropanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
(<b>24</b>)</h3><div class="NLM_p last">Title compound <b>24</b> (TFA salt,
off-white solid). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.32 (br s, ∼3H), 8.31 (app br m,
0.11H), 8.24 (app d, <i>J</i> = 6.7 Hz, 0.77H), 8.21–8.03
(m, 1.78H), 8.03–7.88 (m, 7.48H), 7.87–7.64 (series
of m, 1.7H), 7.46–7.24 (series of m, 4.62H), 7.05 (app s, 0.54H),
5.89–5.66 (m, 0.24H), 5.57–5.46 (m, 0.79H), 5.40 (app
d, <i>J</i> = 7.3 Hz, 0.21H), 5.28–5.08 (m, 1.76H),
4.57 (app quint, <i>J</i> = 6.9 Hz, 0.82H), 4.31–4.13
(m, 0.18H), 3.99–3.91 (m, 1H), 3.91–3.83 (m, 1H), 3.69–3.58
(m, 1.17H), 3.54/3.53 (2 s, 3H), 3.25–3.12 (m, 0.83H), 2.47–2.33
(m, 1.58H), 2.33–2.15 (m, 1.04H), 2.15–1.96 (m, 4.38H),
1.96–1.88 (m, 1H), 1.87 (s, 2.25H), 1.82/1.81 (2 s, 0.75H),
1.23–1.21 (m, 2.69H), 0.93 (app d, <i>J</i> = 6.4
Hz, 0.31H). LC (method 2): <i>t</i><sub>R</sub> = 20.9 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>45</sub>N<sub>8</sub>O<sub>5</sub>, 729.4; found, 729.0. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>45</sub>N<sub>8</sub>O<sub>5</sub>, 729.3513; found, 729.3530.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-acetamidopropanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
(<b>25</b>)</h3><div class="NLM_p last">Title compound <b>25</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.48 (br s, ∼3H), 8.33 (app d, <i>J</i> = 7.3 Hz, 0.15H), 8.24 (app d, <i>J</i> = 7.3
Hz, 0.11H), 8.22−8.08 (m, 2.79H), 8.04−7.88 (m, 7.62H),
7.88−7.65 (m, 1.36H), 7.46−7.23 (m, 4.54H), 7.10−7.00
(m, 0.43H), 5.81−5.71 (m, 0.1H), 5.57−5.48 (m, 0.82H),
5.48−5.37 (m, 0.27H), 5.26−5.11 (m, 1.81H), 4.58 (app
quint, <i>J</i> = 7.0 Hz, 0.93H), 4.39−4.28 (m, 0.07H),
4.00−3.88 (m, 0.83H), 3.88−3.61 (m, 2.22H), 3.55/3.54/3.53
(3 s, 3H), 3.47−3.34 (m, 0.17H), 3.28−3.10 (m, 0.78H),
2.47−2.34 (m, 1.35H), 2.34−2.19 (m, 0.91H), 2.19−1.84
(2 m, 5.74H), 1.82 (s, 2.64H), 1.69 (s, 0.36H), 1.30−1.19 (m,
3H). LC (method 2): <i>t</i><sub>R</sub> = 20.4 min. LC/MS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>41</sub>H<sub>45</sub>N<sub>8</sub>O<sub>5</sub>, 729.35;
found, 729.33.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Methyl <i>N</i>-[(1<i>R</i>)-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-[(methoxycarbonyl)amino]propanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
(<b>26</b>)</h3><div class="NLM_p last">Title compound <b>26</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.44 (br s, ∼3H), 8.21−8.00
(m, 2.07H), 8.00−7.85 (m, 7.65H), 7.85−7.59 (m, 1.35H),
7.45−7.27 (m, 5.26H), 7.05 (app br s, 0.67H), 5.75−5.63
(m, 0.11H), 5.51 (app d, <i>J</i> = 7.6 Hz, 0.81H), 5.45−5.31
(m, 0.3H), 5.25−5.09 (m, 1.78H), 4.38 (app quint, <i>J</i> = 7.1 Hz, 0.82H), 4.18−4.09 (m, 0.09H), 4.09−4.01
(m, 0.09H), 3.99−3.88 (m, 0.94H), 3.86−3.78 (m, 0.91H),
3.78−3.59 (m, 1.24H), 3.55/3.53 (2 s, 5.7H), 3.37 (s, 0.3H),
3.24−3.12 (m, 0.91H), 2.47−2.32 (m, 1.37H), 2.32−2.16
(m, 1.04H), 2.16−1.97 (m, 4.24H), 1.97−1.73 (m, 1.35H),
1.21 (d, <i>J</i> = 6.7 Hz, 3H). LC (method 4): <i>t</i><sub>R</sub> = 26.9 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>45</sub>N<sub>8</sub>O<sub>6</sub>, 745.3; found, 745.2. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>41</sub>H<sub>45</sub>N<sub>8</sub>O<sub>6</sub>, 745.3462;
found, 745.3486.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-[(methoxycarbonyl)amino]propanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate
(<b>27</b>)</h3><div class="NLM_p last">Title compound <b>27</b> (TFA salt,
light yellow foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.50 (br s, ∼3H), 8.14 (app s, 2H),
7.97 (overlap of d & m, <i>J</i> = 8.5 Hz, 4.5H), 7.90
(d, <i>J</i> = 8.5 Hz, 3.5H), 7.48–7.44 (m, 1.85H),
7.03 (app br s, 0.15H), 5.42 (app br d, <i>J</i> = 8.5 Hz,
0.2H), 5.16 (m, 1.8H), 4.38 (app quint, <i>J</i> = 7.1 Hz,
1.8H), 4.11 (app quint, <i>J</i> = 7.2 Hz, 0.2H), 3.87–3.78
(m, 1.9H), 3.78–3.66 (m, 2.1H), 3.53 (s, 5.5H), 3.35 (s, 0.5H),
2.45–2.32 (m, 2H), 2.17–1.7 (1 major and 2 minor m,
6H), 1.21 (d, <i>J</i> = 7.0 Hz, 6H). LC (method 4): <i>t</i><sub>R</sub> = 20.5 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>36</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 683.3; found, 682.2. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>36</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 683.3306;
found, 683.3305.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Methyl <i>N</i>-[(2<i>R</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-[(methoxycarbonyl)amino]propanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate
(<b>28</b>)</h3><div class="NLM_p last">Title compound <b>28</b> (TFA salt,
white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.32 (br s, ∼3H), 8.16 (s, 1.77H), 8.07
(app br s, 0.30H), 7.98−7.95 (m, 3.65H), 7.92−7.91 (m,
4.28H), 7.65 (d, <i>J</i> = 4.6 Hz, 0.19H), 7.38 (d, <i>J</i> = 7.3 Hz, 1.66H), 6.89 (app br s, 0.15H), 5.76 (app br
s, 0.2H), 5.17 (m, 1.8H), 4.39 (app quint, <i>J</i> = 7.0
Hz, 1.59H), 4.30 (br m, 0.18H), 4.13−4.00 (m, 0.23H), 3.91−3.79
(m, 1.76H), 3.71−3.59 (m, 2.07H), 3.54 (overlapped s &
m, 6.17H), 2.46−2.32 (m, 2.21H), 2.23−2.00 (m, 5.29H),
1.97−1.77 (2 m, 0.5H), 1.21 (d, <i>J</i> = 7.0 Hz,
5.3H), 0.93 (d, <i>J</i> = 6.4 Hz, 0.7H). LC (method 6): <i>t</i><sub>R</sub> = 13.0 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>36</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 683.3; found, 683.4. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>36</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 683.3306;
found, 683.3318.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Ethyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-[(ethoxycarbonyl)amino]propanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate
(<b>29</b>)</h3><div class="NLM_p last">Title compound <b>29</b> (TFA salt,
white foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.48 (br s, ∼3H), 8.13 (s, 2H), 7.98−7.94
(m, 4.3H), 7.89 (d, <i>J</i> = 8.5 Hz, 3.7H), 7.42−7.38
(m, 1.85H), 7.02 (app d, <i>J</i> = 6.0 Hz, 0.15H), 5.40
(app d, <i>J</i> = 8.1 Hz, 0.15H), 5.16 (m, 1.85H), 4.37
(app quint, <i>J</i> = 7.1 Hz, 1.8H), 4.16−4.08 (m,
0.2H), 4.05−3.91 (m, 3.8H), 3.87−3.67 (m, 4.2H), 2.48−2.27
(m, 2.1H), 2.20−2.00 (m, 5.5H), 2.00−1.73 (m, 0.4H),
1.20 (app d, <i>J</i> = 6.8 Hz, 5.84H), 1.15 (app t, <i>J</i> = 7.1 Hz, 5.56H), 0.99 (app t, <i>J</i> = 7.1
Hz, 0.6H). LC (method 6): <i>t</i><sub>R</sub> = 14.2 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.4; found, 711.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.3619; found, 711.3621.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Methyl <i>N</i>-{1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-{2-[(methoxycarbonyl)amino]-2-methylpropanoyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-methyl-1-oxopropan-2-yl}carbamate
(<b>30</b>)</h3><div class="NLM_p last">Title compound <b>30</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.11 (br s, ∼3H), 8.17 (s, 2H), 8.08–7.81
(m, 10H), 5.22 (m, 2H), 3.87–3.69 (m, 3.45H), 3.67 (s, 6H),
3.55–3.38 (m, 0.55H), 2.46–2.23 (m, 2.1H), 2.21–2.05
(m, 2.1H), 2.05–1.87 (m, 3.8H), 1.34 (s, 12H). LC (method 9): <i>t</i><sub>R</sub> = 1.21 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.4; found, 711.5. HRMS
(ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd
for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.3619;
found, 711.3652.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Methyl <i>N</i>-{1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-{1-[(methoxycarbonyl)amino]cyclopropanecarbonyl}pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidine-1-carbonyl]cyclopropyl}carbamate
(<b>31</b>)</h3><div class="NLM_p last">Title compound <b>31</b> (TFA salt,
off-white solid). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.36 (br s, ∼3H), 8.21−8.06
(m, 3.33H), 8.02−7.88 (m, 8.03H), 7.82 (app br s, 0.36H), 7.73
(app br s, 0.28H), 5.65 (app br s, 0.23H), 5.21−5.02 (m, 1.77H),
3.97−3.83 (m, 1.6H), 3.83−3.67 (m, 1.86H), 3.62 (s,
4.43H), 3.47 (br s, 1.57H), 3.19 (br s, 0.54H), 2.46−2.27 (m,
1.9H), 2.27−1.81 (m, 5.1H), 1.80−1.43 (m, 1H), 1.38−1.21
(m, 2H), 1.21−1.06 (m, 2H), 1.06−0.90 (m, 2.2H), 0.90−0.65
(m, 1.8H). LC (method 9): <i>t</i><sub>R</sub> = 1.12 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 707.33; found, 707.45. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>43</sub>N<sub>8</sub>O<sub>6</sub>, 707.3306; found, 707.3309.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-[(methoxycarbonyl)amino]butanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate
(<b>32</b>)</h3><div class="NLM_p last">Title compound <b>32</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.62 (br s, ∼3H), 8.11 (br s, 2H),
8.01–7.92 (m, 4.3H), 7.89 (d, <i>J</i> = 7.9 Hz,
3.7H), 7.42–7.38 (m, 1.87H), 7.04–6.94 (m, 0.13H), 5.48–5.38
(m, 0.15H), 5.15 (dd, <i>J</i> = 7.9, 5.2 Hz, 1.85H), 4.24–4.19
(m, 1.86H), 3.95–3.90 (m, 0.29H), 3.87–3.66 (m, 3.81H),
3.54 (s, 5.34H), 3.45–3.38 (m, 0.26H), 3.36 (s, 0.44H), 2.46–2.30
(m, 2.1H), 2.24–1.98 (m, 5.55H), 1.98–1.90 (m, 0.27H),
1.84–1.63 (m, 2.12H), 1.58–1.35 (m, 1.96H), 0.89–0.84
(m, 6H). LC (method 8): <i>t</i><sub>R</sub> = 1.81 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.4; found, 711.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 711.3619; found, 711.3643.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Methyl <i>N</i>-[(2<i>S</i>,3<i>R</i>)-3-methoxy-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>,3<i>R</i>)-3-methoxy-2-[(methoxycarbonyl)
amino]butanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate
(<b>34</b>)</h3><div class="NLM_p last">Title compound <b>34</b> (TFA salt,
white solid). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.66 (br s, ∼3H), 8.14 (br s, 1.88H), 8.04−7.80
(m, 8.12H), 7.27 (d, <i>J</i> = 8.3 Hz, 1.88H), 6.80 (app
br s, 0.12H), 5.67 (app d, <i>J</i> = 7.0 Hz, 0.15H), 5.16
(app t, <i>J</i> = 7.0 Hz, 1.85H), 4.33 (dd, <i>J</i> = 8.3, 6.3 Hz, 1.65H), 4.28−4.23 (m, 0.35H), 3.97−3.78
(m, 3.7H), 3.64−3.58 (overlapping m & s, 7H), 3.50−3.40
(m, 0.3H), 3.36 (s, 0.5H), 3.29 (s, 0.5H), 3.21/3.19 (2 overlapping
s, 6H), 2.47−2.36 (m, 2.22H), 2.25−1.70 (m, 5.78H),
1.12 (d, <i>J</i> = 6.3 Hz, 0.5H), 1.04 (d, <i>J</i> = 6.3 Hz, 5.5H). LC (method 12): <i>t</i><sub>R</sub> =
2.82 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M +
H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>8</sub>, 771.4; found, 711.2. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>8</sub>, 771.3830; found, 771.3802.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Methyl <i>N</i>-[(1<i>S</i>)-1-cyclopropyl-2-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-cyclopropyl-2-[(methoxycarbonyl) amino]acetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-2-oxoethyl]carbamate
(<b>35</b>)</h3><div class="NLM_p last">Title compound <b>35</b> (TFA salt,
off-white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.59 (br s, ∼3H), 8.12 (br s, 2H),
7.96 (app d, <i>J</i> = 8.2 Hz, 3.7H), 7.90 (app d, <i>J</i> = 8.2 Hz, 4.3H), 7.57 (d, <i>J</i> = 7.9 Hz,
1.69H), 7.44 (app br s, 0.2H), 7.13 (app br s, 0.11H), 5.43 (app br
d, <i>J</i> = 7.6 Hz, 0.2H), 5.15 (app dd, <i>J</i> = 7.9, 5.2 Hz, 1.8H), 3.87–3.71 (3 overlapping m, 5.64H),
3.54 (s, 5.35H), 3.49–3.40 (m, 0.36H), 3.33 (s, 0.65H), 2.45–2.30
(m, 2.2H), 2.21–1.72 (series of m, 5.8H), 1.26–1.02
(m, 2H), 0.53–0.35 (m, 5.9H), 0.35–0.28 (m, 1.7H), 0.28–0.19
(m, 0.4H). LC (method 8): <i>t</i><sub>R</sub> = 1.81 min.
LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 735.36; found, 735.43. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>47</sub>N<sub>8</sub>O<sub>6</sub>, 735.3619; found, 735.3561.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-[(methoxycarbonyl)(methyl)amino]-3-methylbutanoyl]
pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-<i>N</i>-methylcarbamate (<b>36</b>)</h3><div class="NLM_p last">Title compound <b>36</b> (TFA salt, semicrystalline white foam). <sup>1</sup>H NMR
(400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.57 (br
s, ∼3H), 8.11 (app br s, 2H), 7.95 (app d, <i>J</i> = 8.1 Hz, 4H), 7.89 (app d, <i>J</i> = 8.1 Hz, 4H), 5.70−5.55
(2 m, 0.2H), 5.24−5.14 (m, 1.8H), 4.61−4.36 (m, 2H),
3.94−3.73 (2 m, 2.3H), 3.69/3.66 (2 s, 5.4H), 3.64−3.42
(2 m, 1.7H), 3.27/3.19 (2 s, 0.6H), 2.72/2.70/2.63/2.60 (4 s, 6H),
2.46−2.32 (m, 2.06H), 2.24−1.93 (m, 7.68H), 1.81−1.64
(m, 0.26H), 0.91−0.88 (m, 0.63H), 0.81−0.77 (m, 10.49H),
0.74−0.59 (2 m, 0.88H). LC (method 9): <i>t</i><sub>R</sub> = 1.46 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>42</sub>H<sub>55</sub>N<sub>8</sub>O<sub>6</sub>, 767.4; found, 767.4. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>42</sub>H<sub>55</sub>N<sub>8</sub>O<sub>6</sub>, 767.4245; found, 767.4252.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>S</i>)-2-acetamido-3-methylbutanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]acetamide
(<b>37</b>)</h3><div class="NLM_p last">Title compound <b>37</b> (TFA salt,
white solid). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.63 (br s, ∼3H), 8.23–8.09 (m,
2.16H), 8.04 (d, <i>J</i> = 8.5 Hz, 1.92H), 8.01–7.92
(m, 4.39H), 7.90 (app d, <i>J</i> = 8.5 Hz, 3.53H), 5.60
(app d, <i>J</i> = 7.3 Hz, 0.23H), 5.14 (app t, <i>J</i> = 7.2 Hz, 1.77H), 4.38 (app t, <i>J</i> = 7.9
Hz, 1.75H), 4.19 (app t, <i>J</i> = 7.9 Hz, 0.25H), 3.97–3.87
(m, 1.73H), 3.87–3.77 (m, 1.78H), 3.76–3.63 (m, 0.28H),
3.54–3.38 (m, 0.21H), 2.49–2.24 (m, 2.42H), 2.23–1.91
(m, 7.58H), 1.87 (s, 5.41H), 1.74 (s, 0.59H), 0.97–0.88 (m,
1.15H), 0.83 (d, <i>J</i> = 6.7 Hz, 5.25H), 0.80 (d, <i>J</i> = 6.7 Hz, 5.60H). LC (method 13): <i>t</i><sub>R</sub> = 2.05 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>, 707.40; found, 707.77. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>, 707.4033; found, 707.4004.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-[(2<i>R</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-acetamido-3-methylbutanoyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]acetamide
(<b>38</b>)</h3><div class="NLM_p last">Title compound <b>38</b> (TFA salt,
off-white solid). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.33 (br s, ∼3H), 8.30 (br d, <i>J</i> = 6.7 Hz, 0.33H), 8.21−8.03 (m, 3.79H), 8.03−7.79
(m, 7.88H), 6.08−5.88 (m, 0.25H), 5.23 (dd, <i>J</i> = 8.2, 4.0 Hz, 1.75H), 4.43 (app t, <i>J</i> = 7.8 Hz,
1.64H), 3.99−3.87 (m, 2.28H), 3.76−3.62 (m, 1.86H),
3.52−3.40 (m, 0.22H), 2.48−2.26 (m, 2.03H), 2.20−2.00
(m, 5.33H), 2.00−1.91 (m, 2.29H), 1.90 (s, 5.11H), 1.87 (s,
0.89H), 1.84−1.75 (m, 0.35H), 0.97−0.84 (m, 10.44H),
0.73 (d, <i>J</i> = 6.7 Hz, 0.81H), 0.45 (d, <i>J</i> = 6.4 Hz, 0.75H). LC (method 8): <i>t</i><sub>R</sub> =
1.93 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M +
H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>, 707.4; found, 707.6. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>, 707.4033; found, 707.4054.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamate
(<b>39</b>)</h3><div class="NLM_p last">Title compound <b>39</b> (TFA salt,
white foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.61 (br s, ∼2H), 9.82 (br s, ∼1H),
8.13 (s, 1.26H), 8.06 (br s, 0.9H), 8.00−7.85 (m, 7.89H), 7.81−7.64
(m, 2.04H), 7.63−7.51 (m, 2.68H), 7.49−7.42 (m, 0.77H),
7.23 (m, 0.18H), 7.16 (m, 0.26H), 7.03 (m, 0.02H), 5.99 (app br s,
0.1H), 5.55 (app br s, 0.16H), 5.44 (s, 0.96H), 5.24−5.10 (m,
1.78H), 4.44−4.31 (m, 0.93H), 4.16−4.04 (m, 1H), 3.88−3.70
(2 m, 2.07H), 3.53 (s, 2.73H), 3.35 (s, 0.27H), 3.34−3.12 (m,
2H), 3.12−3.01 (m, 1H), 2.98−2.84 (app br s, 1H), 2.65−2.53
(br m partially overlapped with DMSO signal, 1H), 2.47−2.30
(m, 1.16H), 2.30−2.16 (m, 0.94H), 2.16−1.98 (m, 4.5H),
1.98−1.66 (m, 1.4H), 1.34−1.00 (d overlapped with series
of m, <i>J</i> = 7.0 Hz, 9H). LC (method 6): <i>t</i><sub>R</sub> = 12.60 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>43</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>, 743.4; found, 743.5. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>43</sub>H<sub>51</sub>N<sub>8</sub>O<sub>4</sub>: 743.4033; found,
743.4053.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-1-oxobutan-2-yl]carbamate
(<b>40</b>)</h3><div class="NLM_p last">Title compound <b>40</b> (TFA salt,
light-yellow foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.71 (br s, ∼3H), 9.78 (br s, ∼1H),
8.13 (app br s, 1.26H), 8.04 (app br s, 0.97H), 7.99−7.82 (m,
7.80H), 7.78−7.64 (m, 2H), 7.63−7.51 (m, 2.67H), 7.44
(app d, <i>J</i> = 8.5 Hz, 0.09H), 7.39 (d, <i>J</i> = 7.9 Hz, 0.75H), 7.29−7.19 (m, 0.19H), 7.19−7.09
(m, 0.24H), 7.03−6.92 (m, 0.03H), 5.98 (app br s, 0.09H), 5.54
(app br s, 0.13H), 5.49−5.40 (m, 0.98H), 5.25−5.08 (m,
1.8H), 4.28−4.16 (m, 0.97H), 4.16−4.04 (m, 0.93H), 3.91−3.64
(m, 2.16H), 3.54 (s, 2.76H), 3.35 (s, 0.24H), 3.33−3.13 (m,
1.8H), 3.13−2.99 (m, 1.11H), 2.99−2.80 (m, 1.03H), 2.68−2.51
(m, ∼1H), 2.45−2.32 (m, 1.44H), 2.28−1.86 (series
of m, 6.56H), 1.82−1.68 (m, 1H), 1.53−1.42 (m, 1H),
1.34−0.98 (series of m, 5.97H), 0.90−0.84 (m, 3.03H).
LC (method 8): <i>t</i><sub>R</sub> = 1.74 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>44</sub>H<sub>53</sub>N<sub>8</sub>O<sub>4</sub>, 757.4; found, 757.4.
HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>44</sub>H<sub>53</sub>N<sub>8</sub>O<sub>4</sub>, 757.4190; found, 757.4212.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Methyl <i>N</i>-[(2<i>S</i>)-1-[(2<i>S</i>)-2-{5-[4-(4-{2-[(2<i>S</i>)-1-[(2<i>R</i>)-2-(diethylamino)-2-phenylacetyl]pyrrolidin-2-yl]-1<i>H</i>-imidazol-5-yl}phenyl)phenyl]-1<i>H</i>-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
(<b>41</b>)</h3><div class="NLM_p last">Title compound <b>41</b> (TFA salt,
tan foam). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): δ 14.74 (br s, ∼2H), 9.80 (br s, ∼1H),
8.12 (app br s, 1.24H), 8.09–7.82 (m, 8.71H), 7.82–7.65
(m, 2.05H), 7.65–7.42 (m, 2.80H), 7.33 (d, <i>J</i> = 8.5 Hz, 0.79H), 7.27–7.19 (m, 0.20H), 7.18–7.12
(m, 0.21H), 5.96 (app br s, 0.09H), 5.64–5.49 (m, 0.24H), 5.44
(app s, 0.87H), 5.25–5.06 (m, 1.8H), 4.21–4.03 (m, 1.80H),
3.95–3.68 (m, 2.20H), 3.54 (s, 2.75H), 3.34 (s, 0.25H), 3.33–3.13
(m, 2H), 3.13–3.02 (m, 1H), 3.02–2.79 (m, 1H), 2.68–2.54
(m, ∼1H), 2.46–2.30 (m, 1.3H), 2.30–2.14 (m,
1.79H), 2.14–1.96 (m, 4.76H), 1.96–1.84 (m, 0.98H),
1.84–1.63 (m, 0.17H), 1.38–0.96 (series of m, 6H), 0.96–0.85
(m, 1.18H), 0.84 (d, <i>J</i> = 6.7 Hz, 2.32H), 0.79 (d, <i>J</i> = 6.7 Hz, 2.50H). LC (method 8): <i>t</i><sub>R</sub> = 1.76 min. LC/MS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>45</sub>H<sub>55</sub>N<sub>8</sub>O<sub>4</sub>, 771.4; found, 771.5. HRMS (ESI) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>45</sub>H<sub>55</sub>N<sub>8</sub>O<sub>4</sub>, 771.4346; found, 771.4379.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Virology Assay</h3><div class="NLM_p last">The tabulated activity and cytotoxicity
data are mean values of at least two experiments, and in general,
the replicon assay exhibits a maximum of 3-fold variation. GT-1a/-1b
HCV and BVDV EC<sub>50</sub> values were obtained from FRET and Luciferase
assays, respectively. Details of the biological assays used in the
characterizations of final compounds are provided in ref <a onclick="showRef(event, 'cit7d'); return false;" href="javascript:void(0);" class="ref cit7d">(6d)</a>.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> PK Assessment</h3><div class="NLM_p">Rat PK studies (4 and/or 24 h): Two animals
per dosing group were used in the 4 h rat PK screens, where plasma
was sampled at 0.25, 0.5, 1, 2, and 4 h, and liver samples were obtained
at the 4 h study termination. In the case of 24 h rat PK studies,
a total of three animals per dosing group were used, where plasma
was sampled for a total of eight time points (0.25, 0.5, 1, 2, 4,
6, 8, and 24 h), and liver samples were obtained at study termination.
Unless noted otherwise, PEG-400 was the dosing vehicle for the rat
PK studies.</div><div class="NLM_p last">Vehicle information for multispecies PO-PK data
summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>: compound <b>33</b>, rat (100% PEG-400); dog (60% PEG-400, 10% ethanol, 30% water);
monkey (PEG-400/povidone K-30/Vitamin E TPGS/Tween-80 in 95:2:2:1
ratio). Compound <b>39</b>, rat, dog, and monkey (PEG-400/povidone
K-30/Vitamin E TPGS/Tween-80 in 95:2:2:1 ratio).</div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Bioactivation
Study</h3><div class="NLM_p last">The compound (10 μM) was
incubated with human liver microsomes (1 mg protein/mL) in phosphate
buffer (50 mM; pH 7.4) at 37 °C for 30 min. The incubation was
supplemented with NADPH (1 mM) and either GSH (5 mM) or potassium
cyanide (1 mM). The incubation mixture was treated with a single volume
of CH<sub>3</sub>CN and centrifuged at 1000<i>g</i> to obtain
supernatant, which was stored at 4 °C until LC/MS analysis. Chromatographic
separation was carried out using an HPLC system that consisted of
a Waters (Milford, MA) Alliance 2695 Separations Module and a Phenomenex
Luna C18 column (2 × 150 mm, 3 μm). The mobile phase consisted
of 10 mM NH<sub>4</sub>OAc (pH 5) in H<sub>2</sub>O/CH<sub>3</sub>CN (95/5 v/v) (solvent-A) and CH<sub>3</sub>CN (solvent-B) at 200
μL/min with the following gradient conditions: 0% B isocratic
for 5 min, 0–90% B over 25 min, and 90% B isocratic for 15
min. Assessment for the presence of GSH and cyano adducts was made
on the basis of LC/MS and LC/MS/MS data.</div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Solubility Assessment</h3><div class="NLM_p last">The compound is incubated in
25 mM aqueous phosphate buffer (pH 6.5) in a sealed 1 fluid dram glass
vial at 22 °C for 24 h, while being agitated with an Orbitron
Rotator. The mixture was centrifuged and filtered through a 0.45 μm
PTFE filter membrane. To minimize a potential filter-adsorption effect,
the first 100 μL of the filtrate was discarded. Sample concentration
was determined by HPLC using an Agilent 1200 equipped with UV detection.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm401836p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Makonen Belema</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cfa2aea4a0a1aaa1e1adaaa3aaa2ae8fada2bce1aca0a2"><span class="__cf_email__" data-cfemail="7b161a1014151e1555191e171e161a3b19160855181416">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Van N. Nguyen</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carol Bachand</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dan H. Deon</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason
T. Goodrich</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clint A. James</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rico Lavoie</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Omar D. Lopez</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alain Martel</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey L. Romine</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Edward H. Ruediger</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Discovery Chemistry, Bristol-Myers Squibb
Pharmaceutical Research Institute
					, 100 boul. De l’Industrie, Candiac, Que., Canada J5R 1J1 </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence B. Snyder</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denis R. St. Laurent</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fukang Yang</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juliang Zhu</span> - <span class="hlFld-Affiliation affiliation"> Discovery Chemistry
Synthesis
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Henry
S. Wong</span> - <span class="hlFld-Affiliation affiliation"> Discovery Chemistry
Synthesis
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David R. Langley</span> - <span class="hlFld-Affiliation affiliation"> Computer-Assisted
Drug Design
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen P. Adams</span> - <span class="hlFld-Affiliation affiliation"> Pharmaceutical Candidate Optimization
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Glenn H. Cantor</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research
and Development
					, 311 Pennington-Rocky
Hill Road, Pennington, New
Jersey 08534, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anjaneya Chimalakonda</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research
and Development
					, 311 Pennington-Rocky
Hill Road, Pennington, New
Jersey 08534, United
States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aberra Fura</span> - <span class="hlFld-Affiliation affiliation">
					 Department
of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research
and Development
					, Route
206 and Province Line Road, Princeton, New Jersey 08543, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin M. Johnson</span> - <span class="hlFld-Affiliation affiliation"> Pharmaceutical Candidate Optimization
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jay O. Knipe</span> - <span class="hlFld-Affiliation affiliation"> Pharmaceutical Candidate Optimization
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dawn D. Parker</span> - <span class="hlFld-Affiliation affiliation"> Pharmaceutical Candidate Optimization
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kenneth
S. Santone</span> - <span class="hlFld-Affiliation affiliation"> Pharmaceutical Candidate Optimization
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert A. Fridell</span> - <span class="hlFld-Affiliation affiliation"> Virology, Bristol-Myers Squibb Research
and Development
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie A. Lemm</span> - <span class="hlFld-Affiliation affiliation"> Virology, Bristol-Myers Squibb Research
and Development
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Donald R. O’Boyle</span> - <span class="hlFld-Affiliation affiliation"> Virology, Bristol-Myers Squibb Research
and Development
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard J. Colonno</span> - <span class="hlFld-Affiliation affiliation"> Virology, Bristol-Myers Squibb Research
and Development
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Gao</span> - <span class="hlFld-Affiliation affiliation"> Virology, Bristol-Myers Squibb Research
and Development
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas
A. Meanwell</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence G. Hamann</span> - <span class="hlFld-Affiliation affiliation"> Departments of Discovery Chemistry
					
						, , , and , 
					, 5 Research
Parkway, Wallingford, Connecticut 06492, United States </span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no
competing financial interest.<br /></br><p class="inlineNote">The discovery chemistry
effort at Bristol-Myers Squibb Pharmaceutical
Research Institute, Candiac, Que. lasted until June 2007.</p></div></li></ul></div><div class="ack" id="ACK-d7e8554-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i62">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47412" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47412" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the following members of
our analytical and separation
groups for the diverse role they played in enabling the work described
in this manuscript: Jingfang Cutrone, Dieter Drexler, Xiaohu Huang,
Edward S. Kozlowski, and Julia M. Nielson. We thank Gerry G. Everlof
and Lucy Sun for conducting the solubility and the patch-clamp ion
channel inhibition assessments, respectively, and John G. Houston
 and Carl P. Decicco for their guidance and support.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81228" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81228" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 21 other publications.
        </p><ol id="references" class="useLabel"><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Simeprevir: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2093</span>– <span class="NLM_lpage">2106,</span>, and references cited therein</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1007%2Fs40265-013-0153-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24293133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSqsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2093-2106%2C&author=A.+Vaidyaauthor=C.+M.+Perry&title=Simeprevir%3A+First+global+approval"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Simeprevir: First Global Approval</span></div><div class="casAuthors">Vaidya, Asha; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2093-2106</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Simeprevir (SovriadTM) is a new direct-acting antiviral drug and a second-generation small-mol. NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).  Simeprevir antiviral activity is achieved by its non-covalent binding to HCV protease, with a fast assocn. and slow dissocn. rate.  The capsule formulation is approved in Japan and Canada for use in combination with pegylated interferon (peginterferon) and ribavirin for genotype 1 chronic hepatitis C, and has been filed for approval in the US in this indication.  In addn., the capsule formulation has been filed for approval in the EU for use in combination with peginterferon and ribavirin for genotype 1 and 4 chronic hepatitis C. Phase III trials of the capsule formulation of simeprevir are underway in several other regions, including China.  In the pivotal phase III trials, simeprevir was administered once daily for 12 wk in combination with peginterferon and ribavirin for 24 or 48 wk.  This article summarizes the milestones in the development of simeprevir leading to this first approval for chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVExWf01G6I7Vg90H21EOLACvtfcHk0liJMCpWvMXK6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSqsbbM&md5=ace8fa9b2a0b8e84fbce326ae458b6b6</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0153-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0153-9%26sid%3Dliteratum%253Aachs%26aulast%3DVaidya%26aufirst%3DA.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DSimeprevir%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D2093%26epage%3D2106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayali, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arterburn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younossi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir for previously untreated chronic hepatitis C infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1878</span>– <span class="NLM_lpage">1887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1056%2FNEJMoa1214853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23607594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1878-1887&author=E.+Lawitzauthor=A.+Mangiaauthor=D.+Wylesauthor=M.+Rodriguez-Torresauthor=T.+Hassaneinauthor=S.+C.+Gordonauthor=M.+Schultzauthor=M.+N.+Davisauthor=Z.+Kayaliauthor=K.+R.+Reddyauthor=I.+M.+Jacobsonauthor=K.+V.+Kowdleyauthor=L.+Nybergauthor=G.+M.+Subramanianauthor=R.+H.+Hylandauthor=S.+Arterburnauthor=D.+Jiangauthor=J.+McNallyauthor=D.+Brainardauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+M.+Sheikhauthor=Z.+Younossiauthor=E.+J.+Gane&title=Sofosbuvir+for+previously+untreated+chronic+hepatitis+C+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir for previously untreated chronic hepatitis C infection</span></div><div class="casAuthors">Lawitz, Eric; Mangia, Alessandra; Wyles, David; Rodriguez-Torres, Maribel; Hassanein, Tarek; Gordon, Stuart C.; Schultz, Michael; Davis, Mitchell N.; Kayali, Zeid; Reddy, K. Rajender; Jacobson, Ira M.; Kowdley, Kris V.; Nyberg, Lisa; Subramanian, G. Mani; Hyland, Robert H.; Arterburn, Sarah; Jiang, Deyuan; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Sheikh, Aasim M.; Younossi, Zobair; Gane, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1878-1887</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background. In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.  Methods. We conducted two phase 3 studies in previously untreated patients with HCV infection.  In a single-group, open-label study, we administered a 12-wk regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with HCV genotype 1, 4, 5, or 6 (of whom 98% had genotype 1 or 4).  In a noninferiority trial, 499 patients with HCV genotype 2 or 3 infection were randomly assigned to receive sofosbuvir plus ribavirin for 12 wk or peginterferon alfa-2a plus ribavirin for 24 wk.  In the two studies, the primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results. In the single-group study, a sustained virol. response was reported in 90% of patients (95% confidence interval, 87 to 93).  In the noninferiority trial, a sustained response was reported in 67% of patients in both the sofosbuvir-ribavirin group and the peginterferon-ribavirin group.  Response rates in the sofosbuvir-ribavirin group were lower among patients with genotype 3 infection than among those with genotype 2 infection (56% vs. 97%).  Adverse events (including fatigue, headache, nausea, and neutropenia) were less common with sofosbuvir than with peginterferon.  Conclusions. In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virol. response of 90% at 12 wk.  In a noninferiority trial, patients with genotype 2 or 3 infection who received either sofosbuvir or peginterferon with ribavirin had nearly identical rates of response (67%).  Adverse events were less frequent with sofosbuvir than with peginterferon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmr2x-ct3irVg90H21EOLACvtfcHk0liJMCpWvMXK6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrY%253D&md5=09e3e6abc636e8d93a12e3b8382a7f63</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214853%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DSchultz%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DKayali%26aufirst%3DZ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DNyberg%26aufirst%3DL.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DArterburn%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26atitle%3DSofosbuvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1878%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit2c"><span>
					<span class="NLM_label">(c) </span> <span class="NLM_contrib-group">Gilead
Sciences, Inc.</span> U.S. Food and Drug Administration approves
Gilead’s Sovaldi<sup>TM</sup> (sofosbuvir) for the treatment
of chronic hepatitis C. <a href="http://www.gilead.com/news/press-releases" class="extLink">http://www.gilead.com/news/press-releases</a>, Dec. 6, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+Gilead%0ASciences%2C+Inc.+U.S.+Food+and+Drug+Administration+approves%0AGilead%E2%80%99s+SovaldiTM+%28sofosbuvir%29+for+the+treatment%0Aof+chronic+hepatitis+C.+http%3A%2F%2Fwww.gilead.com%2Fnews%2Fpress-releases%2C+Dec.+6%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0lgRDS5a9NL8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit4a"><span>
					<span class="NLM_label">(a) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Link, J. O. </span>; <span class="NLM_string-name">
							Taylor, J. G. </span>; <span class="NLM_string-name">
							Xu, L. </span>; <span class="NLM_string-name">
							Mitchell, M. L. </span>; <span class="NLM_string-name">
							Guo, H. </span>; <span class="NLM_string-name">
							Liu, H. </span>; <span class="NLM_string-name">
							Kato, D. </span>; <span class="NLM_string-name">
							Kirschberg, T. </span>; <span class="NLM_string-name">
							Sun, J. </span>; <span class="NLM_string-name">
							Squires, N. </span>; <span class="NLM_string-name">
							Parrish, J. </span>; <span class="NLM_string-name">
							Kellar, T. </span>; <span class="NLM_string-name">
							Yang, Z.-Y. </span>; <span class="NLM_string-name">
							Yang, C. </span>; <span class="NLM_string-name">
							Matles, M. </span>; <span class="NLM_string-name">
							Wang, Y. </span>; <span class="NLM_string-name">
							Wang, K. </span>; <span class="NLM_string-name">
							Cheng, G. </span>; <span class="NLM_string-name">
							Tian, Y. </span>; <span class="NLM_string-name">
							Mogalian, E. </span>; <span class="NLM_string-name">
							Mondou, E. </span>; <span class="NLM_string-name">
							Cornpropst, M. </span>; <span class="NLM_string-name">
							Perry, J. </span>; <span class="NLM_string-name">
							Desai, M. C. </span> </span> <span> </span><span class="NLM_article-title">The discovery of ledipasvir
(GS-5885), a potent once-daily oral NS5A inhibitor for the treatment
of hepatitis C virus infection</span>.  <i>J. Med. Chem.</i> DOI: <span class="refDoi"> DOI: 10.1021/jm401499</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1021%2Fjm401499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09Link%2C+J.+O.+%3B+%0A%09%09%09%09%09%09%09Taylor%2C+J.+G.+%3B+%0A%09%09%09%09%09%09%09Xu%2C+L.+%3B+%0A%09%09%09%09%09%09%09Mitchell%2C+M.+L.+%3B+%0A%09%09%09%09%09%09%09Guo%2C+H.+%3B+%0A%09%09%09%09%09%09%09Liu%2C+H.+%3B+%0A%09%09%09%09%09%09%09Kato%2C+D.+%3B+%0A%09%09%09%09%09%09%09Kirschberg%2C+T.+%3B+%0A%09%09%09%09%09%09%09Sun%2C+J.+%3B+%0A%09%09%09%09%09%09%09Squires%2C+N.+%3B+%0A%09%09%09%09%09%09%09Parrish%2C+J.+%3B+%0A%09%09%09%09%09%09%09Kellar%2C+T.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+Z.-Y.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+C.+%3B+%0A%09%09%09%09%09%09%09Matles%2C+M.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+K.+%3B+%0A%09%09%09%09%09%09%09Cheng%2C+G.+%3B+%0A%09%09%09%09%09%09%09Tian%2C+Y.+%3B+%0A%09%09%09%09%09%09%09Mogalian%2C+E.+%3B+%0A%09%09%09%09%09%09%09Mondou%2C+E.+%3B+%0A%09%09%09%09%09%09%09Cornpropst%2C+M.+%3B+%0A%09%09%09%09%09%09%09Perry%2C+J.+%3B+%0A%09%09%09%09%09%09%09Desai%2C+M.+C.+The+discovery+of+ledipasvir%0A%28GS-5885%29%2C+a+potent+once-daily+oral+NS5A+inhibitor+for+the+treatment%0Aof+hepatitis+C+virus+infection.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm401499."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fjm401499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26atitle%3DThe%2520discovery%2520of%2520ledipasvir%250A%2528GS-5885%2529%252C%2520a%2520potent%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%250Aof%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm401499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfret, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkison, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Serres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goljer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus NS5A, in healthy subjects and subjects chronically infected with genotype 1 hepatitis C virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5037</span>– <span class="NLM_lpage">5044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.00910-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23896477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVygtLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5037-5044&author=D.+A.+Wilfretauthor=J.+Walkerauthor=K.+K.+Adkisonauthor=L.+A.+Jonesauthor=Y.+Louauthor=J.+Ganauthor=S.+Castellinoauthor=C.+L.+Moseleyauthor=J.+Hortonauthor=M.+de+Serresauthor=A.+Culpauthor=I.+Goljerauthor=W.+Spreen&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+antiviral+activity+of+GSK2336805%2C+an+inhibitor+of+hepatitis+C+virus+NS5A%2C+in+healthy+subjects+and+subjects+chronically+infected+with+genotype+1+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1</span></div><div class="casAuthors">Wilfret, D. A.; Walker, J.; Adkison, K. K.; Jones, L. A.; Lou, Y.; Gan, J.; Castellino, S.; Moseley, C. L.; Horton, J.; de Serres, M.; Culp, A.; Goljer, I.; Spreen, W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5037-5044</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GSK2336805 is an orally bioavailable hepatitis C virus (HCV) inhibitor working through an NS5A-mediated mechanism.  This first-time-in-human study was conducted to assess the safety, tolerability, pharmacokinetics, metab., and efficacy of GSK2336805 in healthy subjects and subjects infected with HCV genotype 1.  We performed a three-part, randomized, double-blind, placebo-controlled study in 46 healthy subjects and 23 HCV-infected subjects.  After an overnight fast, healthy subjects received GSK2336805 as 10 mg, 30 mg, 30 mg plus food, and 60 mg in a single dose and 10 mg (7 days), 30 mg (7 days), and 75 mg (14 days) in a once-daily multiple dose.  Subjects with HCV received GSK2336805 as a 1- to 120-mg single dose.  In subjects with HCV, redns. in HCV RNA were obsd. within 4 h and a single dose of GSK2336805 of ≥10 mg resulted in a statistically significant ≥2-log redn. in HCV RNA compared with placebo at 24 h postdose.  GSK2336805 was readily absorbed in all subjects, and the half-life (t1/2) was suitable for once-daily dosing.  Administration of GSK2336805 with food had no effect on plasma GSK2336805 exposure; however, absorption was delayed, with a median tmax (time to max. concn. of drug in serum) of 4.5 vs. 2.0 h.  Twenty subjects who received GSK2336805 experienced mild to moderate adverse events; none were serious.  GSK2336805 was well tolerated and exhibited rapid, significant antiviral activity after a single dose in HCV-infected subjects.  These results support the conduct of further studies evaluating GSK2336805 administered once daily for longer durations in combination with peginterferon, ribavirin, and other direct-acting antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGopPgP3XCh7Vg90H21EOLACvtfcHk0lgRDS5a9NL8Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVygtLfN&md5=8e9f3eee73c0e688f1dae5510f3c1fc7</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1128%2FAAC.00910-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00910-13%26sid%3Dliteratum%253Aachs%26aulast%3DWilfret%26aufirst%3DD.%2BA.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DMoseley%26aufirst%3DC.%2BL.%26aulast%3DHorton%26aufirst%3DJ.%26aulast%3Dde%2BSerres%26aufirst%3DM.%26aulast%3DCulp%26aufirst%3DA.%26aulast%3DGoljer%26aufirst%3DI.%26aulast%3DSpreen%26aufirst%3DW.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520antiviral%2520activity%2520of%2520GSK2336805%252C%2520an%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS5A%252C%2520in%2520healthy%2520subjects%2520and%2520subjects%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5037%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fcmdc.201300343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24127258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1930-1940&author=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=W.+Changauthor=C.+M.+Fandozziauthor=D.+J.+Grahamauthor=B.+Huauthor=Q.+Huangauthor=S.+Kargmanauthor=J.+Kozlowskiauthor=R.+Liuauthor=J.+A.+McCauleyauthor=A.+A.+Nomeirauthor=R.+M.+Sollauthor=J.+P.+Vaccaauthor=D.+Wangauthor=H.+Wuauthor=B.+Zhongauthor=D.+B.+Olsenauthor=S.+W.+Ludmerer&title=Discovery+of+MK-8742%3A+An+HCV+NS5A+inhibitor+with+broad+genotype+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span></div><div class="casAuthors">Coburn, Craig A.; Meinke, Peter T.; Chang, Wei; Fandozzi, Christine M.; Graham, Donald J.; Hu, Bin; Huang, Qian; Kargman, Stacia; Kozlowski, Joseph; Liu, Rong; McCauley, John A.; Nomeir, Amin A.; Soll, Richard M.; Vacca, Joseph P.; Wang, Dahai; Wu, Hao; Zhong, Bin; Olsen, David B.; Ludmerer, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1930-1940</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The NS5A protein plays a crit. role in the replication of HCV and has been the focus of numerous research efforts over the past few years.  NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens.  Early work in the NS5A arena led to the discovery of our first clin. candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole].  While preclin. proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compds. with increased potency against a no. of genotypes and NS5A resistance mutations.  Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virol. profiles.  Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clin. trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknZKO01aZlLVg90H21EOLACvtfcHk0ljt_BWjlyvOJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN&md5=2f2b3ed2281c43e39b24d4197b9f57ee</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300343%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520MK-8742%253A%2520An%2520HCV%2520NS5A%2520inhibitor%2520with%2520broad%2520genotype%2520activity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1930%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=15793110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span></div><div class="casAuthors">O'Boyle, Donald R., II; Nower, Peter T.; Lemm, Julie A.; Valera, Lourdes; Sun, Jin-Hua; Rigat, Karen; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1346-1353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replicon is a unique system for the development of a high-throughput screen (HTS), since the anal. of inhibitors requires the quantification of a decrease in a steady-state level of HCV RNA.  HCV replicon replication is dependent on host cell factors, and any toxic effects may have a significant impact on HCV replicon replication.  Therefore, detg. the antiviral specificity of compds. presents a challenge for the identification of specific HCV inhibitors.  Here we report the development of an HCV/bovine viral diarrhea virus (BVDV) dual replicon assay suitable for HTS to address these issues.  The HCV reporter enzyme is the endogenous NS3 protease contained within the HCV genome, while the BVDV reporter enzyme is a luciferase enzyme engineered into the BVDV genome.  The HTS uses a mixt. of HCV and BVDV replicon cell lines placed in the same well of a 96-well plate and isolated in the same cell backgrounds (Huh-7).  The format consists of three sep. but compatible assays: the first quantitates the amt. of cytotoxicity based upon the conversion of Alamar blue dye via cellular enzymes, while the second indirectly quantitates HCV replicon replication through measurement of the amt. of NS3 protease activity present.  The final assay measures the amt. of luciferase activity present from the BVDV replicon cells, as an indicator of the specificity of the test compds.  This HCV/BVDV dual replicon assay provides a reliable format to det. the potency and specificity of HCV replicon inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX8Ni-3CK40LVg90H21EOLACvtfcHk0ljt_BWjlyvOJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D&md5=0f9a5c1fa35bf1aa1ea4ac5b2d71b859</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19812153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of hepatitis C virus NS5A inhibitors</span></div><div class="casAuthors">Lemm Julie A; O'Boyle Donald 2nd; Liu Mengping; Nower Peter T; Colonno Richard; Deshpande Milind S; Snyder Lawrence B; Martin Scott W; St Laurent Denis R; Serrano-Wu Michael H; Romine Jeffrey L; Meanwell Nicholas A; Gao Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using a cell-based replicon screen, we identified a class of compounds with a thiazolidinone core structure as inhibitors of hepatitis C virus (HCV) replication.  The concentration of one such compound, BMS-824, that resulted in a 50% inhibition of HCV replicon replication was approximately 5 nM, with a therapeutic index of >10,000.  The compound showed good specificity for HCV, as it was not active against several other RNA and DNA viruses.  Replicon cells resistant to BMS-824 were isolated, and mutations were identified.  A combination of amino acid substitutions of leucine to valine at residue 31 (L31V) and glutamine to leucine at residue 54 (Q54L) in NS5A conferred resistance to this chemotype, as did a single substitution of tyrosine to histidine at amino acid 93 (Y93H) in NS5A.  To further explore the region(s) of NS5A involved in inhibitor sensitivity, genotype-specific NS5A inhibitors were used to evaluate a series of genotype 1a/1b hybrid replicons.  Our results showed that, consistent with resistance mapping, the inhibitor sensitivity domain also mapped to the N terminus of NS5A, but it could be distinguished from the key resistance sites.  In addition, we demonstrated that NS5A inhibitors, as well as an active-site inhibitor that specifically binds NS3 protease, could block the hyperphosphorylation of NS5A, which is believed to play an essential role in the viral life cycle.  Clinical proof of concept has recently been achieved with derivatives of these NS5A inhibitors, indicating that small molecules targeting a nontraditional viral protein like NS5A, without any known enzymatic activity, can also have profound antiviral effects on HCV-infected subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeii-SeNfkQYUSrryheKE6fW6udTcc2eYdwj_5g50Z6rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D&md5=691db815a886509d5b225bbbd068b82c</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3795</span>– <span class="NLM_lpage">3802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21576451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span></div><div class="casAuthors">Lemm, Julie A.; Leet, John E.; O'Boyle, Donald R., II; Romine, Jeffrey L.; Huang, Xiaohua Stella; Schroeder, Daniel R.; Alberts, Jeffrey; Cantone, Joseph L.; Sun, Jin-Hua; Nower, Peter T.; Martin, Scott W.; Serrano-Wu, Michael H.; Meanwell, Nicholas A.; Snyder, Lawrence B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3795-3802</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The exceptional in vitro potency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into an in vivo effect in proof-of-concept clin. trials.  Although the 50% effective concn. (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory species after incubation in cell culture medium.  The biol. profile of BMS-824, including the EC50, the drug concn. required to reduce cell growth by 50% (CC50), and the resistance profile, however, remained unchanged, triggering an investigation to identify the biol. active species.  High-performance liq. chromatog. (HPLC) biogram fractionation of a sample of BMS-824 incubated in medium revealed that the most active fractions could readily be sepd. from the parental compd. and retained the biol. profile of BMS-824.  From mass spectral and NMR data, the active species was detd. to be a dimer of BMS-824 derived from an intermol. radical-mediated reaction of the parent compd.  Based upon an anal. of the structural elements of the dimer deemed necessary for anti-HCV activity, the stilbene deriv. BMS-346 was synthesized.  This compd. exhibited excellent anti-HCV activity and showed a resistance profile similar to that of BMS-824, with changes in compd. sensitivity mapped to the N terminus of NS5A.  The N terminus of NS5A has been crystd. as a dimer, complementing the symmetry of BMS-346 and allowing a potential mode of inhibition of NS5A to be discussed.  Identification of the stable, active pharmacophore assocd. with these NS5A inhibitors provided the foundation for the design of more potent inhibitors with broad genotype inhibition.  This culminated in the identification of BMS-790052, a compd. that preserves the symmetry discovered with BMS-346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YeVXSMPBNLVg90H21EOLACvtfcHk0ljT_0Tzb3kHyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D&md5=8a0fea78b0d42bf7285e6916c40fbc91</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="note"><p class="first last">For additional chemotypes that emerged from screening efforts and were reported to target the NS5A protein based on resistance mapping, see:</p></div><div class="NLM_citation" id="cit6a"><span>
					<span class="NLM_label">(a) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Najarro, P. </span>; <span class="NLM_string-name">
							Mathews, N. </span>; <span class="NLM_string-name">
							Cockerill, S. </span> </span> <span> </span><span class="NLM_article-title">NS5A inhibitors</span>.  <i>Hepatitis
C Viruses</i>, <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Tan, S. -L. </span> </span>, Ed.; <span class="NLM_publisher-name">Horizon Bioscience</span>: <span class="NLM_publisher-loc">Wymondham, U.K</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">292</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=271-292&author=P.+Najarro&author=N.+Mathews&author=S.+Cockerillauthor=S.+-L.+Tan&title=Hepatitis%0AC+Viruses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNajarro%26aufirst%3DP.%26atitle%3DNS5A%2520inhibitors%26btitle%3DHepatitis%250AC%2520Viruses%26aulast%3DTan%26aufirst%3DS.%2B-L.%26pub%3DHorizon%2520Bioscience%26date%3D2006%26spage%3D271%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercolani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neddermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of piperazinyl-<i>N</i>-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2009.01.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19216075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1779-1783&author=I.+Conteauthor=C.+Giulianoauthor=C.+Ercolaniauthor=F.+Narjesauthor=U.+Kochauthor=M.+Rowleyauthor=S.+Altamuraauthor=R.+De+Francescoauthor=P.+Neddermannauthor=G.+Migliaccioauthor=I.+Stansfield&title=Synthesis+and+SAR+of+piperazinyl-N-phenylbenzamides+as+inhibitors+of+hepatitis+C+virus+RNA+replication+in+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture</span></div><div class="casAuthors">Conte, Immacolata; Giuliano, Claudio; Ercolani, Caterina; Narjes, Frank; Koch, Uwe; Rowley, Michael; Altamura, Sergio; De Francesco, Raffaele; Neddermann, Petra; Migliaccio, Giovanni; Stansfield, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1779-1783</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The RNA replication machinery of HCV is a multi-subunit membrane-assocd. complex.  NS5A has emerged as an active component of HCV replicase, possibly involved in regulation of viral replication and resistance to the antiviral effect of interferon.  Substituted piperazinyl-N-(aryl)benzamides were prepd. as potent inhibitors of HCV replication exerted via modulation of the dimerization of NS5A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pdn0bWBLqLVg90H21EOLACvtfcHk0ljT_0Tzb3kHyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltLY%253D&md5=2db305a76f11b417be5581840dd5aa6c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.066%26sid%3Dliteratum%253Aachs%26aulast%3DConte%26aufirst%3DI.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DErcolani%26aufirst%3DC.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DStansfield%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520piperazinyl-N-phenylbenzamides%2520as%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520cell%2520culture%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1779%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madigan, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span> <span> </span><span class="NLM_article-title">Novel hepatitis C virus replicon inhibitors: synthesis and structure–activity relationships of fused pyrimidine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.01.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A280%3ADC%252BC383ot1Kjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2212-2215&author=A.+C.+Kruegerauthor=D.+L.+Madiganauthor=D.+W.+Benoauthor=D.+A.+Betebennerauthor=R.+Carrickauthor=B.+E.+Greenauthor=W.+Heauthor=D.+Liuauthor=C.+J.+Maringauthor=K.+F.+McDanielauthor=H.+Moauthor=A.+Mollaauthor=C.+E.+Motterauthor=T.+J.+Pilot-Matiasauthor=M.+D.+Tufanoauthor=D.+J.+Kempf&title=Novel+hepatitis+C+virus+replicon+inhibitors%3A+synthesis+and+structure%E2%80%93activity+relationships+of+fused+pyrimidine+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives</span></div><div class="casAuthors">Krueger A Chris; Madigan Darold L; Beno David W; Betebenner David A; Carrick Robert; Green Brian E; He Wenping; Liu Dachun; Maring Clarence J; McDaniel Keith F; Mo Hongmei; Molla Akhteruzzaman; Motter Christopher E; Pilot-Matias Tami J; Tufano Michael D; Kempf Dale J</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2212-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqqthqkmhoTUewzGPswiWOfW6udTcc2eYAILrjShlZALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ot1Kjsg%253D%253D&md5=108fdae73f1d9ab8bd69eb5578c247e9</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.096%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DMadigan%26aufirst%3DD.%2BL.%26aulast%3DBeno%26aufirst%3DD.%2BW.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DCarrick%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DB.%2BE.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DMotter%26aufirst%3DC.%2BE.%26aulast%3DPilot-Matias%26aufirst%3DT.%2BJ.%26aulast%3DTufano%26aufirst%3DM.%2BD.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26atitle%3DNovel%2520hepatitis%2520C%2520virus%2520replicon%2520inhibitors%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520fused%2520pyrimidine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2212%26epage%3D2215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grampovnik, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrido[2,3-<i>d</i>]pyrimidine-based inhibitors of HCV NS5A</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2013.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23642966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3627-3630&author=D.+A.+DeGoeyauthor=D.+A+Betebennerauthor=D.+J.+Grampovnikauthor=D.+Liuauthor=J.+K.+Prattauthor=M.+D.+Tufanoauthor=W.+Heauthor=P.+Krishnanauthor=T.+J.+Pilot-Matiasauthor=K.+C.+Marshauthor=A.+Mollaauthor=D.+J.+Kempfauthor=C.+J.+Maring&title=Discovery+of+pyrido%5B2%2C3-d%5Dpyrimidine-based+inhibitors+of+HCV+NS5A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Betebenner, David A.; Grampovnik, David J.; Liu, Dachun; Pratt, John K.; Tufano, Michael D.; He, Wenping; Krishnan, Preethi; Pilot-Matias, Tami J.; Marsh, Kennan C.; Molla, Akhteruzzaman; Kempf, Dale J.; Maring, Clarence J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3627-3630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Efforts to improve the genotype 1a potency and pharmacokinetics of earlier naphthyridine-based HCV NS5A inhibitors resulted in the discovery of a novel series of pyrido[2,3-d]pyrimidine compds., which displayed potent inhibition of HCV genotypes 1a and 1b in the replicon assay.  SAR in this system revealed that the introduction of amides bearing an addnl. 'E' ring provided compds. with improved potency and pharmacokinetics.  Introduction of a chiral center on the amide portion resulted in the observation of a stereochem. dependence for replicon potency and provided a site for the attachment of functional groups useful for improving the soly. of the series.  Compd. 21 was selected for administration in an HCV-infected chimpanzee.  Observation of a robust viral load decline provided pos. proof of concept for inhibition of HCV replication in vivo for the compd. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrel3jepZjyaLVg90H21EOLACvtfcHk0ljtLrsyzz_Hhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyhtrw%253D&md5=a034b541bddfba800487c6b01ce44f79</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA%26aulast%3DGrampovnik%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DTufano%26aufirst%3DM.%2BD.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine-based%2520inhibitors%2520of%2520HCV%2520NS5A%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3627%26epage%3D3630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: From iminothiazolidinones to symmetrical stilbenes</span>. <i>ACS Med. Chem. Lett</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">229</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+From+iminothiazolidinones+to+symmetrical+stilbenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0lgyfFwfA6Cqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520From%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakarla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6063</span>– <span class="NLM_lpage">6066</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22959243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+Investigation+of+stilbene+prolinamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span></div><div class="casAuthors">St. Laurent, Denis R.; Belema, Makonen; Gao, Min; Goodrich, Jason; Kakarla, Ramesh; Knipe, Jay O.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O'Boyle, Donald; Qiu, Yuping; Romine, Jeffrey L.; Serrano-Wu, Michael H.; Sun, Jin-Hua; Valera, Lourdes; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6063-6066</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the preliminary structure-activity relationships and early PK characterization for a series of stilbene prolinamides I [R = Me, Ph, PhCH2, (R)-PhCHMe, 3-pyridylmethyl, 3-indolyl, etc.] and their analogs that formed a basis for the ultimate identification of daclatasvir (BMS-79052), a compd. that has demonstrated clin. proof-of-concept for inhibiting the NS5A replication complex in the treatment of HCV infection, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vTKMN_UrxLVg90H21EOLACvtfcHk0lgyfFwfA6Cqjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK&md5=48ceadc7d3a60a5f99c0d02984e3a2b4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520Investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripka, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogues with distinct core topologies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.11.086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23273521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWhtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+Discovery+of+potent+analogues+with+distinct+core+topologies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 31: discovery of potent analogs with distinct core topologies</span></div><div class="casAuthors">Lopez, Omar D.; Nguyen, Van N.; St. Laurent, Denis R.; Belema, Makonen; Serrano-Wu, Michael H.; Goodrich, Jason T.; Yang, Fukang; Qiu, Yuping; Ripka, Amy S.; Nower, Peter T.; Valera, Lourdes; Liu, Mengping; O'Boyle, Donald R.; Sun, Jin-Hua; Fridell, Robert A.; Lemm, Julie A.; Gao, Min; Good, Andrew C.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">779-784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In a recent disclosure, the authors described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon.  That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region.  From this effort, the contribution of the core region to the overall topol. of the pharmacophore, primarily vector orientation and planarity, was detd., with a set of analogs, e.g., I, exhibiting <10 nM EC50 in a genotype 1b replicon assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqbTPZVn6zrVg90H21EOLACvtfcHk0li6l5B61EBQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWhtbbP&md5=7f329d43d80cec1838eb45378c65335f</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.086%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520Discovery%2520of%2520potent%2520analogues%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7d"><span>
					<span class="NLM_label">(d) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Serrano-Wu, M. H. </span>; <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Ding, M. </span>; <span class="NLM_string-name">
							Fang, H. </span>; <span class="NLM_string-name">
							Gao, M. </span>; <span class="NLM_string-name">
							Goodrich, J. T. </span>; <span class="NLM_string-name">
							Krause, R. G. </span>; <span class="NLM_string-name">
							Lemm, J. A. </span>; <span class="NLM_string-name">
							Liu, M. </span>; <span class="NLM_string-name">
							Lopez, O. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Nower, P. T. </span>; <span class="NLM_string-name">
							O’Boyle, D. R.,  II </span>; <span class="NLM_string-name">
							Pearce, B. C. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							Valera, L. </span>; <span class="NLM_string-name">
							Sun, J.-H. </span>; <span class="NLM_string-name">
							Wang, Y.-K. </span>; <span class="NLM_string-name">
							Yang, F. </span>; <span class="NLM_string-name">
							Yang, X. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span> </span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4:
Optimization for genotype 1a replicon inhibitory activity</span>.  <i>J. Med. Chem.</i> DOI: <span class="refDoi"> DOI: 10.1021/jm301796k</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09St.+Laurent%2C+D.+R.+%3B+%0A%09%09%09%09%09%09%09Serrano-Wu%2C+M.+H.+%3B+%0A%09%09%09%09%09%09%09Belema%2C+M.+%3B+%0A%09%09%09%09%09%09%09Ding%2C+M.+%3B+%0A%09%09%09%09%09%09%09Fang%2C+H.+%3B+%0A%09%09%09%09%09%09%09Gao%2C+M.+%3B+%0A%09%09%09%09%09%09%09Goodrich%2C+J.+T.+%3B+%0A%09%09%09%09%09%09%09Krause%2C+R.+G.+%3B+%0A%09%09%09%09%09%09%09Lemm%2C+J.+A.+%3B+%0A%09%09%09%09%09%09%09Liu%2C+M.+%3B+%0A%09%09%09%09%09%09%09Lopez%2C+O.+%3B+%0A%09%09%09%09%09%09%09Nguyen%2C+V.+N.+%3B+%0A%09%09%09%09%09%09%09Nower%2C+P.+T.+%3B+%0A%09%09%09%09%09%09%09O%E2%80%99Boyle%2C+D.+R.%2C+II+%3B+%0A%09%09%09%09%09%09%09Pearce%2C+B.+C.+%3B+%0A%09%09%09%09%09%09%09Romine%2C+J.+L.+%3B+%0A%09%09%09%09%09%09%09Valera%2C+L.+%3B+%0A%09%09%09%09%09%09%09Sun%2C+J.-H.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.-K.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+F.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+X.+%3B+%0A%09%09%09%09%09%09%09Meanwell%2C+N.+A.+%3B+%0A%09%09%09%09%09%09%09Snyder%2C+L.+B.+HCV+NS5A+replication+complex+inhibitors.+Part+4%3A%0AOptimization+for+genotype+1a+replicon+inhibitory+activity.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm301796k."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%250AOptimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm301796k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4428</span>– <span class="NLM_lpage">4435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2013.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23803586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVShtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=M.+Liuauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+Discovery+of+potent+and+pan-genotypic+glycinamide+cap+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; St. Laurent, Denis R.; Lopez, Omar D.; Qiu, Yuping; Good, Andrew C.; Nower, Peter T.; Valera, Lourdes; O'Boyle, Donald R.; Sun, Jin-Hua; Liu, Mengping; Fridell, Robert A.; Lemm, Julie A.; Gao, Min; Knipe, Jay O.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4428-4435</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The isoquinolinamide series of HCV NS5A inhibitors exemplified by compds. (I) and (II) provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene (III).  Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virol. profile, along with some insights into the pharmacophoric elements assocd. with the GT-1a potency, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxZgPIvpbytrVg90H21EOLACvtfcHk0li6l5B61EBQyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVShtrbO&md5=156e18764c9727e50bfd911f72d875d7</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520Discovery%2520of%2520potent%2520and%2520pan-genotypic%2520glycinamide%2520cap%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7f"><span>
					<span class="NLM_label">(f) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Lopez, O. D. </span>; <span class="NLM_string-name">
							Goodrich, J. </span>; <span class="NLM_string-name">
							Nower, P.
T. </span>; <span class="NLM_string-name">
							O’Boyle, D. R.,  II </span>; <span class="NLM_string-name">
							Lemm, J. A. </span>; <span class="NLM_string-name">
							Fridell, R. A. </span>; <span class="NLM_string-name">
							Gao, M. </span>; <span class="NLM_string-name">
							Fang, H. </span>; <span class="NLM_string-name">
							Krause, R. G. </span>; <span class="NLM_string-name">
							Wang, Y.-K. </span>; <span class="NLM_string-name">
							Oliver, A. J. </span>; <span class="NLM_string-name">
							Good, A. C. </span>; <span class="NLM_string-name">
							Knipe, J. O. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span> </span> <span> </span><span class="NLM_article-title">Hepatitis C
virus NS5A replication complex inhibitors. Part 6: The discovery of
a novel and highly potent biarylimidazole chemotype with inhibitory
activity toward genotypes 1a and 1b replicons</span>.  <i>J. Med. Chem.</i> DOI:<span class="refDoi"> DOI: 10.1021/jm4016203</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09Belema%2C+M.+%3B+%0A%09%09%09%09%09%09%09Nguyen%2C+V.+N.+%3B+%0A%09%09%09%09%09%09%09Romine%2C+J.+L.+%3B+%0A%09%09%09%09%09%09%09St.+Laurent%2C+D.+R.+%3B+%0A%09%09%09%09%09%09%09Lopez%2C+O.+D.+%3B+%0A%09%09%09%09%09%09%09Goodrich%2C+J.+%3B+%0A%09%09%09%09%09%09%09Nower%2C+P.%0AT.+%3B+%0A%09%09%09%09%09%09%09O%E2%80%99Boyle%2C+D.+R.%2C+II+%3B+%0A%09%09%09%09%09%09%09Lemm%2C+J.+A.+%3B+%0A%09%09%09%09%09%09%09Fridell%2C+R.+A.+%3B+%0A%09%09%09%09%09%09%09Gao%2C+M.+%3B+%0A%09%09%09%09%09%09%09Fang%2C+H.+%3B+%0A%09%09%09%09%09%09%09Krause%2C+R.+G.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.-K.+%3B+%0A%09%09%09%09%09%09%09Oliver%2C+A.+J.+%3B+%0A%09%09%09%09%09%09%09Good%2C+A.+C.+%3B+%0A%09%09%09%09%09%09%09Knipe%2C+J.+O.+%3B+%0A%09%09%09%09%09%09%09Meanwell%2C+N.+A.+%3B+%0A%09%09%09%09%09%09%09Snyder%2C+L.+B.+Hepatitis+C%0Avirus+NS5A+replication+complex+inhibitors.+Part+6%3A+The+discovery+of%0Aa+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory%0Aactivity+toward+genotypes+1a+and+1b+replicons.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm4016203."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DHepatitis%2520C%250Avirus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520The%2520discovery%2520of%250Aa%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%250Aactivity%2520toward%2520genotypes%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm4016203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="note"><p class="first last">For details on the PK studies, see the
general <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="note"><p class="first last"><i>Bis</i>-(<i>S</i>)-phenylglycine
diastereomer of <b>2</b>: GT-1a/-1b EC<sub>50</sub> = 1.6 nM/0.046
nM; both GT-1b CC<sub>50</sub> and BVDV EC<sub>50</sub> values were
>10 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0ljSRp840nN_uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%E2%80%94are+too+many+aromatic+rings+a+liability+in+drug+design%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0ljSRp840nN_uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%25E2%2580%2594are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">613</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.01874-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23089758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Srur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=611-613&author=C.+Wangauthor=L.+Valeraauthor=L.+Jiaauthor=M.+J.+Kirkauthor=M.+Gaoauthor=R.+A.+Fridell&title=In+vitro+activity+of+daclatasvir+on+hepatitis+C+virus+genotype+3+NS5A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A</span></div><div class="casAuthors">Wang, Chunfu; Valera, Lourdes; Jia, Lingling; Kirk, Melissa J.; Gao, Min; Fridell, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">611-613</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons contg. hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concns. (EC50s) ranging from 120 to 870 pM.  Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance.  Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBgMuXsGkzW7Vg90H21EOLACvtfcHk0li49lQzqnjsbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Srur8%253D&md5=12c87128212bd241dece7d60085a6fed</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.01874-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01874-12%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DKirk%26aufirst%3DM.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26atitle%3DIn%2520vitro%2520activity%2520of%2520daclatasvir%2520on%2520hepatitis%2520C%2520virus%2520genotype%25203%2520NS5A%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D611%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="note"><p class="first last">A manuscript detailing the ADME characterization of <b>33</b> is in preparation and will be published elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwater, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMicco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vutikullird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Talavera, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span> <span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitic C virus genotype 1</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1956</span>– <span class="NLM_lpage">1965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitic+C+virus+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0li49lQzqnjsbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitic%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindollar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinelli, C.</span></span> <span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0li49lQzqnjsbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chayanna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumada, H.</span></span> <span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21987462" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayannaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayanna%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumada, H.</span></span> <span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span>. <i>J. Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0lgvLe7E8SLeQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatology%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatum, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronowicki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuluvath, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindollar, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diva, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnittman, S.</span></span> <span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2a trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Matorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+Hezodeauthor=J.+K.+Limauthor=J.+P.+Bronowickiauthor=G.+A.+Abramsauthor=N.+Brauauthor=D.+W.+Morrisauthor=P.+J.+Thuluvathauthor=R.+W.+Reindollarauthor=P.+D.+Yinauthor=U.+Divaauthor=R.+Hindesauthor=F.+McPheeauthor=D.+Hernandezauthor=M.+Wind-Rotoloauthor=E.+A.+Hughesauthor=S.+Schnittman&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomized%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding+phase+2a+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0lgvLe7E8SLeQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMatorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BW.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DReindollar%26aufirst%3DR.%2BW.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DDiva%26aufirst%3DU.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomized%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%2520phase%25202a%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span> <span> </span><span class="NLM_article-title">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1337</span>– <span class="NLM_lpage">1346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1517%2F13543784.2013.826189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23931586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1337-1346&author=D.+A.+Herbstauthor=K.+R.+Reddy&title=NS5A+inhibitor%2C+daclatasvir%2C+for+the+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span></div><div class="casAuthors">Herbst, D. Alan; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1346</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chronic Hepatitis C virus (HCV) infection is a major pandemic.  The current std. of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes.  The treatment landscape is rapidly evolving as a no. of direct-acting antivirals (DAA) are being developed in clin. trials.  Areas covered: , formerly labeled BMS-790052, is a first-in-class HCV NS5A inhibitor that has been demonstrated in Phase I and II trials to have a very potent antiviral effect across all genotypes and to have a potent clin. efficacy in both treatment naive and experienced cohorts.  This review covers the whole spectrum of development of daclatasvir from Phase I to III programs.  Expert opinion: While daclatasvir has pangenotypic activity, it has a lower barrier to resistance in Genotype 1a but has been found to be very effective in Genotype 1b patients.  However, Genotype 1a patients can be successfully treated with the addn. of one or more DAAs alone or in combination with peginterferon and ribavirin.  The future for daclatasvir and other DAAs is very encouraging in that all-oral therapies are likely to be effective and well-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouHATdIV9yA7Vg90H21EOLACvtfcHk0lisGqu3oHVp9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK&md5=d1b220d6ed004a580cd6920ffaecde19</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.826189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.826189%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DD.%2BA.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DNS5A%2520inhibitor%252C%2520daclatasvir%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1337%26epage%3D1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit16"><span>
					<span class="NLM_contrib-group"> <span class="NLM_string-name">
							Everson, G. T. </span>; <span class="NLM_string-name">
							Sims, K. D. </span>; <span class="NLM_string-name">
							Rodriguez-Torres, M. </span>; <span class="NLM_string-name">
							Hezode, C. </span>; <span class="NLM_string-name">
							Lawitz, E. </span>; <span class="NLM_string-name">
							Bourliere, M. </span>; <span class="NLM_string-name">
							Loustaud-Ratti, V. </span>; <span class="NLM_string-name">
							Rustgi, V. </span>; <span class="NLM_string-name">
							Schwartz, H. </span>; <span class="NLM_string-name">
							Tatum, H. </span>; <span class="NLM_string-name">
							Marcellin, P. </span>; <span class="NLM_string-name">
							Pol, S. </span>; <span class="NLM_string-name">
							Thuluvath, P. J. </span>; <span class="NLM_string-name">
							Eley, T. </span>; <span class="NLM_string-name">
							Wang, X. </span>; <span class="NLM_string-name">
							Huang, S.-P. </span>; <span class="NLM_string-name">McPhee, F.</span>; ; <span class="NLM_string-name">
							Wind-Rotolo, M. </span>; <span class="NLM_string-name">
							Chung, E. </span>; <span class="NLM_string-name">Pasquinelli, C.</span>; ; <span class="NLM_string-name">
							Grasela, D. M. </span>; <span class="NLM_string-name">
							Gardiner, D. F. </span> </span> <span> </span><span class="NLM_article-title">Efficacy of an interferon- and Ribavirin-free regimen of daclatasvir,
asunaprevir, and BMS-791325 in treatment-naı̈ve patients
with HCV genotype 1 infection</span>.  <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">146</span>,  <span class="NLM_fpage">420</span>− <span class="NLM_lpage">429</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24184132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Everson&author=K.+D.+Sims&author=M.+Rodriguez-Torres&author=C.+Hezode&author=E.+Lawitz&author=M.+Bourliere&author=V.+Loustaud-Ratti&author=V.+Rustgi&author=H.+Schwartz&author=H.+Tatum&author=P.+Marcellin&author=S.+Pol&author=P.+J.+Thuluvath&author=T.+Eley&author=X.+Wang&author=S.-P.+Huang&author=F.+McPhee&author=M.+Wind-Rotolo&author=E.+Chung&author=C.+Pasquinelli&author=D.+M.+Grasela&author=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+Ribavirin-free+regimen+of+daclatasvir%2C%0Aasunaprevir%2C+and+BMS-791325+in+treatment-na%C4%B1%CC%88ve+patients%0Awith+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection</span></div><div class="casAuthors">Everson, Gregory T.; Sims, Karen D.; Rodriguez-Torres, Maribel; Hezode, Christophe; Lawitz, Eric; Bourliere, Marc; Loustaud-Ratti, Veronique; Rustgi, Vinod; Schwartz, Howard; Tatum, Harvey; Marcellin, Patrick; Pol, Stanislas; Thuluvath, Paul J.; Eley, Timothy; Wang, Xiaodong; Huang, Shu-Pang; McPhee, Fiona; Wind-Rotolo, Megan; Chung, Ellen; Pasquinelli, Claudio; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-429</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The combination of peginterferon and ribavirin with telaprevir or boceprevir is the std. treatment of hepatitis C virus (HCV) genotype 1 infection.  However, these drugs are not well tolerated because of their side effects and suboptimal virol. responses.  In a phase 2a, open-label study, we examd. the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection.  We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 wk.  The primary end point was an HCV-RNA level less than 25 IU/mL at 12 wk after treatment (sustained virol. response at 12 wk [SVR12]).  In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatment (including 48 of 49 patients with HCV genotype 1a infection and 45 of 46 patients with the non-CC interleukin 28B genotype).  Sixty-one patients (92%) achieved SVR12, based on a modified intention-to-treat anal.  Virol. responses were similar between 12 and 24 wk of treatment.  During the study, 2 patients experienced viral breakthrough and 1 patient relapsed.  There were no grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resulting from serious adverse events or adverse events related to the treatment regimen.  The most common adverse events were headache, asthenia, and gastrointestinal symptoms.  In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.  Further studies of this regimen are warranted.  ClinicalTrials.gov, no. NCT01455090.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGYjuJmkQI8rVg90H21EOLACvtfcHk0lisGqu3oHVp9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D&md5=c8f83094f49ce5d5d116d75414ab3d93</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520Ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%250Aasunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%250Awith%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Targett-Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, E. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakenhut, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westby, M.</span></span> <span> </span><span class="NLM_article-title">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6353</span>– <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FJVI.00215-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21507963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6353-6368&author=P.+Targett-Adamsauthor=E.+J.+S.+Grahamauthor=J.+Middletonauthor=A.+Palmerauthor=S.+M.+Shawauthor=H.+Lavenderauthor=P.+Brainauthor=T.+D.+Tranauthor=L.+H.+Jonesauthor=F.+Wakenhutauthor=B.+Stammenauthor=D.+Prydeauthor=C.+Pickfordauthor=M.+Westby&title=Small+molecules+targeting+hepatitis+C+virus-encoded+NS5A+cause+subcellular+redistribution+of+their+target%3A+Insights+into+compound+modes+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span></div><div class="casAuthors">Targett-Adams, Paul; Graham, Emily J. S.; Middleton, Jenny; Palmer, Amy; Shaw, Stephen M.; Lavender, Helen; Brain, Philip; Tran, Thien Duc; Jones, Lyn H.; Wakenhut, Florian; Stammen, Blanda; Pryde, David; Pickford, Chris; Westby, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6353-6368</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The current std. of care for hepatitis C virus (HCV)-infected patients consists of lengthy treatment with interferon and ribavirin.  To increase the effectiveness of HCV therapy, future regimens will incorporate multiple direct-acting antiviral (DAA) drugs.  Recently, the HCV-encoded NS5A protein has emerged as a promising DAA target.  Compds. targeting NS5A exhibit remarkable potency in vitro and demonstrate early clin. promise, suggesting that NS5A inhibitors could feature in future DAA combination therapies.  Since the mechanisms through which these mols. operate are unknown, we have used NS5A inhibitors as tools to investigate their modes of action.  Anal. of replicon-contg. cells revealed dramatic phenotypic alterations in NS5A localization following treatment with NS5A inhibitors; NS5A was redistributed from the endoplasmic reticulum to lipid droplets.  The NS5A relocalization did not occur in cells treated with other classes of HCV inhibitors, and NS5A-targeting mols. did not cause similar alterations in the localization of other HCV-encoded proteins.  Time course anal. of the redistribution of NS5A revealed that the transfer of protein to lipid droplets was concomitant with the onset of inhibition, as judged by the kinetic profiles for these compds.  Furthermore, anal. of the kinetic profile of inhibition for a panel of test mols. permitted the sepn. of compds. into different kinetic classes based on their modes of action.  The results from this approach suggested that NS5A inhibitors perturbed the function of new replication complexes, rather than acting on preformed complexes.  The data reveal novel biol. consequences of NS5A inhibition, which may help enable the development of future assay platforms for the identification of new and/or different NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_D0ZIz1nPk7Vg90H21EOLACvtfcHk0ljWc4ZkRGcX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D&md5=99efbc4b114c7f8129b43f51b4d584b7</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1128%2FJVI.00215-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00215-11%26sid%3Dliteratum%253Aachs%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DE.%2BJ.%2BS.%26aulast%3DMiddleton%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DLavender%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DPryde%26aufirst%3DD.%26aulast%3DPickford%26aufirst%3DC.%26aulast%3DWestby%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520targeting%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520cause%2520subcellular%2520redistribution%2520of%2520their%2520target%253A%2520Insights%2520into%2520compound%2520modes%2520of%2520action%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6353%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elazar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J. S.</span></span> <span> </span><span class="NLM_article-title">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.virol.2011.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21513964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=10-18&author=C.+Leeauthor=H.+Maauthor=J.+Q.+Hangauthor=V.+Levequeauthor=E.+H.+Sklanauthor=M.+Elazarauthor=K.+Klumppauthor=J.+S.+Glenn&title=The+hepatitis+C+virus+NS5A+inhibitor+%28BMS-790052%29+alters+the+subcellular+localization+of+the+NS5A+non-structural+viral+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span></div><div class="casAuthors">Lee, Choongho; Ma, Han; Hang, Julie Qi; Leveque, Vincent; Sklan, Ella H.; Elazar, Menashe; Klumpp, Klaus; Glenn, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral RNA by the membrane-assocd. replication complex (RC).  Recently, a putative NS5A inhibitor, BMS-790052, exhibited the highest potency of any known anti-HCV compd. in inhibiting HCV replication in vitro and showed a promising clin. effect in HCV-infected patients.  The precise mechanism of action for this new class of potential anti-HCV therapeutics, however, is still unclear.  In order to gain further insight into its mode of action, we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with the functional assembly of the HCV RC.  We obsd. that BMS-790052 indeed altered the subcellular localization and biochem. fractionation of NS5A.  Taken together, our data suggest that NS5A inhibitors such as BMS-790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYMSRcOmX36rVg90H21EOLACvtfcHk0ljWc4ZkRGcX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D&md5=b4212a1dd1365aedfd384e685afdefeb</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DLeveque%26aufirst%3DV.%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520%2528BMS-790052%2529%2520alters%2520the%2520subcellular%2520localization%2520of%2520the%2520NS5A%2520non-structural%2520viral%2520protein%26jtitle%3DVirology%26date%3D2011%26volume%3D414%26spage%3D10%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guedj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotler, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layden, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uprichard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perelson, A. S.</span></span> <span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3996</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0ljWc4ZkRGcX8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit18"><span>
					<span class="NLM_contrib-group"> <span class="NLM_string-name">
							Bachand, C. </span>; <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Deon, D.
H. </span>; <span class="NLM_string-name">
							Good, A.
C. </span>; <span class="NLM_string-name">
							Goodrich, J. T. </span>; <span class="NLM_string-name">
							James, C. A. </span>; <span class="NLM_string-name">
							Lavoie, R. </span>; <span class="NLM_string-name">
							Lopez, O.
D. </span>; <span class="NLM_string-name">
							Martel, A. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							Ruediger, E. H. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span>; <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Yang, F. </span>; <span class="NLM_string-name">
							Langley, D. R. </span>; <span class="NLM_string-name">
							Wang, G. </span>; <span class="NLM_string-name">
							Hamann, L. G. </span> </span> <span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. PCT
Intl. Application. <span class="NLM_year">2008</span>, Patent No. <span class="NLM_patent">WO2008-021927</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Bachand&author=M.+Belema&author=D.%0AH.+Deon&author=A.%0AC.+Good&author=J.+T.+Goodrich&author=C.+A.+James&author=R.+Lavoie&author=O.%0AD.+Lopez&author=A.+Martel&author=N.+A.+Meanwell&author=V.+N.+Nguyen&author=J.+L.+Romine&author=E.+H.+Ruediger&author=L.+B.+Snyder&author=D.+R.+St.+Laurent&author=F.+Yang&author=D.+R.+Langley&author=G.+Wang&author=L.+G.+Hamann&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachand%26aufirst%3DC.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poitout, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contour-Galcera, M.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannoy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurieau, C.</span></span> <span> </span><span class="NLM_article-title">Identification of potent non-peptide somatostatin antagonists with sst3 selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2990</span>– <span class="NLM_lpage">3000</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0108449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Okuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2990-3000&author=L.+Poitoutauthor=P.+Roubertauthor=M.-O.+Contour-Galceraauthor=C.+Moinetauthor=J.+Lannoyauthor=J.+Pommierauthor=P.+Plasauthor=D.+Biggauthor=C.+Thurieau&title=Identification+of+potent+non-peptide+somatostatin+antagonists+with+sst3+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity</span></div><div class="casAuthors">Poitout, Lydie; Roubert, Pierre; Contour-Galcera, Marie-Odile; Moinet, Christophe; Lannoy, Jacques; Pommier, Jacques; Plas, Pascale; Bigg, Dennis; Thurieau, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2990-3000</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a soln.-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepd., and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were detd.  Imidazolyl derivs. were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype.  Further modifications of these structures led to a more potent class of ligands, the tetrahydro-β-carboline derivs.  Among these, compds. BN81644 and BN81674 bind selectively and with high affinity to the sst3 receptor subtype (Ki = 0.64 and 0.92 nM, resp.).  Furthermore, BN81644 and BN81674 reverse the inhibition of cAMP accumulation induced by 1 nM somatostatin via sst3 receptors, with IC50 = 2.7 and 0.84 nM, resp.  The most potent compd. BN81674 was shown to be a competitive antagonist of human sst3 receptors by increasing the EC50 of SRIF-14-mediated inhibition of cAMP accumulation with a KB of 2.8 nM (where KB is the concn. of antagonist that shifts the agonist dose-response 2-fold).  These new derivs. are, to the authors knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiol. role of sst3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLCGxLWbRQabVg90H21EOLACvtfcHk0ljeZ5Kldxolkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Okuro%253D&md5=757c8a3c9acc656dbdeb22e7283788cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm0108449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0108449%26sid%3Dliteratum%253Aachs%26aulast%3DPoitout%26aufirst%3DL.%26aulast%3DRoubert%26aufirst%3DP.%26aulast%3DContour-Galcera%26aufirst%3DM.-O.%26aulast%3DMoinet%26aufirst%3DC.%26aulast%3DLannoy%26aufirst%3DJ.%26aulast%3DPommier%26aufirst%3DJ.%26aulast%3DPlas%26aufirst%3DP.%26aulast%3DBigg%26aufirst%3DD.%26aulast%3DThurieau%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520potent%2520non-peptide%2520somatostatin%2520antagonists%2520with%2520sst3%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2990%26epage%3D3000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Selective monolithiation of 2,5-dibromopyridine with butyllithium</span>. <i>Tetrahedon Lett</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4335</span>– <span class="NLM_lpage">4338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2FS0040-4039%2800%2900664-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=4335-4338&author=X.+Wangauthor=P.+Rabbatauthor=P.+O%E2%80%99Sheaauthor=R.+Tillyerauthor=E.+J.+J.+Grabowskiauthor=P.+J.+Reider&title=Selective+monolithiation+of+2%2C5-dibromopyridine+with+butyllithium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective monolithiation of 2,5-dibromopyridine with butyllithium</span></div><div class="casAuthors">Wang, Xin; Rabbat, Philippe; O'Shea, Paul; Tillyer, Richard; Grabowski, E. J. J.; Reider, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4335-4338</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Selective monolithiation of 2,5-dibromopyridine at either the 2- or the 5-position is reported.  Solvent and concn. strongly influence the selectivity.  Coordinating solvents and higher concn. favor the 5-position, while non-coordinating solvents and lower concn. favor the 2-position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOERlFYZb7urVg90H21EOLACvtfcHk0ljeZ5Kldxolkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlWgsrk%253D&md5=c09d0455bd9dacfcff32742dd2f9e575</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2900664-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252900664-X%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRabbat%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DP.%26aulast%3DTillyer%26aufirst%3DR.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DSelective%2520monolithiation%2520of%25202%252C5-dibromopyridine%2520with%2520butyllithium%26jtitle%3DTetrahedon%2520Lett%26date%3D2000%26volume%3D41%26spage%3D4335%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span> <span> </span><span class="NLM_article-title">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1517%2F13543784.2013.806482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23735127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1107-1121&author=N.+Shahauthor=T.+Pierceauthor=K.+V.+Kowdley&title=Review+of+direct-acting+antiviral+agents+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Shah, Nihar; Pierce, Tracey; Kowdley, Kris V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic disease.  In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV.  Several DAAs currently in late-stage clin. trials, including NS3/NS4A serine PIs, NS5A inhibitors, NS5B polymerase inhibitors (both nucleoside and non-nucleoside) and cyclophilin inhibitors, both with and without peg-IFN and RBV, are promising for the treatment of HCV.  DAA regimens offer several advantages including that they specifically target HCV viral replication and thus appear to be less dependent on host characteristics, very high SVR rates accompanied by fewer side effects (SE) and lower pill burdens.  A review on the treatment of HCV is important and timely as the development on DAAs is progressing rapidly and the health-care providers need to be aware about this as these regimens are anticipated to become clin. available soon.  Areas covered: The literature was searched and reviewed using PubMed as well as data gathered from those presented at the international liver meetings, AASLD and EASL as well as CROI.  Expert opinion: With the potential of eliminating IFN and RBV, several DAAs under clin. development appear to be promising using novel approaches with good antiviral effects, shorter duration and lower SE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZExgJKmkr7Vg90H21EOLACvtfcHk0ljeZ5Kldxolkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO&md5=f761cff6a6710f4de9473db6509d20a9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.806482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.806482%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DPierce%26aufirst%3DT.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26atitle%3DReview%2520of%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1107%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">The generic description of the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> is a slightly modified version of a paragraph provided in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a> for a related work disclosed by the same authors.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4a','cit4b','cit4c'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6a','cit6b','cit6c','cit6d'],'ref7':['cit7a','cit7b','cit7c','cit7d','cit7e','cit7f'],'ref8':[],'ref9':[],'ref10':['cit10a','cit10b'],'ref11':['cit11'],'ref12':[],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c','cit14d'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':[]}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 61 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hongming Xie, Haiwang Liu, Yingjun Zhang, Enhuo Huang, Yahui Feng, Xuwen Xiang, Qinghong Fang, Zhihong Peng, Wanrong Dong, <span class="NLM_string-name hlFld-ContribAuthor">Delie An</span>. </span><span class="cited-content_cbyCitation_article-title">Development of a Synthesis Process for a Novel HCV NS5A Inhibitor, Emitasvir. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 838-848. <a href="https://doi.org/10.1021/acs.oprd.0c00519" title="DOI URL">https://doi.org/10.1021/acs.oprd.0c00519</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.0c00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.0c00519%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ba%252BSynthesis%252BProcess%252Bfor%252Ba%252BNovel%252BHCV%252BNS5A%252BInhibitor%25252C%252BEmitasvir%26aulast%3DXie%26aufirst%3DHongming%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D30112020%26date%3D02042021%26volume%3D25%26issue%3D4%26spage%3D838%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Nicholas A. Meanwell, Gunda I. Georg, <span class="NLM_string-name hlFld-ContribAuthor">Shaomeng Wang</span>. </span><span class="cited-content_cbyCitation_article-title">The 2020 Nobel Prize in Physiology or Medicine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (22)
                                     , 13197-13204. <a href="https://doi.org/10.1021/acs.jmedchem.0c01877" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01877</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01877%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252B2020%252BNobel%252BPrize%252Bin%252BPhysiology%252Bor%252BMedicine%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2020%26date%3D2020%26date%3D05112020%26volume%3D63%26issue%3D22%26spage%3D13197%26epage%3D13204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Vidya Ramdas, Rashmi Talwar, Moloy Banerjee, Advait Arun Joshi, Amit Kumar Das, Deepak Sahebrao Walke, Prashant Borhade, Usha Dhayagude, Rajesh Loriya, Ganesh Gote, Apparao Bommakanti, Aruna Sivaram, Gautam Agarwal, Arnab Goswami, Prashant Nigade, Maneesh Mehta, Vinod Patil, Dipak Modi, Hemant Kumar, Sadanand Mallurwar, Amruta Dash, Falguni Modi, Sandip Kuldharan, Pratima Srivastava, Minakshi Singh, Lakshmi Narasimham, Jayasagar Gundu, Sharad Sharma, Rajender Kumar Kamboj, <span class="NLM_string-name hlFld-ContribAuthor">Venkata P. Palle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Characterization of Potent Pan-Genotypic HCV NS5A Inhibitors Containing Novel Tricyclic Central Core Leading to Clinical Candidate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (23)
                                     , 10563-10582. <a href="https://doi.org/10.1021/acs.jmedchem.9b01562" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01562%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BCharacterization%252Bof%252BPotent%252BPan-Genotypic%252BHCV%252BNS5A%252BInhibitors%252BContaining%252BNovel%252BTricyclic%252BCentral%252BCore%252BLeading%252Bto%252BClinical%252BCandidate%26aulast%3DRamdas%26aufirst%3DVidya%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D19092019%26date%3D22112019%26date%3D11112019%26volume%3D62%26issue%3D23%26spage%3D10563%26epage%3D10582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yahui Feng, Zhongqing Wang, Zhonghua Luo, Jinqiang Lai, Hongming Xie, Zhenxiu Luo, Lei Zhang, Ridong Li, <span class="NLM_string-name hlFld-ContribAuthor">Yingjun Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of an Efficient and Scalable Biocatalytic Route to (1S,4R)-8-Hydroxy-1,2,3,4- tetrahydro-1,4-methanonaphthalen-5-yl Propionate via Enantioselective Enzymatic Desymmetrization of a Prochiral Diester. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (6)
                                     , 1243-1251. <a href="https://doi.org/10.1021/acs.oprd.9b00188" title="DOI URL">https://doi.org/10.1021/acs.oprd.9b00188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.9b00188%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ban%252BEfficient%252Band%252BScalable%252BBiocatalytic%252BRoute%252Bto%252B%2525281S%25252C4R%252529-8-Hydroxy-1%25252C2%25252C3%25252C4-%252Btetrahydro-1%25252C4-methanonaphthalen-5-yl%252BPropionate%252Bvia%252BEnantioselective%252BEnzymatic%252BDesymmetrization%252Bof%252Ba%252BProchiral%252BDiester%26aulast%3DFeng%26aufirst%3DYahui%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30042019%26date%3D23052019%26date%3D13052019%26volume%3D23%26issue%3D6%26spage%3D1243%26epage%3D1251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Ling    Tong </span><span class="hlFld-ContribAuthor "> Joseph A.    Kozlowski </span><span class="hlFld-ContribAuthor "> Louis-Charles    Campeau </span><span class="hlFld-ContribAuthor "> Jingjun    Yin </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Ruzasvir: An Investigational Next Generation Pan-Genotype HCV Nonstructural Protein 5A (NS5A) Inhibitor for the Cure of Hepatitis C Virus Infections. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 115-149. <a href="https://doi.org/10.1021/bk-2018-1307.ch005" title="DOI URL">https://doi.org/10.1021/bk-2018-1307.ch005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2018-1307.ch005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2018-1307.ch005%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BRuzasvir%25253A%252BAn%252BInvestigational%252BNext%252BGeneration%252BPan-Genotype%252BHCV%252BNonstructural%252BProtein%252B5A%252B%252528NS5A%252529%252BInhibitor%252Bfor%252Bthe%252BCure%252Bof%252BHepatitis%252BC%252BVirus%252BInfections%26aulast%3DTong%26aufirst%3DLing%26date%3D2018%26date%3D2018%26spage%3D115%26epage%3D149%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B1%26aulast%3DAbdel-Magid%26aufirst%3DAhmed%2BF.%26date%3D2018%26date%3D2018%26volume%3D1307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Robert  Mazzola</span>, <span class="hlFld-ContribAuthor ">Jae-Hun  Kim</span>, <span class="hlFld-ContribAuthor ">Deyou  Sha</span>, <span class="hlFld-ContribAuthor ">Jingjun  Yin</span>, <span class="hlFld-ContribAuthor ">Rebecca T.  Ruck</span>, <span class="hlFld-ContribAuthor ">Ian W.  Davies</span>, <span class="hlFld-ContribAuthor ">Bin  Hu</span>, <span class="hlFld-ContribAuthor ">Bin  Zhong</span>, <span class="hlFld-ContribAuthor ">Jinglai  Hao</span>, <span class="hlFld-ContribAuthor ">Tao  Ji</span>, <span class="hlFld-ContribAuthor ">Shuai  Zan</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Stephanie  Curry</span>, <span class="hlFld-ContribAuthor ">Patricia  McMonagle</span>, <span class="hlFld-ContribAuthor ">Karin  Bystol</span>, <span class="hlFld-ContribAuthor ">Frederick  Lahser</span>, <span class="hlFld-ContribAuthor ">Donna  Carr</span>, <span class="hlFld-ContribAuthor ">Laura  Rokosz</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Shiying  Chen</span>, <span class="hlFld-ContribAuthor ">Kung-I  Feng</span>, <span class="hlFld-ContribAuthor ">Mark  Cartwright</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, and <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (1)
                                     , 290-306. <a href="https://doi.org/10.1021/acs.jmedchem.6b01310" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01310%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BRuzasvir%252B%252528MK-8408%252529%25253A%252BA%252BPotent%25252C%252BPan-Genotype%252BHCV%252BNS5A%252BInhibitor%252Bwith%252BOptimized%252BActivity%252Bagainst%252BCommon%252BResistance-Associated%252BPolymorphisms%26aulast%3DTong%26aufirst%3DLing%26date%3D2017%26date%3D2016%26date%3D2016%26date%3D31082016%26date%3D15112016%26date%3D12012017%26date%3D03112016%26volume%3D60%26issue%3D1%26spage%3D290%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7311-7351. <a href="https://doi.org/10.1021/acs.jmedchem.6b00915" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00915</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00915%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2015%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship.%252BCuring%252BHepatitis%252BC%252BVirus%252BInfection%252Bwith%252BDirect-Acting%252BAntiviral%252BAgents%25253A%252BThe%252BArc%252Bof%252Ba%252BMedicinal%252BChemistry%252BTriumph%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D18062016%26date%3D08082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7311%26epage%3D7351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David L.  Hughes</span>  . </span><span class="cited-content_cbyCitation_article-title">Patent Highlights: Recently Approved HCV NS5a Drugs. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2016,</strong> <em>20 </em>
                                    (8)
                                     , 1404-1415. <a href="https://doi.org/10.1021/acs.oprd.6b00241" title="DOI URL">https://doi.org/10.1021/acs.oprd.6b00241</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.6b00241&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.6b00241%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DPatent%252BHighlights%25253A%252BRecently%252BApproved%252BHCV%252BNS5a%252BDrugs%26aulast%3DHughes%26aufirst%3DDavid%2BL.%26date%3D2016%26date%3D2016%26date%3D15072016%26date%3D21072016%26date%3D19082016%26volume%3D20%26issue%3D8%26spage%3D1404%26epage%3D1415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Na  Ye</span>, <span class="hlFld-ContribAuthor ">Haiying  Chen</span>, <span class="hlFld-ContribAuthor ">Eric A.  Wold</span>, <span class="hlFld-ContribAuthor ">Pei-Yong  Shi</span>, and <span class="hlFld-ContribAuthor ">Jia  Zhou</span>  . </span><span class="cited-content_cbyCitation_article-title">Therapeutic Potential of Spirooxindoles as Antiviral Agents. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2016,</strong> <em>2 </em>
                                    (6)
                                     , 382-392. <a href="https://doi.org/10.1021/acsinfecdis.6b00041" title="DOI URL">https://doi.org/10.1021/acsinfecdis.6b00041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.6b00041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.6b00041%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DTherapeutic%252BPotential%252Bof%252BSpirooxindoles%252Bas%252BAntiviral%252BAgents%26aulast%3DYe%26aufirst%3DNa%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D17032016%26date%3D05052016%26date%3D10062016%26date%3D26042016%26volume%3D2%26issue%3D6%26spage%3D382%26epage%3D392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2016,</strong> <em>29 </em>
                                    (4)
                                     , 564-616. <a href="https://doi.org/10.1021/acs.chemrestox.6b00043" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.6b00043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.6b00043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.6b00043%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DImproving%252BDrug%252BDesign%25253A%252BAn%252BUpdate%252Bon%252BRecent%252BApplications%252Bof%252BEfficiency%252BMetrics%25252C%252BStrategies%252Bfor%252BReplacing%252BProblematic%252BElements%25252C%252Band%252BCompounds%252Bin%252BNontraditional%252BDrug%252BSpace%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D03022016%26date%3D14032016%26date%3D18042016%26volume%3D29%26issue%3D4%26spage%3D564%26epage%3D616" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James H.  Nettles</span>, <span class="hlFld-ContribAuthor ">Richard A.  Stanton</span>, <span class="hlFld-ContribAuthor ">Joshua  Broyde</span>, <span class="hlFld-ContribAuthor ">Franck  Amblard</span>, <span class="hlFld-ContribAuthor ">Hongwang  Zhang</span>, <span class="hlFld-ContribAuthor ">Longhu  Zhou</span>, <span class="hlFld-ContribAuthor ">Junxing  Shi</span>, <span class="hlFld-ContribAuthor ">Tamara R.  McBrayer</span>, <span class="hlFld-ContribAuthor ">Tony  Whitaker</span>, <span class="hlFld-ContribAuthor ">Steven J.  Coats</span>, <span class="hlFld-ContribAuthor ">James J.  Kohler</span>, and <span class="hlFld-ContribAuthor ">Raymond F.  Schinazi</span>  . </span><span class="cited-content_cbyCitation_article-title">Asymmetric Binding to NS5A by Daclatasvir (BMS-790052) and Analogs Suggests Two Novel Modes of HCV Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (23)
                                     , 10031-10043. <a href="https://doi.org/10.1021/jm501291c" title="DOI URL">https://doi.org/10.1021/jm501291c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501291c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501291c%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAsymmetric%252BBinding%252Bto%252BNS5A%252Bby%252BDaclatasvir%252B%252528BMS-790052%252529%252Band%252BAnalogs%252BSuggests%252BTwo%252BNovel%252BModes%252Bof%252BHCV%252BInhibition%26aulast%3DNettles%26aufirst%3DJames%2BH.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D23082014%26date%3D03112014%26date%3D11122014%26volume%3D57%26issue%3D23%26spage%3D10031%26epage%3D10043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandre V.  Ivachtchenko</span>, <span class="hlFld-ContribAuthor ">Oleg D.  Mitkin</span>, <span class="hlFld-ContribAuthor ">Pavel M.  Yamanushkin</span>, <span class="hlFld-ContribAuthor ">Irina V.  Kuznetsova</span>, <span class="hlFld-ContribAuthor ">Elena A.  Bulanova</span>, <span class="hlFld-ContribAuthor ">Natalia A.  Shevkun</span>, <span class="hlFld-ContribAuthor ">Angela G.  Koryakova</span>, <span class="hlFld-ContribAuthor ">Ruben N.  Karapetian</span>, <span class="hlFld-ContribAuthor ">Vadim V.  Bichko</span>, <span class="hlFld-ContribAuthor ">Andrey S.  Trifelenkov</span>, <span class="hlFld-ContribAuthor ">Dmitry V.  Kravchenko</span>, <span class="hlFld-ContribAuthor ">Natalia V.  Vostokova</span>, <span class="hlFld-ContribAuthor ">Mark S.  Veselov</span>, <span class="hlFld-ContribAuthor ">Nina V.  Chufarova</span>, and <span class="hlFld-ContribAuthor ">Yan A.  Ivanenkov</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Highly Potent Hepatitis C Virus NS5A Inhibitor (AV4025). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (18)
                                     , 7716-7730. <a href="https://doi.org/10.1021/jm500951r" title="DOI URL">https://doi.org/10.1021/jm500951r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500951r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500951r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BHighly%252BPotent%252BHepatitis%252BC%252BVirus%252BNS5A%252BInhibitor%252B%252528AV4025%252529%26aulast%3DIvachtchenko%26aufirst%3DAlexandre%2BV.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D23062014%26date%3D09092014%26date%3D25092014%26date%3D22082014%26volume%3D57%26issue%3D18%26spage%3D7716%26epage%3D7730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makonen  Belema</span> and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Daclatasvir, a Pan-Genotypic Hepatitis C Virus NS5A Replication Complex Inhibitor with Potent Clinical Effect. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (12)
                                     , 5057-5071. <a href="https://doi.org/10.1021/jm500335h" title="DOI URL">https://doi.org/10.1021/jm500335h</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500335h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500335h%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDaclatasvir%25252C%252Ba%252BPan-Genotypic%252BHepatitis%252BC%252BVirus%252BNS5A%252BReplication%252BComplex%252BInhibitor%252Bwith%252BPotent%252BClinical%252BEffect%26aulast%3DBelema%26aufirst%3DMakonen%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D03032014%26date%3D21042014%26date%3D26062014%26volume%3D57%26issue%3D12%26spage%3D5057%26epage%3D5071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makonen  Belema</span>, <span class="hlFld-ContribAuthor ">Omar D.  Lopez</span>, <span class="hlFld-ContribAuthor ">John A.  Bender</span>, <span class="hlFld-ContribAuthor ">Jeffrey L.  Romine</span>, <span class="hlFld-ContribAuthor ">Denis R.  St. Laurent</span>, <span class="hlFld-ContribAuthor ">David R.  Langley</span>, <span class="hlFld-ContribAuthor ">Julie A.  Lemm</span>, <span class="hlFld-ContribAuthor ">Donald R.  O’Boyle, II</span>, <span class="hlFld-ContribAuthor ">Jin-Hua  Sun</span>, <span class="hlFld-ContribAuthor ">Chunfu  Wang</span>, <span class="hlFld-ContribAuthor ">Robert A.  Fridell</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (5)
                                     , 1643-1672. <a href="https://doi.org/10.1021/jm401793m" title="DOI URL">https://doi.org/10.1021/jm401793m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm401793m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm401793m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BHepatitis%252BC%252BVirus%252BNS5A%252BReplication%252BComplex%252BInhibitors%26aulast%3DBelema%26aufirst%3DMakonen%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D19112013%26date%3D03022014%26date%3D13032014%26volume%3D57%26issue%3D5%26spage%3D1643%26epage%3D1672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sulaiman  Krait</span>, <span class="hlFld-ContribAuthor ">Antonio  Salgado</span>, <span class="hlFld-ContribAuthor ">Paola  Peluso</span>, <span class="hlFld-ContribAuthor ">Milo  Malanga</span>, <span class="hlFld-ContribAuthor ">Tamas  Sohajda</span>, <span class="hlFld-ContribAuthor ">Gábor  Benkovics</span>, <span class="hlFld-ContribAuthor ">Lukas  Naumann</span>, <span class="hlFld-ContribAuthor ">Christian  Neusüß</span>, <span class="hlFld-ContribAuthor ">Bezhan  Chankvetadze</span>, <span class="hlFld-ContribAuthor ">Gerhard K.E.  Scriba</span>. </span><span class="cited-content_cbyCitation_article-title">Complexation of daclatasvir by single isomer methylated β-cyclodextrins studied by capillary electrophoresis, NMR spectroscopy and mass spectrometry. </span><span class="cited-content_cbyCitation_journal-name">Carbohydrate Polymers</span><span> <strong>2021,</strong> <em>57 </em>, 118486. <a href="https://doi.org/10.1016/j.carbpol.2021.118486" title="DOI URL">https://doi.org/10.1016/j.carbpol.2021.118486</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.carbpol.2021.118486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.carbpol.2021.118486%26sid%3Dliteratum%253Aachs%26jtitle%3DCarbohydrate%2520Polymers%26atitle%3DComplexation%252Bof%252Bdaclatasvir%252Bby%252Bsingle%252Bisomer%252Bmethylated%252B%2525CE%2525B2-cyclodextrins%252Bstudied%252Bby%252Bcapillary%252Belectrophoresis%25252C%252BNMR%252Bspectroscopy%252Band%252Bmass%252Bspectrometry%26aulast%3DKrait%26aufirst%3DSulaiman%26date%3D2021%26volume%3D57%26spage%3D118486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Kunisuke  Izawa</span>, <span class="hlFld-ContribAuthor ">Tatsunori  Sato</span>, <span class="hlFld-ContribAuthor ">Sarah  White</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclic tailor-made amino acids in the design of modern pharmaceuticals. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>208 </em>, 112736. <a href="https://doi.org/10.1016/j.ejmech.2020.112736" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112736</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112736&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112736%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclic%252Btailor-made%252Bamino%252Bacids%252Bin%252Bthe%252Bdesign%252Bof%252Bmodern%252Bpharmaceuticals%26aulast%3DLiu%26aufirst%3DJiang%26date%3D2020%26volume%3D208%26spage%3D112736" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ana  Matošević</span>, <span class="hlFld-ContribAuthor ">Anita  Bosak</span>. </span><span class="cited-content_cbyCitation_article-title">Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Archives of Industrial Hygiene and Toxicology</span><span> <strong>2020,</strong> <em>71 </em>
                                    (4)
                                     , 285-299. <a href="https://doi.org/10.2478/aiht-2020-71-3466" title="DOI URL">https://doi.org/10.2478/aiht-2020-71-3466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2478/aiht-2020-71-3466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2478%2Faiht-2020-71-3466%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Industrial%2520Hygiene%2520and%2520Toxicology%26atitle%3DCarbamate%252Bgroup%252Bas%252Bstructural%252Bmotif%252Bin%252Bdrugs%25253A%252Ba%252Breview%252Bof%252Bcarbamate%252Bderivatives%252Bused%252Bas%252Btherapeutic%252Bagents%26aulast%3DMato%25C5%25A1evi%25C4%2587%26aufirst%3DAna%26date%3D2020%26date%3D2020%26volume%3D71%26issue%3D4%26spage%3D285%26epage%3D299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sulaiman  Krait</span>, <span class="hlFld-ContribAuthor ">Antonio  Salgado</span>, <span class="hlFld-ContribAuthor ">Claudio  Villani</span>, <span class="hlFld-ContribAuthor ">Lukas  Naumann</span>, <span class="hlFld-ContribAuthor ">Christian  Neusüß</span>, <span class="hlFld-ContribAuthor ">Bezhan  Chankvetadze</span>, <span class="hlFld-ContribAuthor ">Gerhard K.E.  Scriba</span>. </span><span class="cited-content_cbyCitation_article-title">Unusual complexation behavior between daclatasvir and γ-Cyclodextrin. A multiplatform study. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chromatography A</span><span> <strong>2020,</strong> <em>1628 </em>, 461448. <a href="https://doi.org/10.1016/j.chroma.2020.461448" title="DOI URL">https://doi.org/10.1016/j.chroma.2020.461448</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chroma.2020.461448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chroma.2020.461448%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chromatography%2520A%26atitle%3DUnusual%252Bcomplexation%252Bbehavior%252Bbetween%252Bdaclatasvir%252Band%252B%2525CE%2525B3-Cyclodextrin.%252BA%252Bmultiplatform%252Bstudy%26aulast%3DKrait%26aufirst%3DSulaiman%26date%3D2020%26volume%3D1628%26spage%3D461448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kunihiro  Sumoto</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Studies on Developments for Bioactive New Leads of Oligovalent Symmetrical Molecules. </span><span class="cited-content_cbyCitation_journal-name">YAKUGAKU ZASSHI</span><span> <strong>2020,</strong> <em>140 </em>
                                    (4)
                                     , 529-541. <a href="https://doi.org/10.1248/yakushi.19-00222" title="DOI URL">https://doi.org/10.1248/yakushi.19-00222</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/yakushi.19-00222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fyakushi.19-00222%26sid%3Dliteratum%253Aachs%26jtitle%3DYAKUGAKU%2520ZASSHI%26atitle%3DSynthetic%252BStudies%252Bon%252BDevelopments%252Bfor%252BBioactive%252BNew%252BLeads%252Bof%252BOligovalent%252BSymmetrical%252BMolecules%26aulast%3DSumoto%26aufirst%3DKunihiro%26date%3D2020%26volume%3D140%26issue%3D4%26spage%3D529%26epage%3D541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Nakamura</span>, <span class="hlFld-ContribAuthor ">Yusuke  Akagi</span>, <span class="hlFld-ContribAuthor ">Takashi  Terui</span>, <span class="hlFld-ContribAuthor ">Shingo  Fujioka</span>, <span class="hlFld-ContribAuthor ">Yasumasa  Komoda</span>, <span class="hlFld-ContribAuthor ">Wataru  Kinoshita</span>, <span class="hlFld-ContribAuthor ">Kimiya  Maeda</span>, <span class="hlFld-ContribAuthor ">Yutaka  Ukaji</span>, <span class="hlFld-ContribAuthor ">Takashi  Inaba</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel unsymmetrical structural class of HCV NS5A inhibitors with low picomolar antiviral activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (5)
                                     , 126932. <a href="https://doi.org/10.1016/j.bmcl.2019.126932" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.126932</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.126932&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.126932%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bunsymmetrical%252Bstructural%252Bclass%252Bof%252BHCV%252BNS5A%252Binhibitors%252Bwith%252Blow%252Bpicomolar%252Bantiviral%252Bactivity%26aulast%3DNakamura%26aufirst%3DHiroshi%26date%3D2020%26volume%3D30%26issue%3D5%26spage%3D126932" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohit  Tyagi</span>, <span class="hlFld-ContribAuthor ">Fabio  Begnini</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Bradley C.  Doak</span>, <span class="hlFld-ContribAuthor ">Jan  Kihlberg</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Syntheses Beyond the Rule of 5. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (1)
                                     , 49-88. <a href="https://doi.org/10.1002/chem.201902716" title="DOI URL">https://doi.org/10.1002/chem.201902716</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201902716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201902716%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DDrug%252BSyntheses%252BBeyond%252Bthe%252BRule%252Bof%252B5%26aulast%3DTyagi%26aufirst%3DMohit%26date%3D2020%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D49%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shaoyi  Sun</span>, <span class="hlFld-ContribAuthor ">Qi  Jia</span>, <span class="hlFld-ContribAuthor ">Zaihui  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of amide isosteres in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2535-2550. <a href="https://doi.org/10.1016/j.bmcl.2019.07.033" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DApplications%252Bof%252Bamide%252Bisosteres%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DSun%26aufirst%3DShaoyi%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2535%26epage%3D2550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad Usman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Kanzal  Iman</span>, <span class="hlFld-ContribAuthor ">Muhammad Farhan  Khalid</span>, <span class="hlFld-ContribAuthor ">Hafiz Muhammad  Salman</span>, <span class="hlFld-ContribAuthor ">Talha  Shafi</span>, <span class="hlFld-ContribAuthor ">Momal  Rafi</span>, <span class="hlFld-ContribAuthor ">Nida  Javaid</span>, <span class="hlFld-ContribAuthor ">Rashid  Hussain</span>, <span class="hlFld-ContribAuthor ">Fayyaz  Ahmad</span>, <span class="hlFld-ContribAuthor ">Syed  Shahzad‐Ul‐Hussan</span>, <span class="hlFld-ContribAuthor ">Shaper  Mirza</span>, <span class="hlFld-ContribAuthor ">Muhammad  Shafiq</span>, <span class="hlFld-ContribAuthor ">Samia  Afzal</span>, <span class="hlFld-ContribAuthor ">Sadia  Hamera</span>, <span class="hlFld-ContribAuthor ">Saima  Anwar</span>, <span class="hlFld-ContribAuthor ">Romena  Qazi</span>, <span class="hlFld-ContribAuthor ">Muhammad  Idrees</span>, <span class="hlFld-ContribAuthor ">Sohail A.  Qureshi</span>, <span class="hlFld-ContribAuthor ">Safee Ullah  Chaudhary</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of efficacious pangenotypic hepatitis C virus therapies. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (3)
                                     , 1091-1136. <a href="https://doi.org/10.1002/med.21554" title="DOI URL">https://doi.org/10.1002/med.21554</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21554%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DEvolution%252Bof%252Befficacious%252Bpangenotypic%252Bhepatitis%252BC%252Bvirus%252Btherapies%26aulast%3DAshraf%26aufirst%3DMuhammad%2BUsman%26date%3D2019%26date%3D2018%26volume%3D39%26issue%3D3%26spage%3D1091%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert G.  Gentles</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Beclabuvir: A Potent Allosteric Inhibitor of the Hepatitis C Virus Polymerase. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 193-228. <a href="https://doi.org/10.1007/7355_2018_38" title="DOI URL">https://doi.org/10.1007/7355_2018_38</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_38%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Bof%252BBeclabuvir%25253A%252BA%252BPotent%252BAllosteric%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BPolymerase%26aulast%3DGentles%26aufirst%3DRobert%2BG.%26date%3D2019%26date%3D2019%26spage%3D193%26epage%3D228%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Makonen  Belema</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replication Complex. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 27-55. <a href="https://doi.org/10.1007/7355_2018_47" title="DOI URL">https://doi.org/10.1007/7355_2018_47</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_47%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BDevelopment%252Bof%252BDaclatasvir%25253A%252BAn%252BInhibitor%252Bof%252Bthe%252BHepatitis%252BC%252BVirus%252BNS5A%252BReplication%252BComplex%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2019%26date%3D2019%26spage%3D27%26epage%3D55%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D32" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>, <span class="hlFld-ContribAuthor ">Li-Qiang  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery and Early Clinical Evaluation of the HCV NS3/4A Protease Inhibitor Asunaprevir (BMS-650032). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 317-354. <a href="https://doi.org/10.1007/7355_2018_58" title="DOI URL">https://doi.org/10.1007/7355_2018_58</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2018_58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2018_58%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Band%252BEarly%252BClinical%252BEvaluation%252Bof%252Bthe%252BHCV%252BNS3%25252F4A%252BProtease%252BInhibitor%252BAsunaprevir%252B%252528BMS-650032%252529%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2019%26date%3D2019%26spage%3D317%26epage%3D354%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHCV%25253A%252BThe%252BJourney%252Bfrom%252BDiscovery%252Bto%252Ba%252BCure%26aulast%3DSofia%26aufirst%3DMichael%2BJ.%26date%3D2019%26volume%3D31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Venkat R.  Gadhachanda</span>, <span class="hlFld-ContribAuthor ">Kyle J.  Eastman</span>, <span class="hlFld-ContribAuthor ">Qiuping  Wang</span>, <span class="hlFld-ContribAuthor ">Avinash S.  Phadke</span>, <span class="hlFld-ContribAuthor ">Dharaben  Patel</span>, <span class="hlFld-ContribAuthor ">Wengang  Yang</span>, <span class="hlFld-ContribAuthor ">Christopher W.  Marlor</span>, <span class="hlFld-ContribAuthor ">Milind  Deshpande</span>, <span class="hlFld-ContribAuthor ">Mingjun  Huang</span>, <span class="hlFld-ContribAuthor ">Jason A.  Wiles</span>. </span><span class="cited-content_cbyCitation_article-title">Ferrocene-based inhibitors of hepatitis C virus replication that target NS5A with low picomolar in vitro antiviral activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (21)
                                     , 3463-3471. <a href="https://doi.org/10.1016/j.bmcl.2018.09.023" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.09.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.09.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.09.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DFerrocene-based%252Binhibitors%252Bof%252Bhepatitis%252BC%252Bvirus%252Breplication%252Bthat%252Btarget%252BNS5A%252Bwith%252Blow%252Bpicomolar%252Bin%252Bvitro%252Bantiviral%252Bactivity%26aulast%3DGadhachanda%26aufirst%3DVenkat%2BR.%26date%3D2018%26volume%3D28%26issue%3D21%26spage%3D3463%26epage%3D3471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ola M.  Abdallah</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Abdel-Megied</span>, <span class="hlFld-ContribAuthor ">Amira S.  Gouda</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacokinetic evaluation of daclatasvir and ledipasvir in healthy volunteers using a validated highly sensitive spectrofluorimetric method. </span><span class="cited-content_cbyCitation_journal-name">Luminescence</span><span> <strong>2018,</strong> <em>33 </em>
                                    (6)
                                     , 1094-1100. <a href="https://doi.org/10.1002/bio.3514" title="DOI URL">https://doi.org/10.1002/bio.3514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bio.3514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbio.3514%26sid%3Dliteratum%253Aachs%26jtitle%3DLuminescence%26atitle%3DPharmacokinetic%252Bevaluation%252Bof%252Bdaclatasvir%252Band%252Bledipasvir%252Bin%252Bhealthy%252Bvolunteers%252Busing%252Ba%252Bvalidated%252Bhighly%252Bsensitive%252Bspectrofluorimetric%252Bmethod%26aulast%3DAbdallah%26aufirst%3DOla%2BM.%26date%3D2018%26date%3D2018%26volume%3D33%26issue%3D6%26spage%3D1094%26epage%3D1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ola M.  Abdallah</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Abdel-Megied</span>, <span class="hlFld-ContribAuthor ">Amira S.  Gouda</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of LC-MS/MS method for simultaneous determination of sofosbuvir and daclatasvir in human Plasma: Application to pharmacokinetic study. </span><span class="cited-content_cbyCitation_journal-name">Biomedical Chromatography</span><span> <strong>2018,</strong> <em>32 </em>
                                    (6)
                                     , e4186. <a href="https://doi.org/10.1002/bmc.4186" title="DOI URL">https://doi.org/10.1002/bmc.4186</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bmc.4186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbmc.4186%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedical%2520Chromatography%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252BLC-MS%25252FMS%252Bmethod%252Bfor%252Bsimultaneous%252Bdetermination%252Bof%252Bsofosbuvir%252Band%252Bdaclatasvir%252Bin%252Bhuman%252BPlasma%25253A%252BApplication%252Bto%252Bpharmacokinetic%252Bstudy%26aulast%3DAbdallah%26aufirst%3DOla%2BM.%26date%3D2018%26date%3D2018%26volume%3D32%26issue%3D6%26spage%3De4186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Kerry  Keertikar</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Dwyer</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Bandarpalle  Shankar</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Robert  Mazzola</span>, <span class="hlFld-ContribAuthor ">John  Caldwell</span>, <span class="hlFld-ContribAuthor ">Haiqun  Tang</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Amin  Nomeir</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 1954-1957. <a href="https://doi.org/10.1016/j.bmcl.2018.03.049" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.03.049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.03.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.03.049%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMK-8325%25253A%252BA%252Bsilyl%252Bproline-containing%252BNS5A%252Binhibitor%252Bwith%252Bpan-genotype%252Bactivity%252Bfor%252Btreatment%252Bof%252BHCV%26aulast%3DNair%26aufirst%3DAnilkumar%2BG.%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D1954%26epage%3D1957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian L.  Venables</span>, <span class="hlFld-ContribAuthor ">Ny  Sin</span>, <span class="hlFld-ContribAuthor ">Alan Xiangdong  Wang</span>, <span class="hlFld-ContribAuthor ">Li-Qiang  Sun</span>, <span class="hlFld-ContribAuthor ">Yong  Tu</span>, <span class="hlFld-ContribAuthor ">Dennis  Hernandez</span>, <span class="hlFld-ContribAuthor ">Amy  Sheaffer</span>, <span class="hlFld-ContribAuthor ">Min  Lee</span>, <span class="hlFld-ContribAuthor ">Cindy  Dunaj</span>, <span class="hlFld-ContribAuthor ">Guangzhi  Zhai</span>, <span class="hlFld-ContribAuthor ">Diana  Barry</span>, <span class="hlFld-ContribAuthor ">Jacques  Friborg</span>, <span class="hlFld-ContribAuthor ">Fei  Yu</span>, <span class="hlFld-ContribAuthor ">Jay  Knipe</span>, <span class="hlFld-ContribAuthor ">Jason  Sandquist</span>, <span class="hlFld-ContribAuthor ">Paul  Falk</span>, <span class="hlFld-ContribAuthor ">Dawn  Parker</span>, <span class="hlFld-ContribAuthor ">Andrew C.  Good</span>, <span class="hlFld-ContribAuthor ">Ramkumar  Rajamani</span>, <span class="hlFld-ContribAuthor ">Fiona  McPhee</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Paul M.  Scola</span>. </span><span class="cited-content_cbyCitation_article-title">P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (10)
                                     , 1853-1859. <a href="https://doi.org/10.1016/j.bmcl.2018.04.009" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DP3-P4%252Bureas%252Band%252Breverse%252Bcarbamates%252Bas%252Bpotent%252BHCV%252BNS3%252Bprotease%252Binhibitors%25253A%252BEffective%252Btransposition%252Bof%252Bthe%252BP4%252Bhydrogen%252Bbond%252Bdonor%26aulast%3DVenables%26aufirst%3DBrian%2BL.%26date%3D2018%26volume%3D28%26issue%3D10%26spage%3D1853%26epage%3D1859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bárbara I.  Díaz-Eufracio</span>, <span class="hlFld-ContribAuthor ">Oscar  Palomino-Hernández</span>, <span class="hlFld-ContribAuthor ">Richard A.  Houghten</span>, <span class="hlFld-ContribAuthor ">José L.  Medina-Franco</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the chemical space of peptides for drug discovery: a focus on linear and cyclic penta-peptides. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2018,</strong> <em>22 </em>
                                    (2)
                                     , 259-267. <a href="https://doi.org/10.1007/s11030-018-9812-9" title="DOI URL">https://doi.org/10.1007/s11030-018-9812-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-018-9812-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-018-9812-9%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DExploring%252Bthe%252Bchemical%252Bspace%252Bof%252Bpeptides%252Bfor%252Bdrug%252Bdiscovery%25253A%252Ba%252Bfocus%252Bon%252Blinear%252Band%252Bcyclic%252Bpenta-peptides%26aulast%3DD%25C3%25ADaz-Eufracio%26aufirst%3DB%25C3%25A1rbara%2BI.%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D2%26spage%3D259%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Biaryls. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 83-154. <a href="https://doi.org/10.1002/9781118686263.ch4" title="DOI URL">https://doi.org/10.1002/9781118686263.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DBiaryls%26date%3D2018%26date%3D2018%26spage%3D83%26epage%3D154%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D45" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Baomin  Liu</span>, <span class="hlFld-ContribAuthor ">Kuo  Gai</span>, <span class="hlFld-ContribAuthor ">Hui  Qin</span>, <span class="hlFld-ContribAuthor ">Xushi  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Cao</span>, <span class="hlFld-ContribAuthor ">Qin  Lu</span>, <span class="hlFld-ContribAuthor ">Dandan  Lu</span>, <span class="hlFld-ContribAuthor ">Deyang  Chen</span>, <span class="hlFld-ContribAuthor ">Hengqiao  Shen</span>, <span class="hlFld-ContribAuthor ">Wei  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaojin  Wang</span>, <span class="hlFld-ContribAuthor ">Hongjiang  Xu</span>, <span class="hlFld-ContribAuthor ">Yinsheng  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 95-105. <a href="https://doi.org/10.1016/j.ejmech.2018.02.025" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.025%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bidentification%252Bof%252Bsilicon-containing%252BHCV%252BNS5A%252Binhibitors%252Bwith%252Bpan-genotype%252Bactivity%26aulast%3DLiu%26aufirst%3DBaomin%26date%3D2018%26volume%3D148%26spage%3D95%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joseph M.  Fortunak</span>, <span class="hlFld-ContribAuthor ">Ji  Zhang</span>, <span class="hlFld-ContribAuthor ">Frederick E.  Nytko</span>, <span class="hlFld-ContribAuthor ">Tiffany N.  Ellison</span>. </span><span class="cited-content_cbyCitation_article-title">Green Process Chemistry in the Pharmaceutical Industry: Case Studies Update (2012-2016). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 621-647. <a href="https://doi.org/10.1002/9781119288152.ch23" title="DOI URL">https://doi.org/10.1002/9781119288152.ch23</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781119288152.ch23&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781119288152.ch23%26sid%3Dliteratum%253Aachs%26atitle%3DGreen%252BProcess%252BChemistry%252Bin%252Bthe%252BPharmaceutical%252BIndustry%25253A%252BCase%252BStudies%252BUpdate%2525C2%2525A0%2525282012-2016%252529%26aulast%3DFortunak%26aufirst%3DJoseph%2BM.%26date%3D2018%26date%3D2018%26spage%3D621%26epage%3D647%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DGreen%252BTechniques%252Bfor%252BOrganic%252BSynthesis%252Band%252BMedicinal%252BChemistry%26aulast%3DZhang%26aufirst%3DWei%26date%3D2018%26volume%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya P.  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Viruses. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 35-65. <a href="https://doi.org/10.1016/B978-0-12-813330-9.00003-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-813330-9.00003-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813330-9.00003-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813330-9.00003-X%26sid%3Dliteratum%253Aachs%26atitle%3DInhibition%252Bof%252BViruses%26aulast%3DGupta%26aufirst%3DSatya%2BP.%26date%3D2018%26spage%3D35%26epage%3D65%26pub%3DElsevier%26atitle%3DStudies%252Bon%252BHepatitis%252BViruses%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satya P.  Gupta</span>. </span><span class="cited-content_cbyCitation_article-title">The Medicinal Chemistry of Antihepatitis Agents III. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 133-210. <a href="https://doi.org/10.1016/B978-0-12-813330-9.00007-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-813330-9.00007-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-813330-9.00007-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-813330-9.00007-7%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BMedicinal%252BChemistry%252Bof%252BAntihepatitis%252BAgents%252BIII%26aulast%3DGupta%26aufirst%3DSatya%2BP.%26date%3D2018%26spage%3D133%26epage%3D210%26pub%3DElsevier%26atitle%3DStudies%252Bon%252BHepatitis%252BViruses%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhigang  Yi</span>, <span class="hlFld-ContribAuthor ">Zhenghong  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Aggregation of a hepatitis C virus replicase module induced by ablation of p97/VCP. </span><span class="cited-content_cbyCitation_journal-name">Journal of General Virology</span><span> <strong>2017,</strong> <em>98 </em>
                                    (7)
                                     , 1667-1678. <a href="https://doi.org/10.1099/jgv.0.000828" title="DOI URL">https://doi.org/10.1099/jgv.0.000828</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1099/jgv.0.000828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1099%2Fjgv.0.000828%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520General%2520Virology%26atitle%3DAggregation%252Bof%252Ba%252Bhepatitis%252BC%252Bvirus%252Breplicase%252Bmodule%252Binduced%252Bby%252Bablation%252Bof%252Bp97%25252FVCP%26aulast%3DYi%26aufirst%3DZhigang%26date%3D2017%26volume%3D98%26issue%3D7%26spage%3D1667%26epage%3D1678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David C.  McGowan</span>, <span class="hlFld-ContribAuthor ">Mourad D.  Khamlichi</span>, <span class="hlFld-ContribAuthor ">Alex  De Groot</span>, <span class="hlFld-ContribAuthor ">Frederik  Pauwels</span>, <span class="hlFld-ContribAuthor ">Frédéric  Delouvroy</span>, <span class="hlFld-ContribAuthor ">Kristof  Van Emelen</span>, <span class="hlFld-ContribAuthor ">Kenneth  Simmen</span>, <span class="hlFld-ContribAuthor ">Pierre  Raboisson</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel HCV replication inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2017,</strong> <em>21 </em>
                                    (2)
                                     , 475-481. <a href="https://doi.org/10.1007/s11030-017-9733-z" title="DOI URL">https://doi.org/10.1007/s11030-017-9733-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-017-9733-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-017-9733-z%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252BHCV%252Breplication%252Binhibitors%26aulast%3DMcGowan%26aufirst%3DDavid%2BC.%26date%3D2017%26date%3D2017%26volume%3D21%26issue%3D2%26spage%3D475%26epage%3D481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kyle J.  Eastman</span>, <span class="hlFld-ContribAuthor ">Kyle  Parcella</span>, <span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Katharine A.  Grant-Young</span>, <span class="hlFld-ContribAuthor ">Juliang  Zhu</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Zhongxing  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Yin</span>, <span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Steven  Sheriff</span>, <span class="hlFld-ContribAuthor ">Kevin  Kish</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Tredup</span>, <span class="hlFld-ContribAuthor ">Adam G.  Jardel</span>, <span class="hlFld-ContribAuthor ">Vivek  Halan</span>, <span class="hlFld-ContribAuthor ">Kaushik  Ghosh</span>, <span class="hlFld-ContribAuthor ">Dawn  Parker</span>, <span class="hlFld-ContribAuthor ">Kathy  Mosure</span>, <span class="hlFld-ContribAuthor ">Hua  Fang</span>, <span class="hlFld-ContribAuthor ">Ying-Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Julie  Lemm</span>, <span class="hlFld-ContribAuthor ">Xiaoliang  Zhuo</span>, <span class="hlFld-ContribAuthor ">Umesh  Hanumegowda</span>, <span class="hlFld-ContribAuthor ">Karen  Rigat</span>, <span class="hlFld-ContribAuthor ">Maria  Donoso</span>, <span class="hlFld-ContribAuthor ">Maria  Tuttle</span>, <span class="hlFld-ContribAuthor ">Tatyana  Zvyaga</span>, <span class="hlFld-ContribAuthor ">Zuzana  Haarhoff</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>, <span class="hlFld-ContribAuthor ">Matthew G.  Soars</span>, <span class="hlFld-ContribAuthor ">Susan B.  Roberts</span>, <span class="hlFld-ContribAuthor ">John F.  Kadow</span>. </span><span class="cited-content_cbyCitation_article-title">The discovery of a pan-genotypic, primer grip inhibitor of HCV NS5B polymerase. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (4)
                                     , 796-806. <a href="https://doi.org/10.1039/C6MD00636A" title="DOI URL">https://doi.org/10.1039/C6MD00636A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00636A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00636A%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DThe%252Bdiscovery%252Bof%252Ba%252Bpan-genotypic%25252C%252Bprimer%252Bgrip%252Binhibitor%252Bof%252BHCV%252BNS5B%252Bpolymerase%26aulast%3DEastman%26aufirst%3DKyle%2BJ.%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D4%26spage%3D796%26epage%3D806" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulio  Nannetti</span>, <span class="hlFld-ContribAuthor ">Lorenzo  Messa</span>, <span class="hlFld-ContribAuthor ">Marta  Celegato</span>, <span class="hlFld-ContribAuthor ">Silvana  Pagni</span>, <span class="hlFld-ContribAuthor ">Monica  Basso</span>, <span class="hlFld-ContribAuthor ">Saverio G.  Parisi</span>, <span class="hlFld-ContribAuthor ">Giorgio  Palù</span>, <span class="hlFld-ContribAuthor ">Arianna  Loregian</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of a simple and robust HPLC method with UV detection for quantification of the hepatitis C virus inhibitor daclatasvir in human plasma. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical and Biomedical Analysis</span><span> <strong>2017,</strong> <em>134 </em>, 275-281. <a href="https://doi.org/10.1016/j.jpba.2016.11.032" title="DOI URL">https://doi.org/10.1016/j.jpba.2016.11.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jpba.2016.11.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jpba.2016.11.032%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520and%2520Biomedical%2520Analysis%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252Ba%252Bsimple%252Band%252Brobust%252BHPLC%252Bmethod%252Bwith%252BUV%252Bdetection%252Bfor%252Bquantification%252Bof%252Bthe%252Bhepatitis%252BC%252Bvirus%252Binhibitor%252Bdaclatasvir%252Bin%252Bhuman%252Bplasma%26aulast%3DNannetti%26aufirst%3DGiulio%26date%3D2017%26volume%3D134%26spage%3D275%26epage%3D281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Direct-Acting Antiviral Agents for the Treatment of Hepatitis C Virus Infection. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 553-627. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12406-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12406-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12406-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12406-0%26sid%3Dliteratum%253Aachs%26atitle%3DDirect-Acting%252BAntiviral%252BAgents%252Bfor%252Bthe%252BTreatment%252Bof%252BHepatitis%252BC%252BVirus%252BInfection%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D553%26epage%3D627%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antiinfectives for Systemic Use, 3. Antivirals. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-21. <a href="https://doi.org/10.1002/14356007.c13_c01.pub3" title="DOI URL">https://doi.org/10.1002/14356007.c13_c01.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.c13_c01.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.c13_c01.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntiinfectives%252Bfor%252BSystemic%252BUse%25252C%252B3.%252BAntivirals%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D21%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Zhong</span>, <span class="hlFld-ContribAuthor ">Eric  Peng</span>, <span class="hlFld-ContribAuthor ">Ningwu  Huang</span>, <span class="hlFld-ContribAuthor ">Qi  Huang</span>, <span class="hlFld-ContribAuthor ">Anja  Huq</span>, <span class="hlFld-ContribAuthor ">Meiyen  Lau</span>, <span class="hlFld-ContribAuthor ">Richard  Colonno</span>, <span class="hlFld-ContribAuthor ">Leping  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of ravidasvir (PPI-668) as a potent pan-genotypic HCV NS5A inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (18)
                                     , 4508-4512. <a href="https://doi.org/10.1016/j.bmcl.2016.07.066" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.07.066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.07.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.07.066%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bravidasvir%252B%252528PPI-668%252529%252Bas%252Ba%252Bpotent%252Bpan-genotypic%252BHCV%252BNS5A%252Binhibitor%26aulast%3DZhong%26aufirst%3DMin%26date%3D2016%26volume%3D26%26issue%3D18%26spage%3D4508%26epage%3D4512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael P.  Dwyer</span>, <span class="hlFld-ContribAuthor ">Kerry M.  Keertikar</span>, <span class="hlFld-ContribAuthor ">Lei  Chen</span>, <span class="hlFld-ContribAuthor ">Ling  Tong</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Anilkumar G.  Nair</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Guowei  Zhou</span>, <span class="hlFld-ContribAuthor ">Brian J.  Lavey</span>, <span class="hlFld-ContribAuthor ">De-Yi  Yang</span>, <span class="hlFld-ContribAuthor ">Michael  Wong</span>, <span class="hlFld-ContribAuthor ">Seong Heon  Kim</span>, <span class="hlFld-ContribAuthor ">Craig A.  Coburn</span>, <span class="hlFld-ContribAuthor ">Stuart B.  Rosenblum</span>, <span class="hlFld-ContribAuthor ">Qingbei  Zeng</span>, <span class="hlFld-ContribAuthor ">Yueheng  Jiang</span>, <span class="hlFld-ContribAuthor ">Bandarpalle B.  Shankar</span>, <span class="hlFld-ContribAuthor ">Razia  Rizvi</span>, <span class="hlFld-ContribAuthor ">Amin A.  Nomeir</span>, <span class="hlFld-ContribAuthor ">Rong  Liu</span>, <span class="hlFld-ContribAuthor ">Sony  Agrawal</span>, <span class="hlFld-ContribAuthor ">Ellen  Xia</span>, <span class="hlFld-ContribAuthor ">Rong  Kong</span>, <span class="hlFld-ContribAuthor ">Ying  Zhai</span>, <span class="hlFld-ContribAuthor ">Paul  Ingravallo</span>, <span class="hlFld-ContribAuthor ">Ernest  Asante-Appiah</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (16)
                                     , 4106-4111. <a href="https://doi.org/10.1016/j.bmcl.2016.06.063" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.06.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.06.063%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DMatched%252Band%252Bmixed%252Bcap%252Bderivatives%252Bin%252Bthe%252Btetracyclic%252Bindole%252Bclass%252Bof%252BHCV%252BNS5A%252Binhibitors%26aulast%3DDwyer%26aufirst%3DMichael%2BP.%26date%3D2016%26volume%3D26%26issue%3D16%26spage%3D4106%26epage%3D4111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew C.  Flick</span>, <span class="hlFld-ContribAuthor ">Hong X.  Ding</span>, <span class="hlFld-ContribAuthor ">Carolyn A.  Leverett</span>, <span class="hlFld-ContribAuthor ">Robert E.  Kyne</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Sarah J.  Fink</span>, <span class="hlFld-ContribAuthor ">Christopher J.  O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic approaches to the 2014 new drugs. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (9)
                                     , 1937-1980. <a href="https://doi.org/10.1016/j.bmc.2016.03.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252Bapproaches%252Bto%252Bthe%252B2014%252Bnew%252Bdrugs%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2016%26volume%3D24%26issue%3D9%26spage%3D1937%26epage%3D1980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">W.  Li</span>, <span class="hlFld-ContribAuthor ">W.  Zhao</span>, <span class="hlFld-ContribAuthor ">X.  Liu</span>, <span class="hlFld-ContribAuthor ">X.  Huang</span>, <span class="hlFld-ContribAuthor ">O. D.  Lopez</span>, <span class="hlFld-ContribAuthor ">J. E.  Leet</span>, <span class="hlFld-ContribAuthor ">R. M.  Fancher</span>, <span class="hlFld-ContribAuthor ">V.  Nguyen</span>, <span class="hlFld-ContribAuthor ">J.  Goodrich</span>, <span class="hlFld-ContribAuthor ">J.  Easter</span>, <span class="hlFld-ContribAuthor ">Y.  Hong</span>, <span class="hlFld-ContribAuthor ">J.  Caceres-Cortes</span>, <span class="hlFld-ContribAuthor ">S. Y.  Chang</span>, <span class="hlFld-ContribAuthor ">L.  Ma</span>, <span class="hlFld-ContribAuthor ">M.  Belema</span>, <span class="hlFld-ContribAuthor ">L. G.  Hamann</span>, <span class="hlFld-ContribAuthor ">M.  Gao</span>, <span class="hlFld-ContribAuthor ">M.  Zhu</span>, <span class="hlFld-ContribAuthor ">Y.-Z.  Shu</span>, <span class="hlFld-ContribAuthor ">W. G.  Humphreys</span>, <span class="hlFld-ContribAuthor ">B. M.  Johnson</span>. </span><span class="cited-content_cbyCitation_article-title">Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine  -Oxidation and Rearrangement. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism and Disposition</span><span> <strong>2016,</strong> <em>44 </em>
                                    (6)
                                     , 809-820. <a href="https://doi.org/10.1124/dmd.115.068866" title="DOI URL">https://doi.org/10.1124/dmd.115.068866</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/dmd.115.068866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fdmd.115.068866%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520and%2520Disposition%26atitle%3DBiotransformation%252Bof%252BDaclatasvir%252BIn%252BVitro%252Band%252Bin%252BNonclinical%252BSpecies%25253A%252BFormation%252Bof%252Bthe%252BMain%252BMetabolite%252Bby%252BPyrrolidine%252B%2525C2%2525A0-Oxidation%252Band%252BRearrangement%26aulast%3DLi%26aufirst%3DW.%26date%3D2016%26date%3D2016%26volume%3D44%26issue%3D6%26spage%3D809%26epage%3D820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John A.  Easter</span>, <span class="hlFld-ContribAuthor ">Richard C.  Burrell</span>, <span class="hlFld-ContribAuthor ">Samuel J.  Bonacorsi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of isotopically labeled daclatasvir for use in human clinical studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2016,</strong> <em>59 </em>
                                    (4)
                                     , 164-170. <a href="https://doi.org/10.1002/jlcr.3386" title="DOI URL">https://doi.org/10.1002/jlcr.3386</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3386%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DSynthesis%252Bof%252Bisotopically%252Blabeled%252Bdaclatasvir%252Bfor%252Buse%252Bin%252Bhuman%252Bclinical%252Bstudies%26aulast%3DEaster%26aufirst%3DJohn%2BA.%26date%3D2016%26date%3D2016%26volume%3D59%26issue%3D4%26spage%3D164%26epage%3D170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael  Houghton</span>. </span><span class="cited-content_cbyCitation_article-title">Towards the Control of Hepatitis C. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 3-14. <a href="https://doi.org/10.1007/978-4-431-56098-2_1" title="DOI URL">https://doi.org/10.1007/978-4-431-56098-2_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-4-431-56098-2_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-4-431-56098-2_1%26sid%3Dliteratum%253Aachs%26atitle%3DTowards%252Bthe%252BControl%252Bof%252BHepatitis%252BC%26aulast%3DHoughton%26aufirst%3DMichael%26date%3D2016%26date%3D2016%26spage%3D3%26epage%3D14%26pub%3DSpringer%2520Japan%26atitle%3DHepatitis%252BC%252BVirus%252BI%26aulast%3DMiyamura%26aufirst%3DTatsuo%26date%3D2016%26volume%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas O.  Moore</span>, <span class="hlFld-ContribAuthor ">Michael  Paradowski</span>, <span class="hlFld-ContribAuthor ">Simon E.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">An atom-efficient and convergent approach to the preparation of NS5A inhibitors by C–H activation. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2016,</strong> <em>14 </em>
                                    (12)
                                     , 3307-3313. <a href="https://doi.org/10.1039/C6OB00340K" title="DOI URL">https://doi.org/10.1039/C6OB00340K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6OB00340K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6OB00340K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DAn%252Batom-efficient%252Band%252Bconvergent%252Bapproach%252Bto%252Bthe%252Bpreparation%252Bof%252BNS5A%252Binhibitors%252Bby%252BC%2525E2%252580%252593H%252Bactivation%26aulast%3DMoore%26aufirst%3DThomas%2BO.%26date%3D2016%26date%3D2016%26volume%3D14%26issue%3D12%26spage%3D3307%26epage%3D3313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nobuko  Mibu</span>, <span class="hlFld-ContribAuthor ">Kazumi  Yokomizo</span>, <span class="hlFld-ContribAuthor ">Kana  Murakami</span>, <span class="hlFld-ContribAuthor ">Yurika  Ono</span>, <span class="hlFld-ContribAuthor ">Masato  Ishimaru</span>, <span class="hlFld-ContribAuthor ">Marie  Otsubo</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Inao</span>, <span class="hlFld-ContribAuthor ">Yutaro  Ono</span>, <span class="hlFld-ContribAuthor ">Jian-Rong  Zhou</span>, <span class="hlFld-ContribAuthor ">Kunihiro  Sumoto</span>. </span><span class="cited-content_cbyCitation_article-title">Antiviral Activity and Molecular Geometry of Some New Symmetrical Tris(aminoalkyl)amine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">CHEMICAL & PHARMACEUTICAL BULLETIN</span><span> <strong>2016,</strong> <em>64 </em>
                                    (12)
                                     , 1769-1780. <a href="https://doi.org/10.1248/cpb.c16-00682" title="DOI URL">https://doi.org/10.1248/cpb.c16-00682</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1248/cpb.c16-00682&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1248%2Fcpb.c16-00682%26sid%3Dliteratum%253Aachs%26jtitle%3DCHEMICAL%2520%2526%2520PHARMACEUTICAL%2520BULLETIN%26atitle%3DAntiviral%252BActivity%252Band%252BMolecular%252BGeometry%252Bof%252BSome%252BNew%252BSymmetrical%252BTris%252528aminoalkyl%252529amine%252BDerivatives%26aulast%3DMibu%26aufirst%3DNobuko%26date%3D2016%26volume%3D64%26issue%3D12%26spage%3D1769%26epage%3D1780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Makonen  Belema</span>, <span class="hlFld-ContribAuthor ">Shawn K.  Pack</span>, <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 43-60. <a href="https://doi.org/10.1002/9781118819951.ch3" title="DOI URL">https://doi.org/10.1002/9781118819951.ch3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118819951.ch3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118819951.ch3%26sid%3Dliteratum%253Aachs%26atitle%3DDaclatasvir%252B%252528Daklinza%252529%25253A%252BThe%252BFirst-in-Class%252BHCV%252BNS5A%252BReplication%252BComplex%252BInhibitor%26aulast%3DBelema%26aufirst%3DMakonen%26date%3D2015%26date%3D2015%26spage%3D43%26epage%3D60%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DInnovative%252BDrug%252BSynthesis%26aulast%3DLi%26aufirst%3DJie%2BJack%26date%3D2015%26volume%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Il Hak  Bae</span>, <span class="hlFld-ContribAuthor ">Hee Sun  Kim</span>, <span class="hlFld-ContribAuthor ">Youngsu  You</span>, <span class="hlFld-ContribAuthor ">Chieyeon  Chough</span>, <span class="hlFld-ContribAuthor ">Weonu  Choe</span>, <span class="hlFld-ContribAuthor ">Min Kyung  Seon</span>, <span class="hlFld-ContribAuthor ">Seung Gi  Lee</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>, <span class="hlFld-ContribAuthor ">Sung Key  Jang</span>, <span class="hlFld-ContribAuthor ">B.  Moon Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>101 </em>, 163-178. <a href="https://doi.org/10.1016/j.ejmech.2015.06.033" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.06.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.06.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.06.033%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bbenzidine%252Band%252Bdiaminofluorene%252Bprolinamide%252Bderivatives%252Bas%252Bpotent%252Bhepatitis%252BC%252Bvirus%252BNS5A%252Binhibitors%26aulast%3DBae%26aufirst%3DIl%2BHak%26date%3D2015%26volume%3D101%26spage%3D163%26epage%3D178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Erik  De Clercq</span>. </span><span class="cited-content_cbyCitation_article-title">Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace. </span><span class="cited-content_cbyCitation_journal-name">Reviews in Medical Virology</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 254-267. <a href="https://doi.org/10.1002/rmv.1842" title="DOI URL">https://doi.org/10.1002/rmv.1842</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rmv.1842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frmv.1842%26sid%3Dliteratum%253Aachs%26jtitle%3DReviews%2520in%2520Medical%2520Virology%26atitle%3DDevelopment%252Bof%252Bantiviral%252Bdrugs%252Bfor%252Bthe%252Btreatment%252Bof%252Bhepatitis%252BC%252Bat%252Ban%252Baccelerating%252Bpace%26aulast%3DDe%2BClercq%26aufirst%3DErik%26date%3D2015%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D254%26epage%3D267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessio  Aghemo</span>, <span class="hlFld-ContribAuthor ">Raffaele  De Francesco</span>. </span><span class="cited-content_cbyCitation_article-title">Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C. </span><span class="cited-content_cbyCitation_journal-name">Gut</span><span> <strong>2015,</strong> <em>64 </em>
                                    (6)
                                     , 860-862. <a href="https://doi.org/10.1136/gutjnl-2014-307958" title="DOI URL">https://doi.org/10.1136/gutjnl-2014-307958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1136/gutjnl-2014-307958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1136%2Fgutjnl-2014-307958%26sid%3Dliteratum%253Aachs%26jtitle%3DGut%26atitle%3DDaclatasvir%25253A%252Ba%252Bteam%252Bplayer%252Brather%252Bthan%252Ba%252Bprima%252Bdonna%252Bin%252Bthe%252Btreatment%252Bof%252Bhepatitis%252BC%26aulast%3DAghemo%26aufirst%3DAlessio%26date%3D2015%26date%3D2014%26volume%3D64%26issue%3D6%26spage%3D860%26epage%3D862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zsofia  Igloi</span>, <span class="hlFld-ContribAuthor ">Bjorn-Patrick  Mohl</span>, <span class="hlFld-ContribAuthor ">Jonathan D.  Lippiat</span>, <span class="hlFld-ContribAuthor ">Mark  Harris</span>, <span class="hlFld-ContribAuthor ">Jamel  Mankouri</span>, . </span><span class="cited-content_cbyCitation_article-title">Requirement for Chloride Channel Function during the Hepatitis C Virus Life Cycle. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2015,</strong> <em>89 </em>
                                    (7)
                                     , 4023-4029. <a href="https://doi.org/10.1128/JVI.02946-14" title="DOI URL">https://doi.org/10.1128/JVI.02946-14</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.02946-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.02946-14%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DRequirement%252Bfor%252BChloride%252BChannel%252BFunction%252Bduring%252Bthe%252BHepatitis%252BC%252BVirus%252BLife%252BCycle%26aulast%3DIgloi%26aufirst%3DZsofia%26date%3D2015%26volume%3D89%26issue%3D7%26spage%3D4023%26epage%3D4029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Giroux</span>, <span class="hlFld-ContribAuthor ">Darius  Bilimoria</span>, <span class="hlFld-ContribAuthor ">Caroline  Cadilhac</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Cottrell</span>, <span class="hlFld-ContribAuthor ">Francois  Denis</span>, <span class="hlFld-ContribAuthor ">Evelyne  Dietrich</span>, <span class="hlFld-ContribAuthor ">Nigel  Ewing</span>, <span class="hlFld-ContribAuthor ">James A.  Henderson</span>, <span class="hlFld-ContribAuthor ">Lucille  L’Heureux</span>, <span class="hlFld-ContribAuthor ">Nagraj  Mani</span>, <span class="hlFld-ContribAuthor ">Mark  Morris</span>, <span class="hlFld-ContribAuthor ">Olivier  Nicolas</span>, <span class="hlFld-ContribAuthor ">T. Jagadeeswar  Reddy</span>, <span class="hlFld-ContribAuthor ">Subajini  Selliah</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Shawgo</span>, <span class="hlFld-ContribAuthor ">Jinwang  Xu</span>, <span class="hlFld-ContribAuthor ">Nathalie  Chauret</span>, <span class="hlFld-ContribAuthor ">Francoise  Berlioz-Seux</span>, <span class="hlFld-ContribAuthor ">Laval C.  Chan</span>, <span class="hlFld-ContribAuthor ">Sanjoy K.  Das</span>, <span class="hlFld-ContribAuthor ">Anne-Laure  Grillot</span>, <span class="hlFld-ContribAuthor ">Youssef L.  Bennani</span>, <span class="hlFld-ContribAuthor ">John P.  Maxwell</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: Non-symmetric inhibitors with potent activity against genotype 1a and 1b. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 940-943. <a href="https://doi.org/10.1016/j.bmcl.2014.12.044" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.044%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bthienoimidazole-based%252BHCV%252BNS5A%252Binhibitors.%252BPart%252B2%25253A%252BNon-symmetric%252Binhibitors%252Bwith%252Bpotent%252Bactivity%252Bagainst%252Bgenotype%252B1a%252Band%252B1b%26aulast%3DGiroux%26aufirst%3DSimon%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D940%26epage%3D943" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Giroux</span>, <span class="hlFld-ContribAuthor ">Darius  Bilimoria</span>, <span class="hlFld-ContribAuthor ">Caroline  Cadilhac</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Cottrell</span>, <span class="hlFld-ContribAuthor ">Francois  Denis</span>, <span class="hlFld-ContribAuthor ">Evelyne  Dietrich</span>, <span class="hlFld-ContribAuthor ">Nigel  Ewing</span>, <span class="hlFld-ContribAuthor ">James A.  Henderson</span>, <span class="hlFld-ContribAuthor ">Lucille  L’Heureux</span>, <span class="hlFld-ContribAuthor ">Nagraj  Mani</span>, <span class="hlFld-ContribAuthor ">Mark  Morris</span>, <span class="hlFld-ContribAuthor ">Olivier  Nicolas</span>, <span class="hlFld-ContribAuthor ">T. Jagadeeswar  Reddy</span>, <span class="hlFld-ContribAuthor ">Subajini  Selliah</span>, <span class="hlFld-ContribAuthor ">Rebecca S.  Shawgo</span>, <span class="hlFld-ContribAuthor ">Jinwang  Xu</span>, <span class="hlFld-ContribAuthor ">Nathalie  Chauret</span>, <span class="hlFld-ContribAuthor ">Francoise  Berlioz-Seux</span>, <span class="hlFld-ContribAuthor ">Laval C.  Chan</span>, <span class="hlFld-ContribAuthor ">Sanjoy K.  Das</span>, <span class="hlFld-ContribAuthor ">Anne-Laure  Grillot</span>, <span class="hlFld-ContribAuthor ">Youssef L.  Bennani</span>, <span class="hlFld-ContribAuthor ">John P.  Maxwell</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-Symmetric inhibitors with diyne and biphenyl linkers. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (4)
                                     , 936-939. <a href="https://doi.org/10.1016/j.bmcl.2014.12.046" title="DOI URL">https://doi.org/10.1016/j.bmcl.2014.12.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2014.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2014.12.046%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bthienoimidazole-based%252BHCV%252BNS5A%252Binhibitors.%252BPart%252B1%25253A%252BC2-Symmetric%252Binhibitors%252Bwith%252Bdiyne%252Band%252Bbiphenyl%252Blinkers%26aulast%3DGiroux%26aufirst%3DSimon%26date%3D2015%26volume%3D25%26issue%3D4%26spage%3D936%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hugh  Adler</span>, <span class="hlFld-ContribAuthor ">John S  Lambert</span>. </span><span class="cited-content_cbyCitation_article-title">Daclatasvir for the treatment of hepatitis C virus infection. </span><span class="cited-content_cbyCitation_journal-name">Expert Review of Gastroenterology & Hepatology</span><span> <strong>2014,</strong> <em>8 </em>
                                    (7)
                                     , 725-738. <a href="https://doi.org/10.1586/17474124.2014.925798" title="DOI URL">https://doi.org/10.1586/17474124.2014.925798</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1586/17474124.2014.925798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1586%2F17474124.2014.925798%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Review%2520of%2520Gastroenterology%2520%2526%2520Hepatology%26atitle%3DDaclatasvir%252Bfor%252Bthe%252Btreatment%252Bof%252Bhepatitis%252BC%252Bvirus%252Binfection%26aulast%3DAdler%26aufirst%3DHugh%26date%3D2014%26date%3D2014%26volume%3D8%26issue%3D7%26spage%3D725%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniele  Serranti</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Indolfi</span>, <span class="hlFld-ContribAuthor ">Massimo  Resti</span>. </span><span class="cited-content_cbyCitation_article-title">New treatments for chronic hepatitis C: An overview for paediatricians. </span><span class="cited-content_cbyCitation_journal-name">World Journal of Gastroenterology</span><span> <strong>2014,</strong> <em>20 </em>
                                    (43)
                                     , 15965. <a href="https://doi.org/10.3748/wjg.v20.i43.15965" title="DOI URL">https://doi.org/10.3748/wjg.v20.i43.15965</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3748/wjg.v20.i43.15965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3748%2Fwjg.v20.i43.15965%26sid%3Dliteratum%253Aachs%26jtitle%3DWorld%2520Journal%2520of%2520Gastroenterology%26atitle%3DNew%252Btreatments%252Bfor%252Bchronic%252Bhepatitis%252BC%25253A%252BAn%252Boverview%252Bfor%252Bpaediatricians%26aulast%3DSerranti%26aufirst%3DDaniele%26date%3D2014%26volume%3D20%26issue%3D43%26spage%3D15965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Initial strategies pursued to enhance PK properties of <b>2</b> and <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Intermediates <b>48a</b>, <b>48c</b>,
and <b>52b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a)
Br<sub>2</sub>, HBr, CH<sub>2</sub>Cl<sub>2</sub>; (b) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-proline, Et<sub>3</sub>N, CH<sub>3</sub>CN; (c) NH<sub>4</sub>OAc, xylenes, 140 °C; (d) <i>n</i>-BuLi, <i>t</i>-butyl 2-(methoxy(methyl)amino)-2-oxoethylcarbamate; −78
°C to −15 °C; (e) 48% HBr, dioxane; (f) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-proline, HATU, DIEA, DMF; (g) NaH, SEM-Cl, DMF; (h)
tributyl(1-ethoxyvinyl)tin, PdCl<sub>2</sub>(Ph<sub>3</sub>P)<sub>2</sub>, DMF, 100 °C; (i) NBS, H<sub>2</sub>O/THF, 0 °C.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Aza-Core Analogues <b>4</b>–<b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a)
Pd(Ph<sub>3</sub>P)<sub>4</sub>, NaHCO<sub>3</sub>, DME/H<sub>2</sub>O, 90 °C; (b) 25% TFA/CH<sub>2</sub>Cl<sub>2</sub>; (c) (2<i>R</i>)-2-[(methoxycarbonyl)amino]-2-phenylacetic acid, HATU,
DIEA, DMF; (d) Pd(Ph<sub>3</sub>P)<sub>4</sub>, NaHCO<sub>3</sub>,
DME/H<sub>2</sub>O, 80 °C.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/medium/jm-2013-01836p_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Homodimeric
and Mixed-Cap Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-5/jm401836p/20190625/images/large/jm-2013-01836p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401836p&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions:
(a)
R<sub>1</sub>CO<sub>2</sub>H, HATU, DIEA, DMF; (b) 25% TFA/CH<sub>2</sub>Cl<sub>2</sub> or 4 N HCl/dioxane; (c) R<sub>2</sub>CO<sub>2</sub>H, HATU, DIEA, DMF.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i63">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84152" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84152" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 21 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidya, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C. M.</span></span> <span> </span><span class="NLM_article-title">Simeprevir: First global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">2093</span>– <span class="NLM_lpage">2106,</span>, and references cited therein</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1007%2Fs40265-013-0153-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24293133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFSqsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=2093-2106%2C&author=A.+Vaidyaauthor=C.+M.+Perry&title=Simeprevir%3A+First+global+approval"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Simeprevir: First Global Approval</span></div><div class="casAuthors">Vaidya, Asha; Perry, Caroline M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2093-2106</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Simeprevir (SovriadTM) is a new direct-acting antiviral drug and a second-generation small-mol. NS3/4A serine protease inhibitor developed by Janssen and Medivir for the oral treatment of adults with genotype 1 and/or genotype 4 chronic hepatitis C virus (HCV) infection (chronic hepatitis C).  Simeprevir antiviral activity is achieved by its non-covalent binding to HCV protease, with a fast assocn. and slow dissocn. rate.  The capsule formulation is approved in Japan and Canada for use in combination with pegylated interferon (peginterferon) and ribavirin for genotype 1 chronic hepatitis C, and has been filed for approval in the US in this indication.  In addn., the capsule formulation has been filed for approval in the EU for use in combination with peginterferon and ribavirin for genotype 1 and 4 chronic hepatitis C. Phase III trials of the capsule formulation of simeprevir are underway in several other regions, including China.  In the pivotal phase III trials, simeprevir was administered once daily for 12 wk in combination with peginterferon and ribavirin for 24 or 48 wk.  This article summarizes the milestones in the development of simeprevir leading to this first approval for chronic hepatitis C.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVExWf01G6I7Vg90H21EOLACvtfcHk0lhv8BqUu5WChA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFSqsbbM&md5=ace8fa9b2a0b8e84fbce326ae458b6b6</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0153-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0153-9%26sid%3Dliteratum%253Aachs%26aulast%3DVaidya%26aufirst%3DA.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DSimeprevir%253A%2520First%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D2093%26epage%3D2106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassanein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayali, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nyberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arterburn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNally, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symonds, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHutchison, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheikh, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Younossi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gane, E. J.</span></span> <span> </span><span class="NLM_article-title">Sofosbuvir for previously untreated chronic hepatitis C infection</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1878</span>– <span class="NLM_lpage">1887</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1056%2FNEJMoa1214853" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23607594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=1878-1887&author=E.+Lawitzauthor=A.+Mangiaauthor=D.+Wylesauthor=M.+Rodriguez-Torresauthor=T.+Hassaneinauthor=S.+C.+Gordonauthor=M.+Schultzauthor=M.+N.+Davisauthor=Z.+Kayaliauthor=K.+R.+Reddyauthor=I.+M.+Jacobsonauthor=K.+V.+Kowdleyauthor=L.+Nybergauthor=G.+M.+Subramanianauthor=R.+H.+Hylandauthor=S.+Arterburnauthor=D.+Jiangauthor=J.+McNallyauthor=D.+Brainardauthor=W.+T.+Symondsauthor=J.+G.+McHutchisonauthor=A.+M.+Sheikhauthor=Z.+Younossiauthor=E.+J.+Gane&title=Sofosbuvir+for+previously+untreated+chronic+hepatitis+C+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Sofosbuvir for previously untreated chronic hepatitis C infection</span></div><div class="casAuthors">Lawitz, Eric; Mangia, Alessandra; Wyles, David; Rodriguez-Torres, Maribel; Hassanein, Tarek; Gordon, Stuart C.; Schultz, Michael; Davis, Mitchell N.; Kayali, Zeid; Reddy, K. Rajender; Jacobson, Ira M.; Kowdley, Kris V.; Nyberg, Lisa; Subramanian, G. Mani; Hyland, Robert H.; Arterburn, Sarah; Jiang, Deyuan; McNally, John; Brainard, Diana; Symonds, William T.; McHutchison, John G.; Sheikh, Aasim M.; Younossi, Zobair; Gane, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1878-1887</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background. In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.  Methods. We conducted two phase 3 studies in previously untreated patients with HCV infection.  In a single-group, open-label study, we administered a 12-wk regimen of sofosbuvir plus peginterferon alfa-2a and ribavirin in 327 patients with HCV genotype 1, 4, 5, or 6 (of whom 98% had genotype 1 or 4).  In a noninferiority trial, 499 patients with HCV genotype 2 or 3 infection were randomly assigned to receive sofosbuvir plus ribavirin for 12 wk or peginterferon alfa-2a plus ribavirin for 24 wk.  In the two studies, the primary end point was a sustained virol. response at 12 wk after the end of therapy.  Results. In the single-group study, a sustained virol. response was reported in 90% of patients (95% confidence interval, 87 to 93).  In the noninferiority trial, a sustained response was reported in 67% of patients in both the sofosbuvir-ribavirin group and the peginterferon-ribavirin group.  Response rates in the sofosbuvir-ribavirin group were lower among patients with genotype 3 infection than among those with genotype 2 infection (56% vs. 97%).  Adverse events (including fatigue, headache, nausea, and neutropenia) were less common with sofosbuvir than with peginterferon.  Conclusions. In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virol. response of 90% at 12 wk.  In a noninferiority trial, patients with genotype 2 or 3 infection who received either sofosbuvir or peginterferon with ribavirin had nearly identical rates of response (67%).  Adverse events were less frequent with sofosbuvir than with peginterferon.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHmr2x-ct3irVg90H21EOLACvtfcHk0lg1pGUNr2R_Kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsl2gsrY%253D&md5=09e3e6abc636e8d93a12e3b8382a7f63</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214853%26sid%3Dliteratum%253Aachs%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMangia%26aufirst%3DA.%26aulast%3DWyles%26aufirst%3DD.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DHassanein%26aufirst%3DT.%26aulast%3DGordon%26aufirst%3DS.%2BC.%26aulast%3DSchultz%26aufirst%3DM.%26aulast%3DDavis%26aufirst%3DM.%2BN.%26aulast%3DKayali%26aufirst%3DZ.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26aulast%3DJacobson%26aufirst%3DI.%2BM.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26aulast%3DNyberg%26aufirst%3DL.%26aulast%3DSubramanian%26aufirst%3DG.%2BM.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DArterburn%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DMcNally%26aufirst%3DJ.%26aulast%3DBrainard%26aufirst%3DD.%26aulast%3DSymonds%26aufirst%3DW.%2BT.%26aulast%3DMcHutchison%26aufirst%3DJ.%2BG.%26aulast%3DSheikh%26aufirst%3DA.%2BM.%26aulast%3DYounossi%26aufirst%3DZ.%26aulast%3DGane%26aufirst%3DE.%2BJ.%26atitle%3DSofosbuvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520infection%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D1878%26epage%3D1887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit2c"><span>
					<span class="NLM_label">(c) </span> <span class="NLM_contrib-group">Gilead
Sciences, Inc.</span> U.S. Food and Drug Administration approves
Gilead’s Sovaldi<sup>TM</sup> (sofosbuvir) for the treatment
of chronic hepatitis C. <a href="http://www.gilead.com/news/press-releases" class="extLink">http://www.gilead.com/news/press-releases</a>, Dec. 6, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+Gilead%0ASciences%2C+Inc.+U.S.+Food+and+Drug+Administration+approves%0AGilead%E2%80%99s+SovaldiTM+%28sofosbuvir%29+for+the+treatment%0Aof+chronic+hepatitis+C.+http%3A%2F%2Fwww.gilead.com%2Fnews%2Fpress-releases%2C+Dec.+6%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chien, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span> <span> </span><span class="NLM_article-title">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>465</i></span>,  <span class="NLM_fpage">96</span>– <span class="NLM_lpage">100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1038%2Fnature08960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=20410884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=96-100&author=M.+Gaoauthor=R.+E.+Nettlesauthor=M.+Belemaauthor=L.+B.+Snyderauthor=V.+N.+Nguyenauthor=R.+A.+Fridellauthor=M.+H.+Serrano-Wuauthor=D.+R.+Langleyauthor=J.-H.+Sunauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=C.+Wangauthor=J.+O.+Knipeauthor=C.+Chienauthor=R.+J.+Colonnoauthor=D.+M.+Graselaauthor=N.+A.+Meanwellauthor=L.+G.+Hamann&title=Chemical+genetics+strategy+identifies+an+HCV+NS5A+inhibitor+with+a+potent+clinical+effect"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect</span></div><div class="casAuthors">Gao, Min; Nettles, Richard E.; Belema, Makonen; Snyder, Lawrence B.; Nguyen, Van N.; Fridell, Robert A.; Serrano-Wu, Michael H.; Langley, David R.; Sun, Jin-Hua; O'Boyle, Donald R., II; Lemm, Julie A.; Wang, Chunfu; Knipe, Jay O.; Chien, Caly; Colonno, Richard J.; Grasela, Dennis M.; Meanwell, Nicholas A.; Hamann, Lawrence G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">465</span>
        (<span class="NLM_cas:issue">7294</span>),
    <span class="NLM_cas:pages">96-100</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estd. to be approaching 200 million people.  Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically assocd. with less than 50% sustained virol. response rate in those infected with genotype 1 virus.  The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA-dependent RNA polymerase NS5B.  Here we describe the profile of BMS-790052, a small mol. inhibitor of the HCV NS5A protein that exhibits picomolar half-max. effective concns. (EC50) towards replicons expressing a broad range of HCV genotypes and the JFH-1 genotype 2a infectious virus in cell culture.  In a phase I clin. trial in patients chronically infected with HCV, administration of a single 100-mg dose of BMS-790052 was assocd. with a 3.3 log10 redn. in mean viral load measured 24 h post-dose that was sustained for an addnl. 120 h in two patients infected with genotype 1b virus.  Genotypic anal. of samples taken at baseline, 24 and 144 h post-dose revealed that the major HCV variants obsd. had substitutions at amino-acid positions identified using the in vitro replicon system.  These results provide the first clin. validation of an inhibitor of HCV NS5A, a protein with no known enzymic function, as an approach to the suppression of virus replication that offers potential as part of a therapeutic regimen based on combinations of HCV inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAY7Lig0xT9LVg90H21EOLACvtfcHk0lj5XWOz5YxThA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGhtbo%253D&md5=620427e987f2bccd153270cde2ef5027</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature08960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08960%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DM.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DLangley%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DChien%26aufirst%3DC.%26aulast%3DColonno%26aufirst%3DR.%2BJ.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26atitle%3DChemical%2520genetics%2520strategy%2520identifies%2520an%2520HCV%2520NS5A%2520inhibitor%2520with%2520a%2520potent%2520clinical%2520effect%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D96%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span>
					<span class="NLM_label">(a) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Link, J. O. </span>; <span class="NLM_string-name">
							Taylor, J. G. </span>; <span class="NLM_string-name">
							Xu, L. </span>; <span class="NLM_string-name">
							Mitchell, M. L. </span>; <span class="NLM_string-name">
							Guo, H. </span>; <span class="NLM_string-name">
							Liu, H. </span>; <span class="NLM_string-name">
							Kato, D. </span>; <span class="NLM_string-name">
							Kirschberg, T. </span>; <span class="NLM_string-name">
							Sun, J. </span>; <span class="NLM_string-name">
							Squires, N. </span>; <span class="NLM_string-name">
							Parrish, J. </span>; <span class="NLM_string-name">
							Kellar, T. </span>; <span class="NLM_string-name">
							Yang, Z.-Y. </span>; <span class="NLM_string-name">
							Yang, C. </span>; <span class="NLM_string-name">
							Matles, M. </span>; <span class="NLM_string-name">
							Wang, Y. </span>; <span class="NLM_string-name">
							Wang, K. </span>; <span class="NLM_string-name">
							Cheng, G. </span>; <span class="NLM_string-name">
							Tian, Y. </span>; <span class="NLM_string-name">
							Mogalian, E. </span>; <span class="NLM_string-name">
							Mondou, E. </span>; <span class="NLM_string-name">
							Cornpropst, M. </span>; <span class="NLM_string-name">
							Perry, J. </span>; <span class="NLM_string-name">
							Desai, M. C. </span> </span> <span> </span><span class="NLM_article-title">The discovery of ledipasvir
(GS-5885), a potent once-daily oral NS5A inhibitor for the treatment
of hepatitis C virus infection</span>.  <i>J. Med. Chem.</i> DOI: <span class="refDoi"> DOI: 10.1021/jm401499</span> .</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1021%2Fjm401499" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09Link%2C+J.+O.+%3B+%0A%09%09%09%09%09%09%09Taylor%2C+J.+G.+%3B+%0A%09%09%09%09%09%09%09Xu%2C+L.+%3B+%0A%09%09%09%09%09%09%09Mitchell%2C+M.+L.+%3B+%0A%09%09%09%09%09%09%09Guo%2C+H.+%3B+%0A%09%09%09%09%09%09%09Liu%2C+H.+%3B+%0A%09%09%09%09%09%09%09Kato%2C+D.+%3B+%0A%09%09%09%09%09%09%09Kirschberg%2C+T.+%3B+%0A%09%09%09%09%09%09%09Sun%2C+J.+%3B+%0A%09%09%09%09%09%09%09Squires%2C+N.+%3B+%0A%09%09%09%09%09%09%09Parrish%2C+J.+%3B+%0A%09%09%09%09%09%09%09Kellar%2C+T.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+Z.-Y.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+C.+%3B+%0A%09%09%09%09%09%09%09Matles%2C+M.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+K.+%3B+%0A%09%09%09%09%09%09%09Cheng%2C+G.+%3B+%0A%09%09%09%09%09%09%09Tian%2C+Y.+%3B+%0A%09%09%09%09%09%09%09Mogalian%2C+E.+%3B+%0A%09%09%09%09%09%09%09Mondou%2C+E.+%3B+%0A%09%09%09%09%09%09%09Cornpropst%2C+M.+%3B+%0A%09%09%09%09%09%09%09Perry%2C+J.+%3B+%0A%09%09%09%09%09%09%09Desai%2C+M.+C.+The+discovery+of+ledipasvir%0A%28GS-5885%29%2C+a+potent+once-daily+oral+NS5A+inhibitor+for+the+treatment%0Aof+hepatitis+C+virus+infection.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm401499."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1021%2Fjm401499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401499%26sid%3Dliteratum%253Aachs%26aulast%3DLink%26aufirst%3DJ.%2BO.%26atitle%3DThe%2520discovery%2520of%2520ledipasvir%250A%2528GS-5885%2529%252C%2520a%2520potent%2520once-daily%2520oral%2520NS5A%2520inhibitor%2520for%2520the%2520treatment%250Aof%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm401499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfret, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adkison, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castellino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moseley, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Serres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Culp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goljer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spreen, W.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus NS5A, in healthy subjects and subjects chronically infected with genotype 1 hepatitis C virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">5037</span>– <span class="NLM_lpage">5044</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.00910-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23896477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVygtLfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=5037-5044&author=D.+A.+Wilfretauthor=J.+Walkerauthor=K.+K.+Adkisonauthor=L.+A.+Jonesauthor=Y.+Louauthor=J.+Ganauthor=S.+Castellinoauthor=C.+L.+Moseleyauthor=J.+Hortonauthor=M.+de+Serresauthor=A.+Culpauthor=I.+Goljerauthor=W.+Spreen&title=Safety%2C+tolerability%2C+pharmacokinetics%2C+and+antiviral+activity+of+GSK2336805%2C+an+inhibitor+of+hepatitis+C+virus+NS5A%2C+in+healthy+subjects+and+subjects+chronically+infected+with+genotype+1+hepatitis+C+virus"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1</span></div><div class="casAuthors">Wilfret, D. A.; Walker, J.; Adkison, K. K.; Jones, L. A.; Lou, Y.; Gan, J.; Castellino, S.; Moseley, C. L.; Horton, J.; de Serres, M.; Culp, A.; Goljer, I.; Spreen, W.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5037-5044</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">GSK2336805 is an orally bioavailable hepatitis C virus (HCV) inhibitor working through an NS5A-mediated mechanism.  This first-time-in-human study was conducted to assess the safety, tolerability, pharmacokinetics, metab., and efficacy of GSK2336805 in healthy subjects and subjects infected with HCV genotype 1.  We performed a three-part, randomized, double-blind, placebo-controlled study in 46 healthy subjects and 23 HCV-infected subjects.  After an overnight fast, healthy subjects received GSK2336805 as 10 mg, 30 mg, 30 mg plus food, and 60 mg in a single dose and 10 mg (7 days), 30 mg (7 days), and 75 mg (14 days) in a once-daily multiple dose.  Subjects with HCV received GSK2336805 as a 1- to 120-mg single dose.  In subjects with HCV, redns. in HCV RNA were obsd. within 4 h and a single dose of GSK2336805 of ≥10 mg resulted in a statistically significant ≥2-log redn. in HCV RNA compared with placebo at 24 h postdose.  GSK2336805 was readily absorbed in all subjects, and the half-life (t1/2) was suitable for once-daily dosing.  Administration of GSK2336805 with food had no effect on plasma GSK2336805 exposure; however, absorption was delayed, with a median tmax (time to max. concn. of drug in serum) of 4.5 vs. 2.0 h.  Twenty subjects who received GSK2336805 experienced mild to moderate adverse events; none were serious.  GSK2336805 was well tolerated and exhibited rapid, significant antiviral activity after a single dose in HCV-infected subjects.  These results support the conduct of further studies evaluating GSK2336805 administered once daily for longer durations in combination with peginterferon, ribavirin, and other direct-acting antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGopPgP3XCh7Vg90H21EOLACvtfcHk0lg8KCClZUa14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVygtLfN&md5=8e9f3eee73c0e688f1dae5510f3c1fc7</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1128%2FAAC.00910-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00910-13%26sid%3Dliteratum%253Aachs%26aulast%3DWilfret%26aufirst%3DD.%2BA.%26aulast%3DWalker%26aufirst%3DJ.%26aulast%3DAdkison%26aufirst%3DK.%2BK.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCastellino%26aufirst%3DS.%26aulast%3DMoseley%26aufirst%3DC.%2BL.%26aulast%3DHorton%26aufirst%3DJ.%26aulast%3Dde%2BSerres%26aufirst%3DM.%26aulast%3DCulp%26aufirst%3DA.%26aulast%3DGoljer%26aufirst%3DI.%26aulast%3DSpreen%26aufirst%3DW.%26atitle%3DSafety%252C%2520tolerability%252C%2520pharmacokinetics%252C%2520and%2520antiviral%2520activity%2520of%2520GSK2336805%252C%2520an%2520inhibitor%2520of%2520hepatitis%2520C%2520virus%2520NS5A%252C%2520in%2520healthy%2520subjects%2520and%2520subjects%2520chronically%2520infected%2520with%2520genotype%25201%2520hepatitis%2520C%2520virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D5037%26epage%3D5044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit4c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Coburn, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinke, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kargman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomeir, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soll, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1930</span>– <span class="NLM_lpage">1940</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fcmdc.201300343" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24127258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1930-1940&author=C.+A.+Coburnauthor=P.+T.+Meinkeauthor=W.+Changauthor=C.+M.+Fandozziauthor=D.+J.+Grahamauthor=B.+Huauthor=Q.+Huangauthor=S.+Kargmanauthor=J.+Kozlowskiauthor=R.+Liuauthor=J.+A.+McCauleyauthor=A.+A.+Nomeirauthor=R.+M.+Sollauthor=J.+P.+Vaccaauthor=D.+Wangauthor=H.+Wuauthor=B.+Zhongauthor=D.+B.+Olsenauthor=S.+W.+Ludmerer&title=Discovery+of+MK-8742%3A+An+HCV+NS5A+inhibitor+with+broad+genotype+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4cR"><div class="casContent"><span class="casTitleNuber">4c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity</span></div><div class="casAuthors">Coburn, Craig A.; Meinke, Peter T.; Chang, Wei; Fandozzi, Christine M.; Graham, Donald J.; Hu, Bin; Huang, Qian; Kargman, Stacia; Kozlowski, Joseph; Liu, Rong; McCauley, John A.; Nomeir, Amin A.; Soll, Richard M.; Vacca, Joseph P.; Wang, Dahai; Wu, Hao; Zhong, Bin; Olsen, David B.; Ludmerer, Steven W.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1930-1940</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The NS5A protein plays a crit. role in the replication of HCV and has been the focus of numerous research efforts over the past few years.  NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays, making them attractive components for inclusion in all oral combination regimens.  Early work in the NS5A arena led to the discovery of our first clin. candidate, MK-4882 [2-((S)-pyrrolidin-2-yl)-5-(2-(4-(5-((S)-pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole].  While preclin. proof-of-concept studies in HCV-infected chimpanzees harboring chronic genotype 1 infections resulted in significant decreases in viral load after both single- and multiple-dose treatments, viral breakthrough proved to be a concern, thus necessitating the development of compds. with increased potency against a no. of genotypes and NS5A resistance mutations.  Modification of the MK-4882 core scaffold by introduction of a cyclic constraint afforded a series of tetracyclic inhibitors, which showed improved virol. profiles.  Herein we describe the research efforts that led to the discovery of MK-8742, a tetracyclic indole-based NS5A inhibitor, which is currently in phase 2b clin. trials as part of an all-oral, interferon-free regimen for the treatment of HCV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqknZKO01aZlLVg90H21EOLACvtfcHk0lg8KCClZUa14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1SkurzN&md5=2f2b3ed2281c43e39b24d4197b9f57ee</span></div><a href="/servlet/linkout?suffix=cit4c&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300343%26sid%3Dliteratum%253Aachs%26aulast%3DCoburn%26aufirst%3DC.%2BA.%26aulast%3DMeinke%26aufirst%3DP.%2BT.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHu%26aufirst%3DB.%26aulast%3DHuang%26aufirst%3DQ.%26aulast%3DKargman%26aufirst%3DS.%26aulast%3DKozlowski%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DNomeir%26aufirst%3DA.%2BA.%26aulast%3DSoll%26aufirst%3DR.%2BM.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26atitle%3DDiscovery%2520of%2520MK-8742%253A%2520An%2520HCV%2520NS5A%2520inhibitor%2520with%2520broad%2520genotype%2520activity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D1930%26epage%3D1940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigat, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">1346</span>– <span class="NLM_lpage">1353</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.49.4.1346-1353.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=15793110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=1346-1353&author=D.+R.+O%E2%80%99Boyleauthor=P.+T.+Nowerauthor=J.+A.+Lemmauthor=L.+Valeraauthor=J.-H.+Sunauthor=K.+Rigatauthor=R.+Colonnoauthor=M.+Gao&title=Development+of+a+cell-based+high-throughput+specificity+screen+using+a+hepatitis+C+virus-bovine+viral+diarrhea+virus+dual+replicon+assay"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5aR"><div class="casContent"><span class="casTitleNuber">5a</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay</span></div><div class="casAuthors">O'Boyle, Donald R., II; Nower, Peter T.; Lemm, Julie A.; Valera, Lourdes; Sun, Jin-Hua; Rigat, Karen; Colonno, Richard; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1346-1353</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) replicon is a unique system for the development of a high-throughput screen (HTS), since the anal. of inhibitors requires the quantification of a decrease in a steady-state level of HCV RNA.  HCV replicon replication is dependent on host cell factors, and any toxic effects may have a significant impact on HCV replicon replication.  Therefore, detg. the antiviral specificity of compds. presents a challenge for the identification of specific HCV inhibitors.  Here we report the development of an HCV/bovine viral diarrhea virus (BVDV) dual replicon assay suitable for HTS to address these issues.  The HCV reporter enzyme is the endogenous NS3 protease contained within the HCV genome, while the BVDV reporter enzyme is a luciferase enzyme engineered into the BVDV genome.  The HTS uses a mixt. of HCV and BVDV replicon cell lines placed in the same well of a 96-well plate and isolated in the same cell backgrounds (Huh-7).  The format consists of three sep. but compatible assays: the first quantitates the amt. of cytotoxicity based upon the conversion of Alamar blue dye via cellular enzymes, while the second indirectly quantitates HCV replicon replication through measurement of the amt. of NS3 protease activity present.  The final assay measures the amt. of luciferase activity present from the BVDV replicon cells, as an indicator of the specificity of the test compds.  This HCV/BVDV dual replicon assay provides a reliable format to det. the potency and specificity of HCV replicon inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX8Ni-3CK40LVg90H21EOLACvtfcHk0lg8KCClZUa14Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjt1GjsrY%253D&md5=0f9a5c1fa35bf1aa1ea4ac5b2d71b859</span></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1128%2FAAC.49.4.1346-1353.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.49.4.1346-1353.2005%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DRigat%26aufirst%3DK.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDevelopment%2520of%2520a%2520cell-based%2520high-throughput%2520specificity%2520screen%2520using%2520a%2520hepatitis%2520C%2520virus-bovine%2520viral%2520diarrhea%2520virus%2520dual%2520replicon%2520assay%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2005%26volume%3D49%26spage%3D1346%26epage%3D1353" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colonno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Identification of hepatitis C virus NS5A inhibitors</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">482</span>– <span class="NLM_lpage">491</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FJVI.01360-09" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19812153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2010&pages=482-491&author=J.+A.+Lemmauthor=D.+R.+O%E2%80%99Boyleauthor=M.+Liuauthor=P.+T.+Nowerauthor=R.+Colonnoauthor=M.+S.+Deshpandeauthor=L.+B.+Snyderauthor=S.+W.+Martinauthor=D.+R.+St.+Laurentauthor=M.+H.+Serrano-Wuauthor=J.+L.+Romineauthor=N.+A.+Meanwellauthor=M.+Gao&title=Identification+of+hepatitis+C+virus+NS5A+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of hepatitis C virus NS5A inhibitors</span></div><div class="casAuthors">Lemm Julie A; O'Boyle Donald 2nd; Liu Mengping; Nower Peter T; Colonno Richard; Deshpande Milind S; Snyder Lawrence B; Martin Scott W; St Laurent Denis R; Serrano-Wu Michael H; Romine Jeffrey L; Meanwell Nicholas A; Gao Min</div><div class="citationInfo"><span class="NLM_cas:title">Journal of virology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">482-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using a cell-based replicon screen, we identified a class of compounds with a thiazolidinone core structure as inhibitors of hepatitis C virus (HCV) replication.  The concentration of one such compound, BMS-824, that resulted in a 50% inhibition of HCV replicon replication was approximately 5 nM, with a therapeutic index of >10,000.  The compound showed good specificity for HCV, as it was not active against several other RNA and DNA viruses.  Replicon cells resistant to BMS-824 were isolated, and mutations were identified.  A combination of amino acid substitutions of leucine to valine at residue 31 (L31V) and glutamine to leucine at residue 54 (Q54L) in NS5A conferred resistance to this chemotype, as did a single substitution of tyrosine to histidine at amino acid 93 (Y93H) in NS5A.  To further explore the region(s) of NS5A involved in inhibitor sensitivity, genotype-specific NS5A inhibitors were used to evaluate a series of genotype 1a/1b hybrid replicons.  Our results showed that, consistent with resistance mapping, the inhibitor sensitivity domain also mapped to the N terminus of NS5A, but it could be distinguished from the key resistance sites.  In addition, we demonstrated that NS5A inhibitors, as well as an active-site inhibitor that specifically binds NS3 protease, could block the hyperphosphorylation of NS5A, which is believed to play an essential role in the viral life cycle.  Clinical proof of concept has recently been achieved with derivatives of these NS5A inhibitors, indicating that small molecules targeting a nontraditional viral protein like NS5A, without any known enzymatic activity, can also have profound antiviral effects on HCV-infected subjects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTeii-SeNfkQYUSrryheKE6fW6udTcc2ebkjwM8lpZLl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mfhslamtg%253D%253D&md5=691db815a886509d5b225bbbd068b82c</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1128%2FJVI.01360-09&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01360-09%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DColonno%26aufirst%3DR.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%26jtitle%3DJ.%2520Virol.%26date%3D2010%26volume%3D84%26spage%3D482%26epage%3D491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantone, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3795</span>– <span class="NLM_lpage">3802</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.00146-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21576451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2011&pages=3795-3802&author=J.+A.+Lemmauthor=J.+E.+Leetauthor=D.+R.+O%E2%80%99Boyleauthor=J.+L.+Romineauthor=X.+S.+Huangauthor=D.+R.+Schroederauthor=J.+Albertsauthor=J.+L.+Cantoneauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=N.+A.+Meanwellauthor=L.+B.+Snyderauthor=M.+Gao&title=Discovery+of+potent+hepatitis+C+virus+NS5A+inhibitors+with+dimeric+structures"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures</span></div><div class="casAuthors">Lemm, Julie A.; Leet, John E.; O'Boyle, Donald R., II; Romine, Jeffrey L.; Huang, Xiaohua Stella; Schroeder, Daniel R.; Alberts, Jeffrey; Cantone, Joseph L.; Sun, Jin-Hua; Nower, Peter T.; Martin, Scott W.; Serrano-Wu, Michael H.; Meanwell, Nicholas A.; Snyder, Lawrence B.; Gao, Min</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3795-3802</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The exceptional in vitro potency of the hepatitis C virus (HCV) NS5A inhibitor BMS-790052 has translated into an in vivo effect in proof-of-concept clin. trials.  Although the 50% effective concn. (EC50) of the initial lead, the thiazolidinone BMS-824, was ∼10 nM in the replicon assay, it underwent transformation to other inhibitory species after incubation in cell culture medium.  The biol. profile of BMS-824, including the EC50, the drug concn. required to reduce cell growth by 50% (CC50), and the resistance profile, however, remained unchanged, triggering an investigation to identify the biol. active species.  High-performance liq. chromatog. (HPLC) biogram fractionation of a sample of BMS-824 incubated in medium revealed that the most active fractions could readily be sepd. from the parental compd. and retained the biol. profile of BMS-824.  From mass spectral and NMR data, the active species was detd. to be a dimer of BMS-824 derived from an intermol. radical-mediated reaction of the parent compd.  Based upon an anal. of the structural elements of the dimer deemed necessary for anti-HCV activity, the stilbene deriv. BMS-346 was synthesized.  This compd. exhibited excellent anti-HCV activity and showed a resistance profile similar to that of BMS-824, with changes in compd. sensitivity mapped to the N terminus of NS5A.  The N terminus of NS5A has been crystd. as a dimer, complementing the symmetry of BMS-346 and allowing a potential mode of inhibition of NS5A to be discussed.  Identification of the stable, active pharmacophore assocd. with these NS5A inhibitors provided the foundation for the design of more potent inhibitors with broad genotype inhibition.  This culminated in the identification of BMS-790052, a compd. that preserves the symmetry discovered with BMS-346.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5YeVXSMPBNLVg90H21EOLACvtfcHk0ljzQP8r80PiIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpslGgs74%253D&md5=8a0fea78b0d42bf7285e6916c40fbc91</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1128%2FAAC.00146-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00146-11%26sid%3Dliteratum%253Aachs%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DHuang%26aufirst%3DX.%2BS.%26aulast%3DSchroeder%26aufirst%3DD.%2BR.%26aulast%3DAlberts%26aufirst%3DJ.%26aulast%3DCantone%26aufirst%3DJ.%2BL.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26aulast%3DGao%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520potent%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitors%2520with%2520dimeric%2520structures%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2011%26volume%3D55%26spage%3D3795%26epage%3D3802" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">5</a></strong><div class="note"><p class="first last">For additional chemotypes that emerged from screening efforts and were reported to target the NS5A protein based on resistance mapping, see:</p></div><div class="NLM_citation" id="rightTab-cit6a"><span>
					<span class="NLM_label">(a) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Najarro, P. </span>; <span class="NLM_string-name">
							Mathews, N. </span>; <span class="NLM_string-name">
							Cockerill, S. </span> </span> <span> </span><span class="NLM_article-title">NS5A inhibitors</span>.  <i>Hepatitis
C Viruses</i>, <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Tan, S. -L. </span> </span>, Ed.; <span class="NLM_publisher-name">Horizon Bioscience</span>: <span class="NLM_publisher-loc">Wymondham, U.K</span>, <span class="NLM_year">2006</span>; pp  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">292</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&pages=271-292&author=P.+Najarro&author=N.+Mathews&author=S.+Cockerillauthor=S.+-L.+Tan&title=Hepatitis%0AC+Viruses"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNajarro%26aufirst%3DP.%26atitle%3DNS5A%2520inhibitors%26btitle%3DHepatitis%250AC%2520Viruses%26aulast%3DTan%26aufirst%3DS.%2B-L.%26pub%3DHorizon%2520Bioscience%26date%3D2006%26spage%3D271%26epage%3D292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Conte, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercolani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altamura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neddermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migliaccio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stansfield, I.</span></span> <span> </span><span class="NLM_article-title">Synthesis and SAR of piperazinyl-<i>N</i>-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1779</span>– <span class="NLM_lpage">1783</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2009.01.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19216075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1779-1783&author=I.+Conteauthor=C.+Giulianoauthor=C.+Ercolaniauthor=F.+Narjesauthor=U.+Kochauthor=M.+Rowleyauthor=S.+Altamuraauthor=R.+De+Francescoauthor=P.+Neddermannauthor=G.+Migliaccioauthor=I.+Stansfield&title=Synthesis+and+SAR+of+piperazinyl-N-phenylbenzamides+as+inhibitors+of+hepatitis+C+virus+RNA+replication+in+cell+culture"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture</span></div><div class="casAuthors">Conte, Immacolata; Giuliano, Claudio; Ercolani, Caterina; Narjes, Frank; Koch, Uwe; Rowley, Michael; Altamura, Sergio; De Francesco, Raffaele; Neddermann, Petra; Migliaccio, Giovanni; Stansfield, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1779-1783</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The RNA replication machinery of HCV is a multi-subunit membrane-assocd. complex.  NS5A has emerged as an active component of HCV replicase, possibly involved in regulation of viral replication and resistance to the antiviral effect of interferon.  Substituted piperazinyl-N-(aryl)benzamides were prepd. as potent inhibitors of HCV replication exerted via modulation of the dimerization of NS5A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5pdn0bWBLqLVg90H21EOLACvtfcHk0lhRj-skcuei4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltLY%253D&md5=2db305a76f11b417be5581840dd5aa6c</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.066%26sid%3Dliteratum%253Aachs%26aulast%3DConte%26aufirst%3DI.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DErcolani%26aufirst%3DC.%26aulast%3DNarjes%26aufirst%3DF.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DAltamura%26aufirst%3DS.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DMigliaccio%26aufirst%3DG.%26aulast%3DStansfield%26aufirst%3DI.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520piperazinyl-N-phenylbenzamides%2520as%2520inhibitors%2520of%2520hepatitis%2520C%2520virus%2520RNA%2520replication%2520in%2520cell%2520culture%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1779%26epage%3D1783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madigan, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beno, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span> <span> </span><span class="NLM_article-title">Novel hepatitis C virus replicon inhibitors: synthesis and structure–activity relationships of fused pyrimidine derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2215</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.01.096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22342631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A280%3ADC%252BC383ot1Kjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2212-2215&author=A.+C.+Kruegerauthor=D.+L.+Madiganauthor=D.+W.+Benoauthor=D.+A.+Betebennerauthor=R.+Carrickauthor=B.+E.+Greenauthor=W.+Heauthor=D.+Liuauthor=C.+J.+Maringauthor=K.+F.+McDanielauthor=H.+Moauthor=A.+Mollaauthor=C.+E.+Motterauthor=T.+J.+Pilot-Matiasauthor=M.+D.+Tufanoauthor=D.+J.+Kempf&title=Novel+hepatitis+C+virus+replicon+inhibitors%3A+synthesis+and+structure%E2%80%93activity+relationships+of+fused+pyrimidine+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6cR"><div class="casContent"><span class="casTitleNuber">6c</span><div class="casTitle"><span class="NLM_cas:atitle">Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives</span></div><div class="casAuthors">Krueger A Chris; Madigan Darold L; Beno David W; Betebenner David A; Carrick Robert; Green Brian E; He Wenping; Liu Dachun; Maring Clarence J; McDaniel Keith F; Mo Hongmei; Molla Akhteruzzaman; Motter Christopher E; Pilot-Matias Tami J; Tufano Michael D; Kempf Dale J</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2212-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The synthesis of several pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine analogs is described with one such analog possessing subnanomolar potency in both genotype 1a and 1b cell culture HCV replicon assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSqqthqkmhoTUewzGPswiWOfW6udTcc2eZnM9DkIdVoc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC383ot1Kjsg%253D%253D&md5=108fdae73f1d9ab8bd69eb5578c247e9</span></div><a href="/servlet/linkout?suffix=cit6c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.01.096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.01.096%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DA.%2BC.%26aulast%3DMadigan%26aufirst%3DD.%2BL.%26aulast%3DBeno%26aufirst%3DD.%2BW.%26aulast%3DBetebenner%26aufirst%3DD.%2BA.%26aulast%3DCarrick%26aufirst%3DR.%26aulast%3DGreen%26aufirst%3DB.%2BE.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DMo%26aufirst%3DH.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DMotter%26aufirst%3DC.%2BE.%26aulast%3DPilot-Matias%26aufirst%3DT.%2BJ.%26aulast%3DTufano%26aufirst%3DM.%2BD.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26atitle%3DNovel%2520hepatitis%2520C%2520virus%2520replicon%2520inhibitors%253A%2520synthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%2520fused%2520pyrimidine%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2212%26epage%3D2215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betebenner, D. A</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grampovnik, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tufano, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilot-Matias, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maring, C. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of pyrido[2,3-<i>d</i>]pyrimidine-based inhibitors of HCV NS5A</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">3627</span>– <span class="NLM_lpage">3630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2013.04.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23642966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6d&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3627-3630&author=D.+A.+DeGoeyauthor=D.+A+Betebennerauthor=D.+J.+Grampovnikauthor=D.+Liuauthor=J.+K.+Prattauthor=M.+D.+Tufanoauthor=W.+Heauthor=P.+Krishnanauthor=T.+J.+Pilot-Matiasauthor=K.+C.+Marshauthor=A.+Mollaauthor=D.+J.+Kempfauthor=C.+J.+Maring&title=Discovery+of+pyrido%5B2%2C3-d%5Dpyrimidine-based+inhibitors+of+HCV+NS5A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6dR"><div class="casContent"><span class="casTitleNuber">6d</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A</span></div><div class="casAuthors">DeGoey, David A.; Betebenner, David A.; Grampovnik, David J.; Liu, Dachun; Pratt, John K.; Tufano, Michael D.; He, Wenping; Krishnan, Preethi; Pilot-Matias, Tami J.; Marsh, Kennan C.; Molla, Akhteruzzaman; Kempf, Dale J.; Maring, Clarence J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3627-3630</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Efforts to improve the genotype 1a potency and pharmacokinetics of earlier naphthyridine-based HCV NS5A inhibitors resulted in the discovery of a novel series of pyrido[2,3-d]pyrimidine compds., which displayed potent inhibition of HCV genotypes 1a and 1b in the replicon assay.  SAR in this system revealed that the introduction of amides bearing an addnl. 'E' ring provided compds. with improved potency and pharmacokinetics.  Introduction of a chiral center on the amide portion resulted in the observation of a stereochem. dependence for replicon potency and provided a site for the attachment of functional groups useful for improving the soly. of the series.  Compd. 21 was selected for administration in an HCV-infected chimpanzee.  Observation of a robust viral load decline provided pos. proof of concept for inhibition of HCV replication in vivo for the compd. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrel3jepZjyaLVg90H21EOLACvtfcHk0lhRj-skcuei4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyhtrw%253D&md5=a034b541bddfba800487c6b01ce44f79</span></div><a href="/servlet/linkout?suffix=cit6d&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.04.009%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DBetebenner%26aufirst%3DD.%2BA%26aulast%3DGrampovnik%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DTufano%26aufirst%3DM.%2BD.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DKrishnan%26aufirst%3DP.%26aulast%3DPilot-Matias%26aufirst%3DT.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26aulast%3DMaring%26aufirst%3DC.%2BJ.%26atitle%3DDiscovery%2520of%2520pyrido%255B2%252C3-d%255Dpyrimidine-based%2520inhibitors%2520of%2520HCV%2520NS5A%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3627%26epage%3D3630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leet, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshpande, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of HCV NS5A: From iminothiazolidinones to symmetrical stilbenes</span>. <i>ACS Med. Chem. Lett</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">229</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml1002647" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=224-229&author=J.+L.+Romineauthor=D.+R.+St.+Laurentauthor=J.+E.+Leetauthor=S.+W.+Martinauthor=M.+H.+Serrano-Wuauthor=F.+Yangauthor=M.+Gaoauthor=D.+R.+O%E2%80%99Boyleauthor=J.+A.+Lemmauthor=J.-H.+Sunauthor=P.+T.+Nowerauthor=X.+Huangauthor=M.+S.+Deshpandeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=Inhibitors+of+HCV+NS5A%3A+From+iminothiazolidinones+to+symmetrical+stilbenes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes</span></div><div class="casAuthors">Romine, Jeffrey L.; St. Laurent, Denis R.; Leet, John E.; Martin, Scott W.; Serrano-Wu, Michael H.; Yang, Fukang; Gao, Min; O'Boyle, Donald R.; Lemm, Julie A.; Sun, Jin-Hua; Nower, Peter T.; Huang, Xiaohua; Deshpande, Milind S.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">224-229</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The iminothiazolidinone BMS-858 (2) was identified as a specific inhibitor of HCV replication in a genotype 1b replicon assay via a high-throughput screening campaign.  A more potent analog, BMS-824 (18), was used in resistance mapping studies, which revealed that inhibitory activity was related to disrupting the function of the HCV nonstructural protein 5A.  Despite the development of coherent and interpretable SAR, it was subsequently discovered that in DMSO 18 underwent an oxidn. and structural rearrangement to afford the thiohydantoin 47, a compd. with reduced HCV inhibitory activity.  However, HPLC bioassay fractionation studies performed after incubation of 18 in assay media led to the identification of fractions contg. a dimeric species 48 that exhibited potent antiviral activity.  Excision of the key elements hypothesized to be responsible for antiviral activity based on SAR observations reduced 48 to a simplified, sym., pharmacophore realized most effectively with the stilbene 55, a compd. that demonstrated potent inhibition of HCV in a genotype 1b replicon with an EC50 = 86 pM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8qij0fE1q7Vg90H21EOLACvtfcHk0lgFlw_HIwL_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvFCmsg%253D%253D&md5=466b1f5dc09b9e2ecc6b581069506169</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1021%2Fml1002647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1002647%26sid%3Dliteratum%253Aachs%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLeet%26aufirst%3DJ.%2BE.%26aulast%3DMartin%26aufirst%3DS.%2BW.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DDeshpande%26aufirst%3DM.%2BS.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DInhibitors%2520of%2520HCV%2520NS5A%253A%2520From%2520iminothiazolidinones%2520to%2520symmetrical%2520stilbenes%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2011%26volume%3D2%26spage%3D224%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kakarla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romine, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">6063</span>– <span class="NLM_lpage">6066</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.08.049" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22959243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=6063-6066&author=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+Gaoauthor=J.+Goodrichauthor=R.+Kakarlaauthor=J.+O.+Knipeauthor=J.+A.+Lemmauthor=M.+Liuauthor=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=P.+T.+Nowerauthor=D.+O%E2%80%99Boyleauthor=Y.+Qiuauthor=J.+L.+Romineauthor=M.+H.+Serrano-Wuauthor=J.-H.+Sunauthor=L.+Valeraauthor=F.+Yangauthor=X.+Yangauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+2%3A+Investigation+of+stilbene+prolinamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides</span></div><div class="casAuthors">St. Laurent, Denis R.; Belema, Makonen; Gao, Min; Goodrich, Jason; Kakarla, Ramesh; Knipe, Jay O.; Lemm, Julie A.; Liu, Mengping; Lopez, Omar D.; Nguyen, Van N.; Nower, Peter T.; O'Boyle, Donald; Qiu, Yuping; Romine, Jeffrey L.; Serrano-Wu, Michael H.; Sun, Jin-Hua; Valera, Lourdes; Yang, Fukang; Yang, Xuejie; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6063-6066</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the preliminary structure-activity relationships and early PK characterization for a series of stilbene prolinamides I [R = Me, Ph, PhCH2, (R)-PhCHMe, 3-pyridylmethyl, 3-indolyl, etc.] and their analogs that formed a basis for the ultimate identification of daclatasvir (BMS-79052), a compd. that has demonstrated clin. proof-of-concept for inhibiting the NS5A replication complex in the treatment of HCV infection, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vTKMN_UrxLVg90H21EOLACvtfcHk0lgFlw_HIwL_UQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlajsLjK&md5=48ceadc7d3a60a5f99c0d02984e3a2b4</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.08.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.08.049%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGoodrich%26aufirst%3DJ.%26aulast%3DKakarla%26aufirst%3DR.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRomine%26aufirst%3DJ.%2BL.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25202%253A%2520Investigation%2520of%2520stilbene%2520prolinamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D6063%26epage%3D6066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano-Wu, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodrich, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ripka, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogues with distinct core topologies</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">784</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2012.11.086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23273521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWhtbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=779-784&author=O.+D.+Lopezauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=M.+Belemaauthor=M.+H.+Serrano-Wuauthor=J.+T.+Goodrichauthor=F.+Yangauthor=Y.+Qiuauthor=A.+S.+Ripkaauthor=P.+T.+Nowerauthor=L.+Valeraauthor=M.+Liuauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=A.+C.+Goodauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+3%3A+Discovery+of+potent+analogues+with+distinct+core+topologies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7cR"><div class="casContent"><span class="casTitleNuber">7c</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 31: discovery of potent analogs with distinct core topologies</span></div><div class="casAuthors">Lopez, Omar D.; Nguyen, Van N.; St. Laurent, Denis R.; Belema, Makonen; Serrano-Wu, Michael H.; Goodrich, Jason T.; Yang, Fukang; Qiu, Yuping; Ripka, Amy S.; Nower, Peter T.; Valera, Lourdes; Liu, Mengping; O'Boyle, Donald R.; Sun, Jin-Hua; Fridell, Robert A.; Lemm, Julie A.; Gao, Min; Good, Andrew C.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">779-784</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In a recent disclosure, the authors described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon.  That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region.  From this effort, the contribution of the core region to the overall topol. of the pharmacophore, primarily vector orientation and planarity, was detd., with a set of analogs, e.g., I, exhibiting <10 nM EC50 in a genotype 1b replicon assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLqbTPZVn6zrVg90H21EOLACvtfcHk0ljIc9m7sUY3vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWhtbbP&md5=7f329d43d80cec1838eb45378c65335f</span></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.086%26sid%3Dliteratum%253Aachs%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DSerrano-Wu%26aufirst%3DM.%2BH.%26aulast%3DGoodrich%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DRipka%26aufirst%3DA.%2BS.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25203%253A%2520Discovery%2520of%2520potent%2520analogues%2520with%2520distinct%2520core%2520topologies%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D779%26epage%3D784" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7d"><span>
					<span class="NLM_label">(d) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Serrano-Wu, M. H. </span>; <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Ding, M. </span>; <span class="NLM_string-name">
							Fang, H. </span>; <span class="NLM_string-name">
							Gao, M. </span>; <span class="NLM_string-name">
							Goodrich, J. T. </span>; <span class="NLM_string-name">
							Krause, R. G. </span>; <span class="NLM_string-name">
							Lemm, J. A. </span>; <span class="NLM_string-name">
							Liu, M. </span>; <span class="NLM_string-name">
							Lopez, O. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Nower, P. T. </span>; <span class="NLM_string-name">
							O’Boyle, D. R.,  II </span>; <span class="NLM_string-name">
							Pearce, B. C. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							Valera, L. </span>; <span class="NLM_string-name">
							Sun, J.-H. </span>; <span class="NLM_string-name">
							Wang, Y.-K. </span>; <span class="NLM_string-name">
							Yang, F. </span>; <span class="NLM_string-name">
							Yang, X. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span> </span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 4:
Optimization for genotype 1a replicon inhibitory activity</span>.  <i>J. Med. Chem.</i> DOI: <span class="refDoi"> DOI: 10.1021/jm301796k</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm301796k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09St.+Laurent%2C+D.+R.+%3B+%0A%09%09%09%09%09%09%09Serrano-Wu%2C+M.+H.+%3B+%0A%09%09%09%09%09%09%09Belema%2C+M.+%3B+%0A%09%09%09%09%09%09%09Ding%2C+M.+%3B+%0A%09%09%09%09%09%09%09Fang%2C+H.+%3B+%0A%09%09%09%09%09%09%09Gao%2C+M.+%3B+%0A%09%09%09%09%09%09%09Goodrich%2C+J.+T.+%3B+%0A%09%09%09%09%09%09%09Krause%2C+R.+G.+%3B+%0A%09%09%09%09%09%09%09Lemm%2C+J.+A.+%3B+%0A%09%09%09%09%09%09%09Liu%2C+M.+%3B+%0A%09%09%09%09%09%09%09Lopez%2C+O.+%3B+%0A%09%09%09%09%09%09%09Nguyen%2C+V.+N.+%3B+%0A%09%09%09%09%09%09%09Nower%2C+P.+T.+%3B+%0A%09%09%09%09%09%09%09O%E2%80%99Boyle%2C+D.+R.%2C+II+%3B+%0A%09%09%09%09%09%09%09Pearce%2C+B.+C.+%3B+%0A%09%09%09%09%09%09%09Romine%2C+J.+L.+%3B+%0A%09%09%09%09%09%09%09Valera%2C+L.+%3B+%0A%09%09%09%09%09%09%09Sun%2C+J.-H.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.-K.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+F.+%3B+%0A%09%09%09%09%09%09%09Yang%2C+X.+%3B+%0A%09%09%09%09%09%09%09Meanwell%2C+N.+A.+%3B+%0A%09%09%09%09%09%09%09Snyder%2C+L.+B.+HCV+NS5A+replication+complex+inhibitors.+Part+4%3A%0AOptimization+for+genotype+1a+replicon+inhibitory+activity.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm301796k."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7d&amp;dbid=16384&amp;doi=10.1021%2Fjm301796k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301796k%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25204%253A%250AOptimization%2520for%2520genotype%25201a%2520replicon%2520inhibitory%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm301796k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7e"><span><span class="NLM_label">(e) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Belema, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St. Laurent, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Good, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nower, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Boyle, D. R.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemm, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knipe, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, L. B.</span></span> <span> </span><span class="NLM_article-title">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">4428</span>– <span class="NLM_lpage">4435</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.bmcl.2013.05.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23803586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7e&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVShtrbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=4428-4435&author=M.+Belemaauthor=V.+N.+Nguyenauthor=D.+R.+St.+Laurentauthor=O.+D.+Lopezauthor=Y.+Qiuauthor=A.+C.+Goodauthor=P.+T.+Nowerauthor=L.+Valeraauthor=D.+R.+O%E2%80%99Boyleauthor=J.-H.+Sunauthor=M.+Liuauthor=R.+A.+Fridellauthor=J.+A.+Lemmauthor=M.+Gaoauthor=J.+O.+Knipeauthor=N.+A.+Meanwellauthor=L.+B.+Snyder&title=HCV+NS5A+replication+complex+inhibitors.+Part+5%3A+Discovery+of+potent+and+pan-genotypic+glycinamide+cap+derivatives"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7eR"><div class="casContent"><span class="casTitleNuber">7e</span><div class="casTitle"><span class="NLM_cas:atitle">HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives</span></div><div class="casAuthors">Belema, Makonen; Nguyen, Van N.; St. Laurent, Denis R.; Lopez, Omar D.; Qiu, Yuping; Good, Andrew C.; Nower, Peter T.; Valera, Lourdes; O'Boyle, Donald R.; Sun, Jin-Hua; Liu, Mengping; Fridell, Robert A.; Lemm, Julie A.; Gao, Min; Knipe, Jay O.; Meanwell, Nicholas A.; Snyder, Lawrence B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4428-4435</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The isoquinolinamide series of HCV NS5A inhibitors exemplified by compds. (I) and (II) provided the first dual genotype-1a/1b (GT-1a/1b) inhibitor class that demonstrated a significant improvement in potency toward GT-1a replicons compared to that of the initial program lead, stilbene (III).  Structure-activity relationship (SAR) studies that uncovered an alternate phenylglycine-based cap series that exhibit further improvements in virol. profile, along with some insights into the pharmacophoric elements assocd. with the GT-1a potency, are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxZgPIvpbytrVg90H21EOLACvtfcHk0ljIc9m7sUY3vA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVShtrbO&md5=156e18764c9727e50bfd911f72d875d7</span></div><a href="/servlet/linkout?suffix=cit7e&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.05.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.05.040%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DV.%2BN.%26aulast%3DSt.%2BLaurent%26aufirst%3DD.%2BR.%26aulast%3DLopez%26aufirst%3DO.%2BD.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGood%26aufirst%3DA.%2BC.%26aulast%3DNower%26aufirst%3DP.%2BT.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DD.%2BR.%26aulast%3DSun%26aufirst%3DJ.-H.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26aulast%3DLemm%26aufirst%3DJ.%2BA.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DKnipe%26aufirst%3DJ.%2BO.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DSnyder%26aufirst%3DL.%2BB.%26atitle%3DHCV%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25205%253A%2520Discovery%2520of%2520potent%2520and%2520pan-genotypic%2520glycinamide%2520cap%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D4428%26epage%3D4435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7f"><span>
					<span class="NLM_label">(f) </span> <span class="NLM_contrib-group"> <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Lopez, O. D. </span>; <span class="NLM_string-name">
							Goodrich, J. </span>; <span class="NLM_string-name">
							Nower, P.
T. </span>; <span class="NLM_string-name">
							O’Boyle, D. R.,  II </span>; <span class="NLM_string-name">
							Lemm, J. A. </span>; <span class="NLM_string-name">
							Fridell, R. A. </span>; <span class="NLM_string-name">
							Gao, M. </span>; <span class="NLM_string-name">
							Fang, H. </span>; <span class="NLM_string-name">
							Krause, R. G. </span>; <span class="NLM_string-name">
							Wang, Y.-K. </span>; <span class="NLM_string-name">
							Oliver, A. J. </span>; <span class="NLM_string-name">
							Good, A. C. </span>; <span class="NLM_string-name">
							Knipe, J. O. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span> </span> <span> </span><span class="NLM_article-title">Hepatitis C
virus NS5A replication complex inhibitors. Part 6: The discovery of
a novel and highly potent biarylimidazole chemotype with inhibitory
activity toward genotypes 1a and 1b replicons</span>.  <i>J. Med. Chem.</i> DOI:<span class="refDoi"> DOI: 10.1021/jm4016203</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/jm4016203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=%0A%09%09%09%09%09+%0A%09%09%09%09%09%09%09Belema%2C+M.+%3B+%0A%09%09%09%09%09%09%09Nguyen%2C+V.+N.+%3B+%0A%09%09%09%09%09%09%09Romine%2C+J.+L.+%3B+%0A%09%09%09%09%09%09%09St.+Laurent%2C+D.+R.+%3B+%0A%09%09%09%09%09%09%09Lopez%2C+O.+D.+%3B+%0A%09%09%09%09%09%09%09Goodrich%2C+J.+%3B+%0A%09%09%09%09%09%09%09Nower%2C+P.%0AT.+%3B+%0A%09%09%09%09%09%09%09O%E2%80%99Boyle%2C+D.+R.%2C+II+%3B+%0A%09%09%09%09%09%09%09Lemm%2C+J.+A.+%3B+%0A%09%09%09%09%09%09%09Fridell%2C+R.+A.+%3B+%0A%09%09%09%09%09%09%09Gao%2C+M.+%3B+%0A%09%09%09%09%09%09%09Fang%2C+H.+%3B+%0A%09%09%09%09%09%09%09Krause%2C+R.+G.+%3B+%0A%09%09%09%09%09%09%09Wang%2C+Y.-K.+%3B+%0A%09%09%09%09%09%09%09Oliver%2C+A.+J.+%3B+%0A%09%09%09%09%09%09%09Good%2C+A.+C.+%3B+%0A%09%09%09%09%09%09%09Knipe%2C+J.+O.+%3B+%0A%09%09%09%09%09%09%09Meanwell%2C+N.+A.+%3B+%0A%09%09%09%09%09%09%09Snyder%2C+L.+B.+Hepatitis+C%0Avirus+NS5A+replication+complex+inhibitors.+Part+6%3A+The+discovery+of%0Aa+novel+and+highly+potent+biarylimidazole+chemotype+with+inhibitory%0Aactivity+toward+genotypes+1a+and+1b+replicons.+J.+Med.+Chem.+DOI%3A+10.1021%2Fjm4016203."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7f&amp;dbid=16384&amp;doi=10.1021%2Fjm4016203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4016203%26sid%3Dliteratum%253Aachs%26aulast%3DBelema%26aufirst%3DM.%26atitle%3DHepatitis%2520C%250Avirus%2520NS5A%2520replication%2520complex%2520inhibitors.%2520Part%25206%253A%2520The%2520discovery%2520of%250Aa%2520novel%2520and%2520highly%2520potent%2520biarylimidazole%2520chemotype%2520with%2520inhibitory%250Aactivity%2520toward%2520genotypes%25201a%2520and%25201b%2520replicons%26jtitle%3DJ.%2520Med.%2520Chem.%26doi%3D10.1021%2Fjm4016203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">7</a></strong><div class="note"><p class="first last">For details on the PK studies, see the
general <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">8</a></strong><div class="note"><p class="first last"><i>Bis</i>-(<i>S</i>)-phenylglycine
diastereomer of <b>2</b>: GT-1a/-1b EC<sub>50</sub> = 1.6 nM/0.046
nM; both GT-1b CC<sub>50</sub> and BVDV EC<sub>50</sub> values were
>10 μM.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bikker, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humblet, C.</span></span> <span> </span><span class="NLM_article-title">Escape from flatland: Increasing saturation as an approach to improving clinical success</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6752</span>– <span class="NLM_lpage">6756</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901241e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6752-6756&author=F.+Loveringauthor=J.+Bikkerauthor=C.+Humblet&title=Escape+from+flatland%3A+Increasing+saturation+as+an+approach+to+improving+clinical+success"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success</span></div><div class="casAuthors">Lovering, Frank; Bikker, Jack; Humblet, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6752-6756</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The medicinal chem. community has become increasingly aware of the value of tracking calcd. phys. properties such as mol. wt., topol. polar surface area, rotatable bonds, and hydrogen bond donors and acceptors.  The authors hypothesized that the shift to high-throughput synthetic practices over the past decade may be another factor that may predispose mols. to fail by steering discovery efforts toward achiral, arom. compds.  The authors have proposed two simple and interpretable measures of the complexity of mols. prepd. as potential drug candidates.  The first is carbon bond satn. as defined by fraction Sp3 (Fsp3) where Fsp3 = (no. of Sp3 hybridized carbons/total carbon count).  The second is simply whether a chiral carbon exists in the mol.  The authors demonstrate that both complexity (as measured by Fsp3) and the presence of chiral centers correlate with success as compds. transition from discovery, through clin. testing, to drugs.  To explain these observations, the authors further demonstrate that satn. correlates with soly., an exptl. phys. property important to success in the drug discovery setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC1f3Ed7nUBbVg90H21EOLACvtfcHk0liS7J7Y_t1ZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1KjtLvN&md5=4ca92c30c17c53d77ad376719bad951e</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1021%2Fjm901241e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901241e%26sid%3Dliteratum%253Aachs%26aulast%3DLovering%26aufirst%3DF.%26aulast%3DBikker%26aufirst%3DJ.%26aulast%3DHumblet%26aufirst%3DC.%26atitle%3DEscape%2520from%2520flatland%253A%2520Increasing%2520saturation%2520as%2520an%2520approach%2520to%2520improving%2520clinical%2520success%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6752%26epage%3D6756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">The impact of aromatic ring count on compound developability—are too many aromatic rings a liability in drug design?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1011</span>– <span class="NLM_lpage">1020</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.drudis.2009.07.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=19729075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=1011-1020&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=The+impact+of+aromatic+ring+count+on+compound+developability%E2%80%94are+too+many+aromatic+rings+a+liability+in+drug+design%3F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10bR"><div class="casContent"><span class="casTitleNuber">10b</span><div class="casTitle"><span class="NLM_cas:atitle">The impact of aromatic ring count on compound developability: Are too many aromatic rings a liability in drug design?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">21/22</span>),
    <span class="NLM_cas:pages">1011-1020</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The impact of arom. ring count (the no. of arom. and heteroarom. rings) in mols. has been analyzed against various developability parameters, aq. soly., lipophilicity, serum albumin binding, CyP450 inhibition and hERG inhibition.  On the basis of this anal., it was concluded that the fewer arom. rings contained in an oral drug candidate, the more developable that candidate is probably to be; in addn., more than three arom. rings in a mol. correlates with poorer compd. developability and, thus, an increased risk of attrition in development.  Data are also presented that demonstrate that even within a defined lipophilicity range, increased arom. ring count leads to decreased aq. soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2hOeD6TNGUbVg90H21EOLACvtfcHk0liS7J7Y_t1ZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlCgt7nP&md5=48454c9809e8225b4336ea76aad3f3ba</span></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2009.07.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2009.07.014%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DThe%2520impact%2520of%2520aromatic%2520ring%2520count%2520on%2520compound%2520developability%25E2%2580%2594are%2520too%2520many%2520aromatic%2520rings%2520a%2520liability%2520in%2520drug%2520design%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2009%26volume%3D14%26spage%3D1011%26epage%3D1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valera, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridell, R. A.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">611</span>– <span class="NLM_lpage">613</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FAAC.01874-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23089758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1Srur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=611-613&author=C.+Wangauthor=L.+Valeraauthor=L.+Jiaauthor=M.+J.+Kirkauthor=M.+Gaoauthor=R.+A.+Fridell&title=In+vitro+activity+of+daclatasvir+on+hepatitis+C+virus+genotype+3+NS5A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A</span></div><div class="casAuthors">Wang, Chunfu; Valera, Lourdes; Jia, Lingling; Kirk, Melissa J.; Gao, Min; Fridell, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">611-613</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons contg. hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concns. (EC50s) ranging from 120 to 870 pM.  Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance.  Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBgMuXsGkzW7Vg90H21EOLACvtfcHk0liS7J7Y_t1ZbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1Srur8%253D&md5=12c87128212bd241dece7d60085a6fed</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.01874-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01874-12%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DValera%26aufirst%3DL.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DKirk%26aufirst%3DM.%2BJ.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DFridell%26aufirst%3DR.%2BA.%26atitle%3DIn%2520vitro%2520activity%2520of%2520daclatasvir%2520on%2520hepatitis%2520C%2520virus%2520genotype%25203%2520NS5A%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D611%26epage%3D613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">11</a></strong><div class="note"><p class="first last">A manuscript detailing the ADME characterization of <b>33</b> is in preparation and will be published elsewhere.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marbury, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldwater, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMicco, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Torres, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vutikullird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Talavera, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span> <span> </span><span class="NLM_article-title">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitic C virus genotype 1</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1956</span>– <span class="NLM_lpage">1965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fhep.24609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21837752" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1956-1965&author=R.+E.+Nettlesauthor=M.+Gaoauthor=M.+Bifanoauthor=E.+Chungauthor=A.+Perssonauthor=T.+C.+Marburyauthor=R.+Goldwaterauthor=M.+P.+DeMiccoauthor=M.+Rodriguez-Torresauthor=A.+Vutikullirdauthor=E.+Fuentesauthor=E.+Lawitzauthor=J.+C.+Lopez-Talaveraauthor=D.+M.+Grasela&title=Multiple+ascending+dose+study+of+BMS-790052%2C+a+nonstructural+protein+5A+replication+complex+inhibitor%2C+in+patients+infected+with+hepatitic+C+virus+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1</span></div><div class="casAuthors">Nettles, Richard E.; Gao, Min; Bifano, Marc; Chung, Ellen; Persson, Anna; Marbury, Thomas C.; Goldwater, Ronald; DeMicco, Michael P.; Rodriguez-Torres, Maribel; Vutikullird, Apinya; Fuentes, Ernesto; Lawitz, Eric; Lopez-Talavera, Juan Carlos; Grasela, Dennis M.</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1956-1965</span>CODEN:
                <span class="NLM_cas:coden">HPTLD9</span>;
        ISSN:<span class="NLM_cas:issn">0270-9139</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS-790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double-blind, placebo-controlled, sequential panel, multiple ascending dose study.  Thirty patients with chronic hepatitis C virus (HCV) genotype 1 infection were randomized to receive a 14-day course of BMS-790052 (1, 10, 30, 60, or 100 mg once daily or 30 mg twice daily) or placebo in a ratio of 4:1.  The mean max. decline from baseline in HCV RNA ranged from 2.8 to 4.1 log10 IU/mL; the placebo group showed no evidence of antiviral activity.  Most patients experienced viral rebound on or before day 7 of treatment with BMS-790052 monotherapy; viral rebound was assocd. with viral variants that had been previously implicated in resistance development in the in vitro replicon system.  The PK profile was supportive of once-daily dosing with median peak plasma concns. at 1-2 h postdose and mean terminal half-life of 12-15 h.  Steady state was achieved following 3-4 days of daily dosing.  BMS-790052 was well tolerated in all dose groups, with adverse events occurring with a similar frequency in BMS-790052- and placebo-treated groups.  There were no clin. relevant changes in vital signs, lab., or ECG parameters.  Conclusion: BMS-7590052 is the first NS5A replication complex inhibitor with multiple dose proof-of-concept in clinic.  At doses of 1-100 mg daily, BMS-790052 was well tolerated, had a PK profile supportive of once-daily dosing, and produced a rapid and substantial decrease in HCV-RNA levels in patients chronically infected with HCV genotype 1. (HEPATOl.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjY1mjsJbg-LVg90H21EOLACvtfcHk0lgB7HOTwOD34w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFCqsLrJ&md5=080f30aec3629e68b832fe6491c54d16</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fhep.24609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24609%26sid%3Dliteratum%253Aachs%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DBifano%26aufirst%3DM.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMarbury%26aufirst%3DT.%2BC.%26aulast%3DGoldwater%26aufirst%3DR.%26aulast%3DDeMicco%26aufirst%3DM.%2BP.%26aulast%3DRodriguez-Torres%26aufirst%3DM.%26aulast%3DVutikullird%26aufirst%3DA.%26aulast%3DFuentes%26aufirst%3DE.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DLopez-Talavera%26aufirst%3DJ.%2BC.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26atitle%3DMultiple%2520ascending%2520dose%2520study%2520of%2520BMS-790052%252C%2520a%2520nonstructural%2520protein%25205A%2520replication%2520complex%2520inhibitor%252C%2520in%2520patients%2520infected%2520with%2520hepatitic%2520C%2520virus%2520genotype%25201%26jtitle%3DHepatology%26date%3D2011%26volume%3D54%26spage%3D1956%26epage%3D1965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lok, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardiner, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawitz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindollar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, D. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquinelli, C.</span></span> <span> </span><span class="NLM_article-title">Preliminary study of two antiviral agents for hepatitis C genotype 1</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>366</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">224</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1056%2FNEJMoa1104430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22256805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2012&pages=216-224&author=A.+S.+Lokauthor=D.+F.+Gardinerauthor=E.+Lawitzauthor=C.+Martorellauthor=G.+T.+Eversonauthor=R.+Ghalibauthor=R.+Reindollarauthor=V.+Rustgiauthor=F.+McPheeauthor=M.+Wind-Rotoloauthor=A.+Perssonauthor=K.+Zhuauthor=D.+I.+Dimitrovaauthor=T.+Eleyauthor=T.+Guoauthor=D.+M.+Graselaauthor=C.+Pasquinelli&title=Preliminary+study+of+two+antiviral+agents+for+hepatitis+C+genotype+1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Preliminary study of two antiviral agents for hepatitis C genotype 1</span></div><div class="casAuthors">Lok, Anna S.; Gardiner, David F.; Lawitz, Eric; Martorell, Claudia; Everson, Gregory T.; Ghalib, Reem; Reindollar, Robert; Rustgi, Vinod; McPhee, Fiona; Wind-Rotolo, Megan; Persson, Anna; Zhu, Kurt; Dimitrova, Dessislava I.; Eley, Timothy; Guo, Tong; Grasela, Dennis M.; Pasquinelli, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">216-224</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Patients with chronic hepatitis C virus (HCV) infection who have not had a response to therapy with peginterferon and ribavirin may benefit from the addn. of multiple direct-acting antiviral agents to their treatment regimen.  METHODS: This open-label, phase 2a study included an exploratory cohort of 21 patients with chronic HCV genotype 1 infection who had not had a response to previous therapy (i.e., had not had ≥2 log10 decline in HCV RNA after ≥12 wk of treatment with peginterferon and ribavirin).  We randomly assigned patients to receive the NS5A replication complex inhibitor daclatasvir (60 mg once daily) and the NS3 protease inhibitor asunaprevir (600 mg twice daily) alone (group A, 11 patients) or in combination with peginterferon alfa-2a and ribavirin (group B, 10 patients) for 24 wk.  The primary end point was the percentage of patients with a sustained virol. response 12 wk after the end of the treatment period.  RESULTS: A total of 4 patients in group A (36%; 2 of 9 with HCV genotype la and 2 of 2 with genotype lb) had a sustained virol. response at 12 wk after treatment and also at 24 wk after treatment.  Six patients (all with HCV genotype la) had viral breakthrough while receiving therapy, and resistance mutations to both antiviral agents were found in all cases; 1 patient had a viral response at the end of treatment but had a relapse after the treatment period.  All 10 patients in group B had a sustained virol. response at 12 wk after treatment, and 9 had a sustained virol. response at 24 wk after treatment Diarrhea was the most common adverse event in both groups.  Six patients had transient elevations of alanine aminotransferase levels to more than 3 times the upper limit of the normal range.  CONCLUSIONS: This preliminary study involving patients with HCV genotype 1 infection who had not had a response to prior therapy showed that a sustained virol. response can be achieved with two direct-acting antiviral agents only.  In addn., a high rate of sustained virol. response was achieved when the two direct-acting antiviral agents were combined with peginterferon alfa-2a and ribavirin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiY7QiDziiRbVg90H21EOLACvtfcHk0lgB7HOTwOD34w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yltrw%253D&md5=5b986bac6ea53144898c91e8e2eaf5bc</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1104430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1104430%26sid%3Dliteratum%253Aachs%26aulast%3DLok%26aufirst%3DA.%2BS.%26aulast%3DGardiner%26aufirst%3DD.%2BF.%26aulast%3DLawitz%26aufirst%3DE.%26aulast%3DMartorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DGhalib%26aufirst%3DR.%26aulast%3DReindollar%26aufirst%3DR.%26aulast%3DRustgi%26aufirst%3DV.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DK.%26aulast%3DDimitrova%26aufirst%3DD.%2BI.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DGrasela%26aufirst%3DD.%2BM.%26aulast%3DPasquinelli%26aufirst%3DC.%26atitle%3DPreliminary%2520study%2520of%2520two%2520antiviral%2520agents%2520for%2520hepatitis%2520C%2520genotype%25201%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2012%26volume%3D366%26spage%3D216%26epage%3D224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chayanna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumada, H.</span></span> <span> </span><span class="NLM_article-title">Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders</span>. <i>Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">742</span>– <span class="NLM_lpage">748</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1002%2Fhep.24724" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21987462" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=742-748&author=K.+Chayannaauthor=S.+Takahashiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Ikedaauthor=H.+Ishikawaauthor=H.+Watanabeauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+therapy+with+the+nonstructural+protein+5A+inhibitor%2C+daclatasvir%2C+and+the+nonstructural+protein+3+protease+inhibitor%2C+asunaprevir%2C+in+hepatitis+C+virus+genotype+1b-infected+null+responders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1002%2Fhep.24724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhep.24724%26sid%3Dliteratum%253Aachs%26aulast%3DChayanna%26aufirst%3DK.%26aulast%3DTakahashi%26aufirst%3DS.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520therapy%2520with%2520the%2520nonstructural%2520protein%25205A%2520inhibitor%252C%2520daclatasvir%252C%2520and%2520the%2520nonstructural%2520protein%25203%2520protease%2520inhibitor%252C%2520asunaprevir%252C%2520in%2520hepatitis%2520C%2520virus%2520genotype%25201b-infected%2520null%2520responders%26jtitle%3DHepatology%26date%3D2012%26volume%3D55%26spage%3D742%26epage%3D748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakami, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumada, H.</span></span> <span> </span><span class="NLM_article-title">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span>. <i>J. Hepatology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">662</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.jhep.2012.09.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23183526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2013&pages=655-662&author=Y.+Suzukiauthor=K.+Ikedaauthor=F.+Suzukiauthor=J.+Toyotaauthor=Y.+Karinoauthor=K.+Chayamaauthor=Y.+Kawakamiauthor=H.+Ishikawaauthor=H.+Watanabeauthor=W.+Huauthor=T.+Eleyauthor=F.+McPheeauthor=E.+Hughesauthor=H.+Kumada&title=Dual+oral+therapy+with+daclatasvir+and+asunaprevir+for+patients+with+HCV+genotype+1b+infection+and+limited+treatment+options"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options</span></div><div class="casAuthors">Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiyasu; Chayama, Kazuaki; Kawakami, Yoshiiku; Ishikawa, Hiroki; Watanabe, Hideaki; Hu, Wenhua; Eley, Timothy; McPhee, Fiona; Hughes, Eric; Kumada, Hiromitsu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hepatology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-662</span>CODEN:
                <span class="NLM_cas:coden">JOHEEC</span>;
        ISSN:<span class="NLM_cas:issn">0168-8278</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Improved therapeutic options for chronic hepatitis C virus (HCV) infection are needed for patients who are poor candidates for treatment with current regimens due to anticipated intolerability or low likelihood of response.  In this open-label, phase 2a study of Japanese patients with chronic HCV genotype 1b infection, 21 null responders (<2 log10 HCV RNA redn. after 12 wk of peginterferon/ribavirin) and 22 patients intolerant to or medically ineligible for peginterferon/ribavirin therapy received dual oral treatment for 24 wk with the NS5A replication complex inhibitor daclatasvir (DCV) and the NS3 protease inhibitor asunaprevir (ASV).  The primary efficacy end point was sustained virol. response at 12 wk post-treatment (SVR12).  Thirty-six of 43 enrolled patients completed 24 wk of therapy.  Serum HCV RNA levels declined rapidly, becoming undetectable in all patients on therapy by week 8.  Overall, 76.7% of patients achieved SVR12 and SVR24, including 90.5% of null responders and 63.6% of ineligible/intolerant patients.  There were no virol. failures among null responders.  Three ineligible/intolerant patients experienced viral breakthrough and four relapsed post-treatment.  Diarrhea, nasopharyngitis, headache, and ALT/AST increases, generally mild, were the most common adverse events; three discontinuations before week 24 were due to adverse events that included hyperbilirubinemia and transaminase elevations (two patients).  Dual therapy with daclatasvir and asunaprevir, without peginterferon/ribavirin, was well tolerated and achieved high SVR rates in two groups of difficult-to-treat patients with hepatitis C virus genotype 1b infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq1ZlrHtPRHLVg90H21EOLACvtfcHk0li7Y6pJHhh2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2jtbw%253D&md5=48caec88fbfc444ea629aac577c2ed95</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1016%2Fj.jhep.2012.09.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jhep.2012.09.037%26sid%3Dliteratum%253Aachs%26aulast%3DSuzuki%26aufirst%3DY.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DF.%26aulast%3DToyota%26aufirst%3DJ.%26aulast%3DKarino%26aufirst%3DY.%26aulast%3DChayama%26aufirst%3DK.%26aulast%3DKawakami%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DH.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHughes%26aufirst%3DE.%26aulast%3DKumada%26aufirst%3DH.%26atitle%3DDual%2520oral%2520therapy%2520with%2520daclatasvir%2520and%2520asunaprevir%2520for%2520patients%2520with%2520HCV%2520genotype%25201b%2520infection%2520and%2520limited%2520treatment%2520options%26jtitle%3DJ.%2520Hepatology%26date%3D2013%26volume%3D58%26spage%3D655%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pol, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghalib, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustgi, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matorell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everson, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tatum, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hezode, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronowicki, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuluvath, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reindollar, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diva, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhee, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wind-Rotolo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnittman, S.</span></span> <span> </span><span class="NLM_article-title">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2a trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">671</span>– <span class="NLM_lpage">677</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2FS1473-3099%2812%2970138-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=22714001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=671-677&author=S.+Polauthor=R.+H.+Ghalibauthor=V.+K.+Rustgiauthor=C.+Matorellauthor=G.+T.+Eversonauthor=H.+A.+Tatumauthor=C.+Hezodeauthor=J.+K.+Limauthor=J.+P.+Bronowickiauthor=G.+A.+Abramsauthor=N.+Brauauthor=D.+W.+Morrisauthor=P.+J.+Thuluvathauthor=R.+W.+Reindollarauthor=P.+D.+Yinauthor=U.+Divaauthor=R.+Hindesauthor=F.+McPheeauthor=D.+Hernandezauthor=M.+Wind-Rotoloauthor=E.+A.+Hughesauthor=S.+Schnittman&title=Daclatasvir+for+previously+untreated+chronic+hepatitis+C+genotype-1+infection%3A+a+randomized%2C+parallel-group%2C+double-blind%2C+placebo-controlled%2C+dose-finding+phase+2a+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial</span></div><div class="casAuthors">Pol, Stanislas; Ghalib, Reem H.; Rustgi, Vinod K.; Martorell, Claudia; Everson, Greg T.; Tatum, Harvey A.; Hezode, Christophe; Lim, Joseph K.; Bronowicki, Jean-Pierre; Abrams, Gary A.; Braeu, Norbert; Morris, David W.; Thuluvath, Paul J.; Reindollar, Robert W.; Yin, Philip D.; Diva, Ulysses; Hindes, Robert; McPhee, Fiona; Hernandez, Dennis; Wind-Rotolo, Megan; Hughes, Eric A.; Schnittman, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">671-677</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules.  Once-daily daclatasvir, a potent NS5A replication complex inhibitor, was generally well tolerated in phase 1 studies.  We assessed daclatasvir in combination with pegylated interferon (peginterferon) and ribavirin for chronic HCV.  Methods: In this double-blind, parallel-group, dose-finding, phase 2a study, treatment-naive patients with HCV genotype-1 infection (without cirrhosis) from 14 centers in the USA and France were randomly assigned (1:1:1:1) to receive peginterferon alfa-2a (180 μg per wk) and ribavirin (1000-1200 mg daily) plus placebo or 3 mg, 10 mg, or 60 mg of daclatasvir taken once daily, for 48 wk.  The primary efficacy endpoint was undetectable HCV RNA at 4 wk and 12 wk after start of treatment (extended rapid virol. response, eRVR).  Anal. was of all participants who received one dose of study drug.  We used descriptive analyses to compare results.  This study is registered with ClinicalTrials.gov, no. NCT00874770.  Findings: 48 patients were randomly assigned (12 per group); all received at least one dose of study drug. 15 patients discontinued treatment before week 48.  Five of 12 patients (42%, 80% CI 22-64%) who received 3 mg daclatasvir achieved eRVR, compared with ten of 12 (83%, 61-96%) who received 10 mg daclatasvir, nine of 12 (75%, 53-90%) who received 60 mg daclatasvir, and one of 12 (8%, 1-29%) who received placebo.  Adverse events and discontinuations as a result of adverse events occurred with similar frequency across groups.  Interpretation: Daclatasvir seems to be a potent NS5A replication complex inhibitor that increases the antiviral potency of peginterferon and ribavirin.  Our findings support the further development of regimens contg. 60 mg daclatasvir for the treatment of chronic genotype-1 HCV infection.  Funding: Bristol-Myers Squibb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0jrF6ixurObVg90H21EOLACvtfcHk0li7Y6pJHhh2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GlsL%252FJ&md5=fb310d15629ecd376196a92faa8291ba</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2812%2970138-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252812%252970138-X%26sid%3Dliteratum%253Aachs%26aulast%3DPol%26aufirst%3DS.%26aulast%3DGhalib%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DV.%2BK.%26aulast%3DMatorell%26aufirst%3DC.%26aulast%3DEverson%26aufirst%3DG.%2BT.%26aulast%3DTatum%26aufirst%3DH.%2BA.%26aulast%3DHezode%26aufirst%3DC.%26aulast%3DLim%26aufirst%3DJ.%2BK.%26aulast%3DBronowicki%26aufirst%3DJ.%2BP.%26aulast%3DAbrams%26aufirst%3DG.%2BA.%26aulast%3DBrau%26aufirst%3DN.%26aulast%3DMorris%26aufirst%3DD.%2BW.%26aulast%3DThuluvath%26aufirst%3DP.%2BJ.%26aulast%3DReindollar%26aufirst%3DR.%2BW.%26aulast%3DYin%26aufirst%3DP.%2BD.%26aulast%3DDiva%26aufirst%3DU.%26aulast%3DHindes%26aufirst%3DR.%26aulast%3DMcPhee%26aufirst%3DF.%26aulast%3DHernandez%26aufirst%3DD.%26aulast%3DWind-Rotolo%26aufirst%3DM.%26aulast%3DHughes%26aufirst%3DE.%2BA.%26aulast%3DSchnittman%26aufirst%3DS.%26atitle%3DDaclatasvir%2520for%2520previously%2520untreated%2520chronic%2520hepatitis%2520C%2520genotype-1%2520infection%253A%2520a%2520randomized%252C%2520parallel-group%252C%2520double-blind%252C%2520placebo-controlled%252C%2520dose-finding%2520phase%25202a%2520trial%26jtitle%3DLancet%26date%3D2012%26volume%3D12%26spage%3D671%26epage%3D677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, K. R.</span></span> <span> </span><span class="NLM_article-title">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1337</span>– <span class="NLM_lpage">1346</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1517%2F13543784.2013.826189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23931586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1337-1346&author=D.+A.+Herbstauthor=K.+R.+Reddy&title=NS5A+inhibitor%2C+daclatasvir%2C+for+the+treatment+of+chronic+hepatitis+C+virus+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection</span></div><div class="casAuthors">Herbst, D. Alan; Reddy, K. Rajender</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1337-1346</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Chronic Hepatitis C virus (HCV) infection is a major pandemic.  The current std. of care includes peginterferon and ribavirin plus one of two protease inhibitors, boceprevir and telaprevir, for Genotype 1 patients and peginterferon and ribavirin for all other genotypes.  The treatment landscape is rapidly evolving as a no. of direct-acting antivirals (DAA) are being developed in clin. trials.  Areas covered: , formerly labeled BMS-790052, is a first-in-class HCV NS5A inhibitor that has been demonstrated in Phase I and II trials to have a very potent antiviral effect across all genotypes and to have a potent clin. efficacy in both treatment naive and experienced cohorts.  This review covers the whole spectrum of development of daclatasvir from Phase I to III programs.  Expert opinion: While daclatasvir has pangenotypic activity, it has a lower barrier to resistance in Genotype 1a but has been found to be very effective in Genotype 1b patients.  However, Genotype 1a patients can be successfully treated with the addn. of one or more DAAs alone or in combination with peginterferon and ribavirin.  The future for daclatasvir and other DAAs is very encouraging in that all-oral therapies are likely to be effective and well-tolerated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouHATdIV9yA7Vg90H21EOLACvtfcHk0li7Y6pJHhh2MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVekurzK&md5=d1b220d6ed004a580cd6920ffaecde19</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.826189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.826189%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DD.%2BA.%26aulast%3DReddy%26aufirst%3DK.%2BR.%26atitle%3DNS5A%2520inhibitor%252C%2520daclatasvir%252C%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%2520virus%2520infection%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1337%26epage%3D1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit16"><span>
					<span class="NLM_contrib-group"> <span class="NLM_string-name">
							Everson, G. T. </span>; <span class="NLM_string-name">
							Sims, K. D. </span>; <span class="NLM_string-name">
							Rodriguez-Torres, M. </span>; <span class="NLM_string-name">
							Hezode, C. </span>; <span class="NLM_string-name">
							Lawitz, E. </span>; <span class="NLM_string-name">
							Bourliere, M. </span>; <span class="NLM_string-name">
							Loustaud-Ratti, V. </span>; <span class="NLM_string-name">
							Rustgi, V. </span>; <span class="NLM_string-name">
							Schwartz, H. </span>; <span class="NLM_string-name">
							Tatum, H. </span>; <span class="NLM_string-name">
							Marcellin, P. </span>; <span class="NLM_string-name">
							Pol, S. </span>; <span class="NLM_string-name">
							Thuluvath, P. J. </span>; <span class="NLM_string-name">
							Eley, T. </span>; <span class="NLM_string-name">
							Wang, X. </span>; <span class="NLM_string-name">
							Huang, S.-P. </span>; <span class="NLM_string-name">McPhee, F.</span>; ; <span class="NLM_string-name">
							Wind-Rotolo, M. </span>; <span class="NLM_string-name">
							Chung, E. </span>; <span class="NLM_string-name">Pasquinelli, C.</span>; ; <span class="NLM_string-name">
							Grasela, D. M. </span>; <span class="NLM_string-name">
							Gardiner, D. F. </span> </span> <span> </span><span class="NLM_article-title">Efficacy of an interferon- and Ribavirin-free regimen of daclatasvir,
asunaprevir, and BMS-791325 in treatment-naı̈ve patients
with HCV genotype 1 infection</span>.  <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume">146</span>,  <span class="NLM_fpage">420</span>− <span class="NLM_lpage">429</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1053%2Fj.gastro.2013.10.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=24184132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2014&pages=420-429&author=G.+T.+Everson&author=K.+D.+Sims&author=M.+Rodriguez-Torres&author=C.+Hezode&author=E.+Lawitz&author=M.+Bourliere&author=V.+Loustaud-Ratti&author=V.+Rustgi&author=H.+Schwartz&author=H.+Tatum&author=P.+Marcellin&author=S.+Pol&author=P.+J.+Thuluvath&author=T.+Eley&author=X.+Wang&author=S.-P.+Huang&author=F.+McPhee&author=M.+Wind-Rotolo&author=E.+Chung&author=C.+Pasquinelli&author=D.+M.+Grasela&author=D.+F.+Gardiner&title=Efficacy+of+an+interferon-+and+Ribavirin-free+regimen+of+daclatasvir%2C%0Aasunaprevir%2C+and+BMS-791325+in+treatment-na%C4%B1%CC%88ve+patients%0Awith+HCV+genotype+1+infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection</span></div><div class="casAuthors">Everson, Gregory T.; Sims, Karen D.; Rodriguez-Torres, Maribel; Hezode, Christophe; Lawitz, Eric; Bourliere, Marc; Loustaud-Ratti, Veronique; Rustgi, Vinod; Schwartz, Howard; Tatum, Harvey; Marcellin, Patrick; Pol, Stanislas; Thuluvath, Paul J.; Eley, Timothy; Wang, Xiaodong; Huang, Shu-Pang; McPhee, Fiona; Wind-Rotolo, Megan; Chung, Ellen; Pasquinelli, Claudio; Grasela, Dennis M.; Gardiner, David F.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-429</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The combination of peginterferon and ribavirin with telaprevir or boceprevir is the std. treatment of hepatitis C virus (HCV) genotype 1 infection.  However, these drugs are not well tolerated because of their side effects and suboptimal virol. responses.  In a phase 2a, open-label study, we examd. the safety and efficacy of an interferon-free, ribavirin-free regimen of direct-acting antivirals, comprising daclatasvir (an NS5A replication complex inhibitor), asunaprevir (an NS3 protease inhibitor), and BMS-791325 (a non-nucleoside NS5B inhibitor), in patients with chronic HCV infection.  We analyzed data from 66 treatment-naive patients with HCV genotype 1 infection without cirrhosis who were assigned randomly to groups given daclatasvir (60 mg, once daily), asunaprevir (200 mg, twice daily), and BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 wk.  The primary end point was an HCV-RNA level less than 25 IU/mL at 12 wk after treatment (sustained virol. response at 12 wk [SVR12]).  In 64 patients, HCV-RNA levels were less than 25 IU/mL by week 4 of treatment (including 48 of 49 patients with HCV genotype 1a infection and 45 of 46 patients with the non-CC interleukin 28B genotype).  Sixty-one patients (92%) achieved SVR12, based on a modified intention-to-treat anal.  Virol. responses were similar between 12 and 24 wk of treatment.  During the study, 2 patients experienced viral breakthrough and 1 patient relapsed.  There were no grade 3-4 increases in levels of alanine or aspartate aminotransferases or bilirubin; there were no deaths or discontinuations resulting from serious adverse events or adverse events related to the treatment regimen.  The most common adverse events were headache, asthenia, and gastrointestinal symptoms.  In a phase 2a study, the all-oral, interferon-free, and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 was well tolerated and achieved high rates of SVR12 in patients with HCV genotype 1 infection.  Further studies of this regimen are warranted.  ClinicalTrials.gov, no. NCT01455090.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGYjuJmkQI8rVg90H21EOLACvtfcHk0lgVaCKEzY26RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyitr4%253D&md5=c8f83094f49ce5d5d116d75414ab3d93</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2013.10.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2013.10.057%26sid%3Dliteratum%253Aachs%26aulast%3DEverson%26aufirst%3DG.%2BT.%26atitle%3DEfficacy%2520of%2520an%2520interferon-%2520and%2520Ribavirin-free%2520regimen%2520of%2520daclatasvir%252C%250Aasunaprevir%252C%2520and%2520BMS-791325%2520in%2520treatment-na%25C4%25B1%25CC%2588ve%2520patients%250Awith%2520HCV%2520genotype%25201%2520infection%26jtitle%3DGastroenterology%26date%3D2014%26volume%3D146%26spage%3D420%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Targett-Adams, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, E. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middleton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brain, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakenhut, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stammen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryde, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickford, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westby, M.</span></span> <span> </span><span class="NLM_article-title">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>85</i></span>,  <span class="NLM_fpage">6353</span>– <span class="NLM_lpage">6368</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1128%2FJVI.00215-11" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21507963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=85&publication_year=2011&pages=6353-6368&author=P.+Targett-Adamsauthor=E.+J.+S.+Grahamauthor=J.+Middletonauthor=A.+Palmerauthor=S.+M.+Shawauthor=H.+Lavenderauthor=P.+Brainauthor=T.+D.+Tranauthor=L.+H.+Jonesauthor=F.+Wakenhutauthor=B.+Stammenauthor=D.+Prydeauthor=C.+Pickfordauthor=M.+Westby&title=Small+molecules+targeting+hepatitis+C+virus-encoded+NS5A+cause+subcellular+redistribution+of+their+target%3A+Insights+into+compound+modes+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action</span></div><div class="casAuthors">Targett-Adams, Paul; Graham, Emily J. S.; Middleton, Jenny; Palmer, Amy; Shaw, Stephen M.; Lavender, Helen; Brain, Philip; Tran, Thien Duc; Jones, Lyn H.; Wakenhut, Florian; Stammen, Blanda; Pryde, David; Pickford, Chris; Westby, Mike</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">85</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6353-6368</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The current std. of care for hepatitis C virus (HCV)-infected patients consists of lengthy treatment with interferon and ribavirin.  To increase the effectiveness of HCV therapy, future regimens will incorporate multiple direct-acting antiviral (DAA) drugs.  Recently, the HCV-encoded NS5A protein has emerged as a promising DAA target.  Compds. targeting NS5A exhibit remarkable potency in vitro and demonstrate early clin. promise, suggesting that NS5A inhibitors could feature in future DAA combination therapies.  Since the mechanisms through which these mols. operate are unknown, we have used NS5A inhibitors as tools to investigate their modes of action.  Anal. of replicon-contg. cells revealed dramatic phenotypic alterations in NS5A localization following treatment with NS5A inhibitors; NS5A was redistributed from the endoplasmic reticulum to lipid droplets.  The NS5A relocalization did not occur in cells treated with other classes of HCV inhibitors, and NS5A-targeting mols. did not cause similar alterations in the localization of other HCV-encoded proteins.  Time course anal. of the redistribution of NS5A revealed that the transfer of protein to lipid droplets was concomitant with the onset of inhibition, as judged by the kinetic profiles for these compds.  Furthermore, anal. of the kinetic profile of inhibition for a panel of test mols. permitted the sepn. of compds. into different kinetic classes based on their modes of action.  The results from this approach suggested that NS5A inhibitors perturbed the function of new replication complexes, rather than acting on preformed complexes.  The data reveal novel biol. consequences of NS5A inhibition, which may help enable the development of future assay platforms for the identification of new and/or different NS5A inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_D0ZIz1nPk7Vg90H21EOLACvtfcHk0lgVaCKEzY26RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXotFOntbg%253D&md5=99efbc4b114c7f8129b43f51b4d584b7</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1128%2FJVI.00215-11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.00215-11%26sid%3Dliteratum%253Aachs%26aulast%3DTargett-Adams%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DE.%2BJ.%2BS.%26aulast%3DMiddleton%26aufirst%3DJ.%26aulast%3DPalmer%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DS.%2BM.%26aulast%3DLavender%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DP.%26aulast%3DTran%26aufirst%3DT.%2BD.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DWakenhut%26aufirst%3DF.%26aulast%3DStammen%26aufirst%3DB.%26aulast%3DPryde%26aufirst%3DD.%26aulast%3DPickford%26aufirst%3DC.%26aulast%3DWestby%26aufirst%3DM.%26atitle%3DSmall%2520molecules%2520targeting%2520hepatitis%2520C%2520virus-encoded%2520NS5A%2520cause%2520subcellular%2520redistribution%2520of%2520their%2520target%253A%2520Insights%2520into%2520compound%2520modes%2520of%2520action%26jtitle%3DJ.%2520Virol.%26date%3D2011%26volume%3D85%26spage%3D6353%26epage%3D6368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leveque, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sklan, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elazar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klumpp, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glenn, J. S.</span></span> <span> </span><span class="NLM_article-title">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span>. <i>Virology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>414</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2Fj.virol.2011.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=21513964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=414&publication_year=2011&pages=10-18&author=C.+Leeauthor=H.+Maauthor=J.+Q.+Hangauthor=V.+Levequeauthor=E.+H.+Sklanauthor=M.+Elazarauthor=K.+Klumppauthor=J.+S.+Glenn&title=The+hepatitis+C+virus+NS5A+inhibitor+%28BMS-790052%29+alters+the+subcellular+localization+of+the+NS5A+non-structural+viral+protein"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein</span></div><div class="casAuthors">Lee, Choongho; Ma, Han; Hang, Julie Qi; Leveque, Vincent; Sklan, Ella H.; Elazar, Menashe; Klumpp, Klaus; Glenn, Jeffrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Virology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">414</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">VIRLAX</span>;
        ISSN:<span class="NLM_cas:issn">0042-6822</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The hepatitis C virus (HCV) non-structural (NS) 5A protein plays an essential role in the replication of the viral RNA by the membrane-assocd. replication complex (RC).  Recently, a putative NS5A inhibitor, BMS-790052, exhibited the highest potency of any known anti-HCV compd. in inhibiting HCV replication in vitro and showed a promising clin. effect in HCV-infected patients.  The precise mechanism of action for this new class of potential anti-HCV therapeutics, however, is still unclear.  In order to gain further insight into its mode of action, we sought to test the hypothesis that the antiviral effect of BMS-790052 might be mediated by interfering with the functional assembly of the HCV RC.  We obsd. that BMS-790052 indeed altered the subcellular localization and biochem. fractionation of NS5A.  Taken together, our data suggest that NS5A inhibitors such as BMS-790052 can suppress viral genome replication by altering the proper localization of NS5A into functional RCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYMSRcOmX36rVg90H21EOLACvtfcHk0lgVaCKEzY26RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVyit7c%253D&md5=b4212a1dd1365aedfd384e685afdefeb</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1016%2Fj.virol.2011.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virol.2011.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DHang%26aufirst%3DJ.%2BQ.%26aulast%3DLeveque%26aufirst%3DV.%26aulast%3DSklan%26aufirst%3DE.%2BH.%26aulast%3DElazar%26aufirst%3DM.%26aulast%3DKlumpp%26aufirst%3DK.%26aulast%3DGlenn%26aufirst%3DJ.%2BS.%26atitle%3DThe%2520hepatitis%2520C%2520virus%2520NS5A%2520inhibitor%2520%2528BMS-790052%2529%2520alters%2520the%2520subcellular%2520localization%2520of%2520the%2520NS5A%2520non-structural%2520viral%2520protein%26jtitle%3DVirology%26date%3D2011%26volume%3D414%26spage%3D10%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guedj, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahari, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansone, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nettles, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotler, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Layden, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uprichard, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perelson, A. S.</span></span> <span> </span><span class="NLM_article-title">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3996</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1073%2Fpnas.1203110110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23431163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17c&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=3991-3996&author=J.+Guedjauthor=H.+Dahariauthor=L.+Rongauthor=N.+D.+Sansoneauthor=R.+E.+Nettlesauthor=S.+J.+Cotlerauthor=T.+J.+Laydenauthor=S.+L.+Uprichardauthor=A.+S.+Perelson&title=Modeling+shows+that+the+NS5A+inhibitor+daclatasvir+has+two+modes+of+action+and+yields+a+shorter+estimate+of+the+hepatitis+C+virus+half-life"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17cR"><div class="casContent"><span class="casTitleNuber">17c</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life</span></div><div class="casAuthors">Guedj, Jeremie; Dahari, Harel; Rong, Libin; Sansone, Natasha D.; Nettles, Richard E.; Cotler, Scott J.; Layden, Thomas J.; Uprichard, Susan L.; Perelson, Alan S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3991-3996, S3991/1-S3991/5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The nonstructural 5A (NS5A) protein is a target for drug development against hepatitis C virus (HCV).  Interestingly, the NS5A inhibitor daclatasvir (BMS-790052) caused a decrease in serum HCV RNA levels by about two orders of magnitude within 6 h of administration.  However, NS5A has no known enzymic functions, making it difficult to understand daclatasvir's mode of action (MOA) and to est. its antiviral effectiveness.  Modeling viral kinetics during therapy has provided important insights into the MOA and effectiveness of a variety of anti-HCV agents.  Here, we show that understanding the effects of daclatasvir in vivo requires a multiscale model that incorporates drug effects on the HCV intracellular lifecycle, and we validated this approach with in vitro HCV infection expts.  The model predicts that daclatasvir efficiently blocks two distinct stages of the viral lifecycle, namely viral RNA synthesis and virion assembly/secretion with mean effectiveness of 99% and 99.8%, resp., and yields a more precise est. of the serum HCV half-life, 45 min, i.e., around four times shorter than previous ests.  Intracellular HCV RNA in HCV-infected cells treated with daclatasvir and the HCV polymerase inhibitor NM107 showed a similar pattern of decline.  However, daclatasvir treatment led to an immediate and rapid decline of extracellular HCV titers compared to a delayed (6-9 h) and slower decline with NM107, confirming an effect of daclatasvir on both viral replication and assembly/secretion.  The multiscale modeling approach, validated with in vitro kinetic expts., brings a unique conceptual framework for understanding the mechanism of action of a variety of agents in development for the treatment of HCV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSYdT4WQUN7LVg90H21EOLACvtfcHk0liiZU0sTDbvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltVWms7g%253D&md5=81f3b8c49b97120f70b440211b4bf979</span></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1203110110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1203110110%26sid%3Dliteratum%253Aachs%26aulast%3DGuedj%26aufirst%3DJ.%26aulast%3DDahari%26aufirst%3DH.%26aulast%3DRong%26aufirst%3DL.%26aulast%3DSansone%26aufirst%3DN.%2BD.%26aulast%3DNettles%26aufirst%3DR.%2BE.%26aulast%3DCotler%26aufirst%3DS.%2BJ.%26aulast%3DLayden%26aufirst%3DT.%2BJ.%26aulast%3DUprichard%26aufirst%3DS.%2BL.%26aulast%3DPerelson%26aufirst%3DA.%2BS.%26atitle%3DModeling%2520shows%2520that%2520the%2520NS5A%2520inhibitor%2520daclatasvir%2520has%2520two%2520modes%2520of%2520action%2520and%2520yields%2520a%2520shorter%2520estimate%2520of%2520the%2520hepatitis%2520C%2520virus%2520half-life%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2013%26volume%3D110%26spage%3D3991%26epage%3D3996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit18"><span>
					<span class="NLM_contrib-group"> <span class="NLM_string-name">
							Bachand, C. </span>; <span class="NLM_string-name">
							Belema, M. </span>; <span class="NLM_string-name">
							Deon, D.
H. </span>; <span class="NLM_string-name">
							Good, A.
C. </span>; <span class="NLM_string-name">
							Goodrich, J. T. </span>; <span class="NLM_string-name">
							James, C. A. </span>; <span class="NLM_string-name">
							Lavoie, R. </span>; <span class="NLM_string-name">
							Lopez, O.
D. </span>; <span class="NLM_string-name">
							Martel, A. </span>; <span class="NLM_string-name">
							Meanwell, N. A. </span>; <span class="NLM_string-name">
							Nguyen, V. N. </span>; <span class="NLM_string-name">
							Romine, J. L. </span>; <span class="NLM_string-name">
							Ruediger, E. H. </span>; <span class="NLM_string-name">
							Snyder, L. B. </span>; <span class="NLM_string-name">
							St. Laurent, D. R. </span>; <span class="NLM_string-name">
							Yang, F. </span>; <span class="NLM_string-name">
							Langley, D. R. </span>; <span class="NLM_string-name">
							Wang, G. </span>; <span class="NLM_string-name">
							Hamann, L. G. </span> </span> <span> </span><span class="NLM_article-title">Hepatitis C Virus Inhibitors</span>. PCT
Intl. Application. <span class="NLM_year">2008</span>, Patent No. <span class="NLM_patent">WO2008-021927</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=C.+Bachand&author=M.+Belema&author=D.%0AH.+Deon&author=A.%0AC.+Good&author=J.+T.+Goodrich&author=C.+A.+James&author=R.+Lavoie&author=O.%0AD.+Lopez&author=A.+Martel&author=N.+A.+Meanwell&author=V.+N.+Nguyen&author=J.+L.+Romine&author=E.+H.+Ruediger&author=L.+B.+Snyder&author=D.+R.+St.+Laurent&author=F.+Yang&author=D.+R.+Langley&author=G.+Wang&author=L.+G.+Hamann&title=Hepatitis+C+Virus+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBachand%26aufirst%3DC.%26atitle%3DHepatitis%2520C%2520Virus%2520Inhibitors%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Poitout, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roubert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contour-Galcera, M.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moinet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannoy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pommier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurieau, C.</span></span> <span> </span><span class="NLM_article-title">Identification of potent non-peptide somatostatin antagonists with sst3 selectivity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2990</span>– <span class="NLM_lpage">3000</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0108449" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1Okuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2990-3000&author=L.+Poitoutauthor=P.+Roubertauthor=M.-O.+Contour-Galceraauthor=C.+Moinetauthor=J.+Lannoyauthor=J.+Pommierauthor=P.+Plasauthor=D.+Biggauthor=C.+Thurieau&title=Identification+of+potent+non-peptide+somatostatin+antagonists+with+sst3+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity</span></div><div class="casAuthors">Poitout, Lydie; Roubert, Pierre; Contour-Galcera, Marie-Odile; Moinet, Christophe; Lannoy, Jacques; Pommier, Jacques; Plas, Pascale; Bigg, Dennis; Thurieau, Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2990-3000</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using a soln.-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepd., and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were detd.  Imidazolyl derivs. were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype.  Further modifications of these structures led to a more potent class of ligands, the tetrahydro-β-carboline derivs.  Among these, compds. BN81644 and BN81674 bind selectively and with high affinity to the sst3 receptor subtype (Ki = 0.64 and 0.92 nM, resp.).  Furthermore, BN81644 and BN81674 reverse the inhibition of cAMP accumulation induced by 1 nM somatostatin via sst3 receptors, with IC50 = 2.7 and 0.84 nM, resp.  The most potent compd. BN81674 was shown to be a competitive antagonist of human sst3 receptors by increasing the EC50 of SRIF-14-mediated inhibition of cAMP accumulation with a KB of 2.8 nM (where KB is the concn. of antagonist that shifts the agonist dose-response 2-fold).  These new derivs. are, to the authors knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiol. role of sst3 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLCGxLWbRQabVg90H21EOLACvtfcHk0liiZU0sTDbvGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1Okuro%253D&md5=757c8a3c9acc656dbdeb22e7283788cd</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm0108449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0108449%26sid%3Dliteratum%253Aachs%26aulast%3DPoitout%26aufirst%3DL.%26aulast%3DRoubert%26aufirst%3DP.%26aulast%3DContour-Galcera%26aufirst%3DM.-O.%26aulast%3DMoinet%26aufirst%3DC.%26aulast%3DLannoy%26aufirst%3DJ.%26aulast%3DPommier%26aufirst%3DJ.%26aulast%3DPlas%26aufirst%3DP.%26aulast%3DBigg%26aufirst%3DD.%26aulast%3DThurieau%26aufirst%3DC.%26atitle%3DIdentification%2520of%2520potent%2520non-peptide%2520somatostatin%2520antagonists%2520with%2520sst3%2520selectivity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2990%26epage%3D3000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Shea, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grabowski, E. J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reider, P. J.</span></span> <span> </span><span class="NLM_article-title">Selective monolithiation of 2,5-dibromopyridine with butyllithium</span>. <i>Tetrahedon Lett</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4335</span>– <span class="NLM_lpage">4338</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1016%2FS0040-4039%2800%2900664-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktlWgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2000&pages=4335-4338&author=X.+Wangauthor=P.+Rabbatauthor=P.+O%E2%80%99Sheaauthor=R.+Tillyerauthor=E.+J.+J.+Grabowskiauthor=P.+J.+Reider&title=Selective+monolithiation+of+2%2C5-dibromopyridine+with+butyllithium"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Selective monolithiation of 2,5-dibromopyridine with butyllithium</span></div><div class="casAuthors">Wang, Xin; Rabbat, Philippe; O'Shea, Paul; Tillyer, Richard; Grabowski, E. J. J.; Reider, Paul J.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4335-4338</span>CODEN:
                <span class="NLM_cas:coden">TELEAY</span>;
        ISSN:<span class="NLM_cas:issn">0040-4039</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Selective monolithiation of 2,5-dibromopyridine at either the 2- or the 5-position is reported.  Solvent and concn. strongly influence the selectivity.  Coordinating solvents and higher concn. favor the 5-position, while non-coordinating solvents and lower concn. favor the 2-position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOERlFYZb7urVg90H21EOLACvtfcHk0lj4UBifg4xUWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktlWgsrk%253D&md5=c09d0455bd9dacfcff32742dd2f9e575</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0040-4039%2800%2900664-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4039%252800%252900664-X%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DRabbat%26aufirst%3DP.%26aulast%3DO%25E2%2580%2599Shea%26aufirst%3DP.%26aulast%3DTillyer%26aufirst%3DR.%26aulast%3DGrabowski%26aufirst%3DE.%2BJ.%2BJ.%26aulast%3DReider%26aufirst%3DP.%2BJ.%26atitle%3DSelective%2520monolithiation%2520of%25202%252C5-dibromopyridine%2520with%2520butyllithium%26jtitle%3DTetrahedon%2520Lett%26date%3D2000%26volume%3D41%26spage%3D4335%26epage%3D4338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kowdley, K. V.</span></span> <span> </span><span class="NLM_article-title">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1121</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401836p&amp;key=10.1517%2F13543784.2013.806482" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401836p&amp;key=23735127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401836p&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2013&pages=1107-1121&author=N.+Shahauthor=T.+Pierceauthor=K.+V.+Kowdley&title=Review+of+direct-acting+antiviral+agents+for+the+treatment+of+chronic+hepatitis+C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Review of direct-acting antiviral agents for the treatment of chronic hepatitis C</span></div><div class="casAuthors">Shah, Nihar; Pierce, Tracey; Kowdley, Kris V.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1107-1121</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Rapid breakthroughs in the treatment of hepatitis C virus (HCV) infection have dramatically altered the treatment landscape for this chronic disease.  In 2011, the protease inhibitors (PIs) boceprevir and telaprevir in combination with peginterferon (peg-IFN) and ribavirin (RBV) were the first direct-acting antivirals (DAAs) approved in the United States for treatment of genotype (GT) 1 HCV.  Several DAAs currently in late-stage clin. trials, including NS3/NS4A serine PIs, NS5A inhibitors, NS5B polymerase inhibitors (both nucleoside and non-nucleoside) and cyclophilin inhibitors, both with and without peg-IFN and RBV, are promising for the treatment of HCV.  DAA regimens offer several advantages including that they specifically target HCV viral replication and thus appear to be less dependent on host characteristics, very high SVR rates accompanied by fewer side effects (SE) and lower pill burdens.  A review on the treatment of HCV is important and timely as the development on DAAs is progressing rapidly and the health-care providers need to be aware about this as these regimens are anticipated to become clin. available soon.  Areas covered: The literature was searched and reviewed using PubMed as well as data gathered from those presented at the international liver meetings, AASLD and EASL as well as CROI.  Expert opinion: With the potential of eliminating IFN and RBV, several DAAs under clin. development appear to be promising using novel approaches with good antiviral effects, shorter duration and lower SE profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXZExgJKmkr7Vg90H21EOLACvtfcHk0lj4UBifg4xUWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Ghur%252FO&md5=f761cff6a6710f4de9473db6509d20a9</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1517%2F13543784.2013.806482&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2013.806482%26sid%3Dliteratum%253Aachs%26aulast%3DShah%26aufirst%3DN.%26aulast%3DPierce%26aufirst%3DT.%26aulast%3DKowdley%26aufirst%3DK.%2BV.%26atitle%3DReview%2520of%2520direct-acting%2520antiviral%2520agents%2520for%2520the%2520treatment%2520of%2520chronic%2520hepatitis%2520C%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2013%26volume%3D22%26spage%3D1107%26epage%3D1121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">The generic description of the <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> is a slightly modified version of a paragraph provided in ref <a onclick="showRef(event, 'cit7f'); return false;" href="javascript:void(0);" class="ref cit7f">(6f)</a> for a related work disclosed by the same authors.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401836p&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Fjm401836p%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-5%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401836p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67991e6de9263c7c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
